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Tuberculosis (TB) is one of the greatest global health challenges society faces. BCG, the only 
licensed vaccine for TB, has profoundly variable efficacy and does not prevent the spread of TB. 
Due to the lack of an effective vaccine, there are no correlates of protection to use in vaccine 
development. The goal of this dissertation was to develop new tools for pre-clinical and clinical 
trials of TB vaccines, including new outcome measures and predictive markers of efficacy. 
Development of these tools will expedite down-selection of vaccinate candidates, reducing their 
ultimate cost and hastening the reduction and eventual elimination of this disease. BCG afforded 
the best levels of protection in the rhesus macaque model of TB, which closely resembled TB 
disease in human infants. Boosting BCG by protein antigens or adenoviral vectored antigens did 
not improve, and in some cases worsened, outcome. A T cell signature in the lung-draining 
lymph nodes (LN) at necropsy, early gamma interferon (IFN-γ) ELISPOT and early PET-CT 
markers correlated with improved outcome in this model.  We further characterized the 
protection afforded by an experimental boost to BCG, H56, which has been shown to prevent 
reactivation TB in cynomolgus macaques. BCG/H56 prevented establishment of disease in lung-
draining LN. BCG/H56 also mitigated lung inflammation, which reduced apparent risk of 
reactivation TB by PET-CT. Early control of disease in the lung-draining LN, as well as a T cell 
signature, was associated with reduced risk of reactivation TB. Both studies provided evidence 
that PET-CT markers correlate with outcome. We thus built a holistic outcome score based 
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 v 
strictly on quantifiable outcomes: gross pathology and bacterial burden determined at necropsy, 
and constructed models that robustly predict this outcome score early using early PET-CT 
markers. Altogether, these studies highlight the importance of the lung-draining LN as a site of 
bacterial persistence and the ability of PET-CT to assess disease and predict vaccine efficacy. 
Further work will build upon these studies to determine the best site of vaccination to prevent 
disease, and develop a blood signature correlate for use in clinical trials.  
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1.0  INTRODUCTION TO TUBERCULOSIS VACCINOLOGY 
1.1 A BRIEF HISTORY OF THE WORLD’S MOST DEADLY MICROBE 
Tuberculosis (TB) is one of the greatest infectious challenges that humanity faces. Over the last 
two centuries alone, TB has claimed the lives of over one billion people. In 2015, there were 
10.4 million new cases of TB and 1.8 million deaths, which is almost 5,000 deaths every day [7]. 
TB is a disease of poverty [8], and disproportionately affects the world’s poorest nations [7]. A 
plethora of evidence suggests that TB has been inflicting human morbidity and mortality for 
thousands of years. Skeletal remains from over 9,000 years ago bear signs of TB, as do 
mummified remains from Ancient Egypt [9]. Hammurabi’s Code, created by the Babylonian 
emperor of the same name, has the first written suggestions of TB or TB-like disease [9]. The 
first thorough description of TB was provided to us by Hippocrates around 400 BC [10], in 
which he describes ‘phthisis,’ or a generalized wasting disease characterized by fever, coughing, 
and night sweats. He posited at the time that phthisis was hereditary from the observation that the 
disease moved from a disease case to other household contacts. Since TB almost always led to 
death, he strongly advised his colleagues from visiting patients exhibiting disease so that they 
might protect their reputations. The infectious nature of TB was first hypothesized by Fracastoro 
in the 16th century [11]. In his posthumously published work, De Contagione, he suggested that 
some diseases including TB were transmitted by ‘fomes,’ or tinder in Latin. Although he was 
 2 
correct about TB’s contagious nature, this was not proven for another 300 years. TB can inhabit 
and cause disease in any physiological compartment [12], so for most of history TB was thought 
to be multiple diseases. Sylvius, observing pathological similarities between these 
manifestations, first proposed that they were all the same disease: phthisis [13]. For the next two 
centuries, until the 19th century, TB was therefore studied as a unified disease. However, during 
this period, the cause of TB was still unknown, and was thought to be anything from bad air, to 
an imbalance of humors, to vampirism [14, 15]. This all changed in 1865, when Jean Villemin 
definitively demonstrated the infectious nature of TB [16]. In this landmark study, he took 
portions of TB lesions from humans and cattle and inoculated them in rabbits and guinea pigs, 
which subsequently developed TB. The most significant study came 18 years later when Robert 
Koch presented his groundbreaking lecture, vaguely titled “The Etiology of Tuberculosis” [17]. 
Not only did Koch show that this newly identified aerobic bacterium, Mycobacterium 
tuberculosis (Mtb), was specifically the causative agent of TB, but he also ushered in a 
revolution in microbiology. Infectious disease could have specific agents that cause them, and 
therefore for the first time be targeted and eliminated.  
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1.2 CLINICAL EPIDEMOLOGY AND TRANSMISSION OF MTB 
 
Figure 1: The infectious cycle of tuberculosis (TB). Infectious aerosolized droplets are expelled from 
humans with active disease (top left). Almost a third of people exposed to these droplets form an infection (purple), 
10% of whom have primary contagious disease (red) and 90% of whom control the infection and are latent (green). 
 
There are classically two clinical manifestations of TB—active and latent (Fig. 1)—although it is 
now understood that a spectrum of disease exists. TB was demonstrated by Jean Villemin to be 
infectious in nature [16], and the identification of Mtb only further cemented this fact [17]. 
However, the aerosol component of transmission was not thoroughly elucidated until the late 
1950s. At the TB ward of Johns Hopkins University, a “penthouse” was constructed in which air 
in the ward was fed into this chamber which contained a multitude of guinea pigs [18]. This pilot 
study demonstrated that the air in the chamber was just as infectious as in the ward. A two-
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chamber experiment was then performed in which one chamber contained the air unfettered but 
the other was exposed to ultraviolet radiation [19]. The first tank of air led to TB in guinea pigs, 
whereas the sterilized air did not, demonstrating that Mtb is transmitted by aerosol. Typically, 
humans with active (but not latent) TB will eject Mtb in aerosol droplets by coughing, sneezing, 
and spitting. In a unique case study, Mtb was also shown to be transmitted in a mini-outbreak of 
a choir by singing [20].  
Approximately 30% of humans exposed to aerosol droplets containing Mtb develop an 
infection (Fig. 1), as determined in household contact studies [21, 22]. The primary method of 
diagnosing Mtb infection is the tuberculin skin test (TST) [23]. Unfortunately, vaccination with 
BCG can confound the results of this test, but Mtb-specific tests using peripheral blood 
overcome this issue [23]. Chest x-ray (CXR) has also been shown to be a highly effective 
diagnostic tool for identifying infection. Early TB and latent TB infection (LTBI) can be 
diagnosed using CXR [24]. A new skin test has been developed using Mtb-specific antigens that 
is 99.3% specific for infection in BCG vaccinated people [25]. However, one of the antigens in 
this skin test is present in a few of the novel TB vaccines in the pipeline, which will likely lead to 
cross reactivity between the new skin test and new vaccines. To overcome this, other 
biochemical markers of infection are under investigation. IP-10 is a promising new marker, as 
leukocytes from infected patients stimulated with Mtb-specific antigens produces more IP-10 
than healthy controls [26]. The African giant pouched rat can specifically detect Mtb versus 
similar bacteria using its olfactory sense with 94% accuracy, and can distinguish between sputum 
naturally inhabited by Mtb and “fake” sputum spiked with Mtb [27]. These data suggest that 
Mtb-specific volatile compounds are present in the sputum that can be further developed as a 
diagnostic.  
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The field of TB is littered with odd and fascinating studies, like the study detailing the 
outbreak in the choir [20]. Another such study was a retrospective contact study in a US Navy 
vessel, in which 66 sailors were discovered post hoc to be confined in close quarters with 7 
fellow seamen with active TB [28]. Thirteen of the sailors (19.8%) remained TST negative after 
six months of exposure to the active TB cases. In a high TB endemic setting, about 50% of 
contacts were TST negative [29]. These data suggest the ability of the innate immune system to 
control Mtb infection. Two genetic loci in a genome-wide linkage study have been associated 
with TST reactivity in similar studies, hinting that innate control of Mtb could also be genetic 
[30]. Greater bacterial burden in expelled aerosol droplets and proximity to and exposure time 
with the contact case additionally correlate with risk of developing infection [31].  
Another fascinating historical study was conducted in the Faroe Islands [32]. In some 
cases, less than a day of exposure to an active case of TB led to TST conversion and primary TB. 
Nearly all persons infected in this large longitudinal study reported for TST conversion had an 
“initial fever” and elevated erythrocyte sedimentation rate (ESR), and 63% of persons not 
selected ended up with “initial fever”, suggesting an inflammatory response that occurs 
regardless of disease outcome [33]. The risk of developing active disease after Mtb infection is 
greatest in the first 1-2 years following infection and declines exponentially afterwards, with 
about 10% of humans infected developing active disease [34]. The risk of primary disease is also 
age dependent, from 4% (ages 0-10), to 9% (10-20), and 14% (30+) [35].  
Diagnosis of active disease is based on clinical presentation of signs and symptoms, 
and/or isolation of Mtb from a patient [23]. Detection of Mtb in the sputum is relatively fast but 
suffers from a lack of sensitivity, in some instances as low as 32% [36]. Culture of Mtb from a 
patient sample is the gold standard for diagnosis, but typically takes six weeks to do with the 
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exception of some systems, e.g. BACTEC, which take about two weeks but are not available in 
all areas [37]. These data, together with the fact that 90% of infected people do not present 
clinically, paint a sorry picture, especially considering that these are the current endpoints for 
clinical trials [38]. Serum-based biomarkers have been developed that appear to distinguish 
pulmonary TB from other diseases [39], and distinguish between different manifestations of TB 
[40]. A meta-analysis in 2009 of 254 studies of serological markers of active TB determined that 
to that date they all suffered from low sensitivity and specificity [41]. What has been achieved by 
the field since then? A breakthrough transcriptomic study identified a blood signature that could 
distinguish between active TB and LTBI with 95% sensitivity and 83% specificity [42]. This 
signature correlated with extent of radiographic pulmonary disease and diminished during 
chemotherapy, and was observed in geographically distinct cohorts and separate studies [43, 44]. 
Other transcriptional signatures have also been identified that distinguish between disease states 
[45]. One only requires three genes, was validated in eight independent data sets from children 
and adults, diminished with chemotherapy, and was not confounded by HIV status, Mtb 
resistance to antibiotics, or prior vaccination with BCG [46]. In addition to transcriptional 
signatures, other putative disease-predictive signatures have been identified using cell 
phenotypes or functionality [47-51], proteomics [52], and metabolomics [53].  
As previously mentioned, active TB is the transmissible form of disease, but clinically 
latent infection (LTBI) is the more prevalent manifestation (90% of infections; Fig. 1)[23]. The 
pool of humans with LTBI is staggering, being approximately 2.3 billion people, or 1/3 of the 
world’s population [7]. Persons with LTBI have their infection under control, but have a 10% per 
lifetime risk of later developing active TB disease [23, 54]. This increases to 10% per year with 
certain co-morbidities like HIV or diabetes. These and other data therefore suggest that TB does 
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not have a binary set of outcomes (active or latent) but a spectrum of outcomes, ranging from 
total control of infection to fulminant disease [55, 56].  
Figure 2: The spectrum of TB. While classically thought of as a binary, TB outcomes are more accurately 
fit to a spectrum, from complete control of infection to fulminant disease. The control of TB depends on a balance of 
pro- and anti-inflammatory factors which are discussed in chapter 1.7 in great detail. Figure adopted from [56]. 
Copyright 2010. The American Association of Immunologists, Inc.  
 
We have provided evidence demonstrating reactivation of a subset of LTBI macaques after CD4 
or TNF depletion [57, 58], demonstrating differential risk of reactivation. In the transcriptional 
study that identified signatures of active TB and LTBI, 10-20% of LTBI patients had a blood 
signature like patients with active TB [42]. In this study and the naval vessel study, not all 
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sputum positive patients had clinical TB [28, 42]. These data together provide compelling 
evidence of subclinical disease and heterogeneity of TB. 
1.3 MOLECULAR PATHOGENESIS OF MTB 
The pathological hallmark of TB is the granuloma [59, 60]. Typically, in humans, the major site 
of pathology in the lungs is termed a Ghon focus [61]. This consists of a lesion (granuloma) 
usually near the subpleural surface or lobar fissures between the upper middle lobe or the lower 
upper lobe, and an associated lung-draining lymph node (LN) with a granuloma [62]. TB lesions 
can form cavities observable on CXR. It is thought that this is the primary mechanism of 
transmission, since 98% of patients with cavities by CXR have Mtb present in their sputum [63]. 
A wide phenotypic variety of granulomas can be found within a single host. This was noted both 
in humans [64], and by our laboratory in nonhuman primates [65].  
 
Figure 3: Histomicrographic examples of TB granulomas. The granuloma on the left is a caseous, or 
necrotizing, granuloma. The central lesion is a non-necrotizing granuloma. The granuloma on the right is a 
fibrocalcific granuloma. Magnification at 200x. Masson’s trichrome stain. 
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Granulomas form when Mtb bacilli are inhaled and begin to interact with the lung 
environment. Much of what we know about the early events are derived from mouse studies, and 
timing and events may be different in humans. Nonetheless, the mouse system provides easier 
opportunities for assessing very early events in infection. Alveolar macrophages are thought to 
be the first cell infected. However, two weeks after Mtb challenge in mice, dendritic cells, 
alveolar macrophages, and neutrophils are all equally infected by Mtb [66]. By three weeks post-
infection (p.i.), CD11bhiCD11chi dendritic cells were the most commonly infected cell type, with 
residential interstitial macrophages in second place. Mtb has myriad means of hiding in these 
phagocytic cells, which shall be discussed later in the section. These infected cells begin to 
respond by producing TNF, which induces ICAM-1 and initiates granuloma formation [67]. 
Mycobacterial lipids on their own have been demonstrated to be sufficient for granuloma 
formation [68]. The macrophages that are present in the granuloma range from classically 
activated macrophages surrounding the necrotic center of the structure, with alternatively 
activated macrophages near the periphery [69]. Infected monocytes/macrophages are not 
responsible for directly priming T cells [70]. Rather, the monocytes must differentiate into 
dendritic cells and transport the bacteria to LN and cooperate there to prime CD4 T cells. These 
infected dendritic cells then traffic to lung-draining LN carrying Mtb with them. Surface proteins 
on Mtb can bind DC-SIGN to induce IL-10, which suppresses activation and delays effector cell 
formation [71]. It also leads to a rapid expansion of T regulatory cells, which also delays priming 
of CD4 and CD8 T cells and their arrival in the lung [72]. Mtb downregulates maturation 
markers while inside dendritic cells, even in the presence of stimulatory factors like tumor 
necrosis factor (TNF), IL-1, and PGE2 [73]. The protein Rv1860, produced by Mtb, leads to loss 
of dendritic cell functions like cytokine secretion and T cell activation, which ultimately leads to 
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defective downstream T cell responses to Mtb [74]. By this point in the infection, Mtb has 
already disseminated from the lung before responses in the LN can be sent back to the lung [75]. 
Activated T cells are first observed in the LN between 8-10 days p.i., but another 12-14 days 
pass until these T cells arrive in the lung [76]. Their arrival then coincides with inhibition of 
growth of Mtb in the lung. By this point, Mtb bacilli have expanded about 40,000 fold before 
these effector cells appear [70]. After the lymphocytes seem to control Mtb infection, secondary 
lymphoid-like structures appear peripherally on the lung granulomas as observed in human and 
nonhuman primate samples [77, 78]. CCL19 and CCL21, which are characteristic chemokines of 
secondary lymphoid organs, are expressed in granulomas, and deficiency of CCR7 (a receptor 
for both chemokines) leads to poor granuloma maintenance [79]. Neutrophils may also be 
infected with Mtb, and granzyme B-producing neutrophils correlate with bacterial burden [80]. 
Infected neutrophils can carry bacteria to airways during late stage inflammation without 
cavitation in humans and nonhuman primates [81]. There is strong evidence that inflammatory 
signaling in human granulomas is spatially organized [82]. Granulomas have been found to be 
hypoxic in their core (in the region of necrosis, or caseation), which could be a mechanism of 
persistence for the bacillus [83]. A connection has been demonstrated between the hypoxic 
response of Mtb and lipid metabolism that may account for bacterial survival in these conditions 
[84]. Mtb DNA is very stable in lung granulomas and can be measured to determine total counts 
of live and dead organisms [85, 86]. Mycobacterial DNA in LTBI humans can be detected in the 
lungs, liver, spleen, and kidneys at autopsy [87]. In fact, in that study, none of the LTBI patients 
(who died of non-TB causes) had Mtb DNA exclusively in the lungs.   
How do macrophages control Mtb, and conversely how are these phagocytic cells 
subverted by infection? The main mechanism of killing, at least in the murine macrophage, is 
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through reactive nitrogen intermediates produced by activated macrophages [88]. Interferon 
gamma (IFN-γ) and TNF can activate macrophages in this fashion, and both molecules together 
result in a more bactericidal macrophage. Uptake of bacteria by opsonophagocytosis via Fc 
receptor leads to respiratory burst enabling killing [89]. Should the macrophage fail to kill Mtb, 
apoptosis may also be utilized as a defense mechanism [90]. Engulfment of apoptotic bodies that 
contain Mtb allows for greater cross presentation of antigens [91]. Induction of antibacterial 
effectors induced by both innate and adaptive signals requires the induction of autophagy in 
macrophages [92]. The atg5 gene is essential for this to occur, but other genes and conventional 
autophagy pathways are not [93]. On the other side of the coin, Mtb has evolved very many 
means of thwarting these host defense mechanisms. Uptake by most macrophage receptors, 
including mannose receptor and complement receptor 3, prevents activation of macrophages and 
leads to cholesterol-dependent prevention of phagosome-lysosome fusion [94]. Roles for toll-like 
receptors (TLR) 2, 4, and 9 have been identified for macrophage control by Mtb [95]. Prolonged 
TLR2 signaling induced by Mtb lipoproteins (LpqH, LpRG, and LpRA) inhibits expression of 
MHC II in macrophages. TLR2 may be one of the many pathways exploited by Mtb to inhibit 
MHC I cross presentation to CD8 T cells as well. Mtb has been shown to use a specific type of 
lipid (phthiocerol dimycocerosate; PDIM) to mask pathogen associated molecular patterns 
(PAMPs) on its surface [96]. Inhibition of these PDIM lipids leads to TLR-dependent 
recruitment of macrophages that can kill Mtb. EsxH, part of the ESX-1 type VII secretion 
system, targets ESCRT and by doing so can block phagosome-lysosome fusion [97]. Mtb may 
also inhibit apoptosis, which is host beneficial [98]. It achieves this specifically through the 
bacterial gene nuoG [99]. Inhibition of macrophage apoptosis leads to reduced control of Mtb 
[100]. Instead, Mtb much prefers to induce necrosis as an additional virulence mechanism [101]. 
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Mtb-driven macrophage necrosis requires ESX-1 and specifically ESAT-6 [102], a secreted 
protein discussed in detail later. Rv3167c in Mtb negatively regulates phagolysosomal escape 
and host cell necrosis [103]. Mtb also utilizes antigen export in macrophage vesicles to divert 
antigens from MHC II [104]. Blocking this export improves CD4 T cell activation.   
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1.4 NONHUMAN PRIMATES: A HUMAN-LIKE MODEL OF TB 
Many animal models are used in TB research, including mice, zebra fish, cattle, rabbits, guinea 
pigs, and nonhuman primates [105, 106]. Mice and nonhuman primates are the two more useful 
models, as the other models suffer from a lack of resources available for immunologic probing. 
Mice have their shortcomings too, as their pathology is not like humans, and they do not have 
LTBI. Thus, the nonhuman primate model is best for capturing the full spectrum of TB, in that it 
Figure 4: Our nonhuman primate model of TB. Cynomolgus macaques are infected with a low dose 
(~15 CFU) of Erdman strain Mtb. Half of the macaques will present with active TB and half will have LTBI. The 
LTBI pool of macaques can naturally reactivate but we can also induce reactivation using SIV, anti-TNF, and 
anti-CD4 treatments. 
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is human-like but also is tractable to experimentation in ways that humans infected with Mtb are 
not [107]. Nonhuman primate models were first explored in rhesus macaques (Macaca mulatta) 
in the 1970s [108, 109]. However, the cynomolgus macaque (Macaca fascicularis) was the first 
to demonstrate evidence of LTBI after low dose Mtb infection [110]. Our laboratory further 
characterized this model and have since developed it extensively.  
We demonstrated that cynomolgus macaques instilled with low dose Erdman strain Mtb 
via bronchoscope develop TB very similarly to humans [111]. 50-60% of macaques had active, 
progressive disease using clinical signs like gastric aspirates [112] and ESR [113], as well as 
CXR. The other macaques had no signs of disease in the 15-20 months of the study. There is 
evidence for LTBI in rhesus macaques using H37Rv delivered at a low dose [114]. We have 
observed formation of a Ghon complex around 5 weeks p.i. [115]. Priming of the T cells 
response was slow in this study and seen only after 4 weeks p.i. Early necropsy of rhesus 
macaques infected with H37Rv via aerosol demonstrates that Mtb reaches the hilar LN around 3 
weeks p.i. Route of challenge in rhesus influences distribution of disease but not the overall 
outcome of the challenge [116]. We have used the cynomolgus macaque model to demonstrate 
that most granulomas form from a single bacterium, and have recapitulated the heterogeneity of 
lesions seen in humans [86]. Medical imaging has been used in nonhuman primates for tracking 
disease using a variety of modalities [117, 118]. We use positron emission tomography and 
computed tomography (PET-CT), which combines a functional map (PET) of the thoracic cavity, 
depending on the PET probe used, with a spatial map (CT) [2]. PET-CT for TB will be discussed 
in length towards the end of this introduction. Comparative genomic studies have been 
performed for rhesus and cynomolgus macaques and found that, while abundant heterogeneity 
exists in each population, there is a high degree of similarity in both species to human genes 
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[119]. Every cynomolgus macaque in one study responded to Mtb epitopes defined in rhesus 
macaques and humans [120].  
1.5 THE RISE AND FALL OF BACILLE CALMETTE-GUERIN 
By the turn of the 20th century, 1 in 7 deaths was due to TB (1 in 4 deaths in children) [7]. The 
identification of Mtb as the causative agent of TB was a turning point for both the TB field and 
microbiology in general [17]. Inspired by the work of Pasteur, thoughts began to turn to 
attenuation for vaccination. In 1902, Edmond Nocard isolated a strain of bacterium from bovine 
mastitis. This bacterium, called ‘lait Nocard,’ was sent to Albert Calmette and his assistant 
Camille Guerin in 1908. After 230 serial passages, this bacterium (now known as 
Mycobacterium bovis) was no longer pathogenic in laboratory animals, and was (apparently) 
ready for trials in humans as BCG [121]. BCG was first tested in infants born from tuberculous 
mothers, and was shown to protect them from disease and to be safe generally [122]. Adoption 
was slow, and was not helped by the “Lübeck catastrophe,” in which 252 vaccinated infants were 
administered BCG accidentally laced with virulent Mtb [123]. Although 67 (27%) of the infants 
died, 68% of those who developed disease exhibited spontaneous resolution, demonstrating 
remarkable resistance to Mtb. Encouragingly, BCG showed efficacy in Europe. As BCG was 
shipped worldwide, though, other nations were reluctant still to embrace the vaccine. A large 
study in the Southern United States had shown little to no efficacy of BCG [124]. These data, 
along with a decline in TB incidence due to economic development, contributed to the decision 
to not deploy BCG in the United States, the main strategy of which was to instead identify LTBI 
patients and give them chemotherapy once available in the 1950s. This was interestingly still 
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contrary to evidence of efficacy in other parts of the world, like a study showing 77% efficacy of 
preventing disease in the United Kingdom [125], another showing efficacy for more than sixty 
years in Native Americans [126], and a very recent study demonstrating efficacy in a Norwegian 
cohort [127]. However, a massive vaccine efficacy study of BCG in Chingleput, India, using two 
versions of BCG showed zero protection [128], thus establishing that BCG has a wide range of 
efficacy depending on where it is administered. BCG demonstrated 64% efficacy against disease 
in Indian children in the United Kingdom, suggesting that variability in efficacy is not due to 
host genetics [129]. Sensitization with soil nontuberculous mycobacteria (NTM) abrogates BCG 
replication and immunity, suggesting that this could be the root of the problem in variable 
efficacy [130]. BCG vaccines in Malawi produce less IFN-γ than British vaccines, with the 
authors suggesting that NTM again are the likely cause of this variation [131]. Overall, a meta-
analysis demonstrated that while BCG does protect infants from the worst manifestations of TB 
disease, e.g. spinal or meningeal TB, it does not prevent infection and provides about 50% 
protection against later TB [132]. Genomic comparisons between BCG and Mtb have identified 
many regions of difference (RD)—deletions in genes during passage to produce BCG—between 
them [133]. BCG induces CD8 T cells in newborns that produce IFN-γ in response to Mtb [134]. 
CD4 T cells are produced in greater quantities, and typically have an effector T cell phenotype 
[135]. BCG exhibits a lack of long-lived central memory T cells, which may be why it fails to 
protect later in life [136, 137]. This was mirrored by the Norwegian BCG efficacy study that had 
shown waning of BCG efficacy over time [127]. Re-vaccination with BCG was pursued as a 
method of boosting immunity, but had no strong results [138]. Interestingly, BCG re-vaccination 
efficacy was geographically dependent (19% in Salvador to 1% in Manaus), with a negative 
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correlation between efficacy and areas with high NTM, consistent with the hypothesis that NTM 
abrogate BCG-induced immunity.  
1.6 THE MENGAGERIE OF MTB ANTIGENS 
There are approximately 4000 genes in Mtb, and therefore myriad proteins which could be 
recognized by T cells. Many different immunodominant and subdominant antigens produced by 
Mtb have been identified, and more continue to be found. One of the earliest was the Ag85 
complex, consisting of Ag85A-C, which has a role in cell wall biogenesis and fibronectin 
binding [139]. These proteins are cross reactive with NTM and are also produced by BCG [51]. 
Expression of Ag85B in BCG correlates with macrophage uptake, but Ag85B deficient BCG has 
the same efficacy as wild type BCG in mice [140]. However, BCG overexpressing Ag85 was 
shown in mice and guinea pigs to be superior to BCG in protection against TB, determined by a 
reduction in bacterial burden or increased survival [141]. ESAT-6 was first identified as a small, 
immunogenic protein from the culture filtrate of Mtb [142], and is arguably the most significant 
virulence factor that Mtb secretes. ESAT-6 stimulated IFN-γ correlates strongly with pathology 
in cattle after BCG vaccination [143]. ESAT-6 specific antibodies are some of the first detected 
during infection and increase with severity of infection [144]. ESAT-6 binds directly to TLR2 
via six C-terminal residues, and prevents cellular activation [145]. ESAT-6 can form pores and 
cause cytolysis of epithelial cells [146]. ESAT-6 can directly inhibit IFN-γ, TNF, and IL-
17 production by CD4 T cells, reduce CD25 and CD69 expression, and block proliferation [147]. 
ESAT-6 has been shown to also be an adhesin which binds to laminin, and is essential for 
dissemination of the bacterium within the host [148]. ESAT-6 permeabilizes the membrane of 
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the phagosomal compartment, allowing the contents of that compartment to mix with the cytosol 
[102]. This activates the NLRP3 inflammasome and drives type I IFN [149], which is 
detrimental to immunity against Mtb [150]. ESAT-6 uses its C-terminal region to accomplish 
this [151]. Mtb can do this and nonpathogenic mycobacteria cannot, and can be made to 
pathogenic by adding ESX-1 and ESAT-6. Recombinant BCG expressing ESAT-6, while more 
able to reduce bacterial burden after challenge, is also more virulent in mice [152], highlighting 
the potential pathogenicity of ESAT-6. CFP-10 is another small, immunodominant Mtb antigen 
found just upstream of ESAT-6 [153]. Both ESAT-6 and CFP-10 are contained in RD1, a genetic 
region deleted in BCG versus Mtb [154]. Both proteins are secreted as a 1:1 homodimer by ESX-
1, a type VII secretion system [155]. Many of the RD1 genes work together to export ESAT-
6/CFP-10 [156]. Infection of mice with Mtb lacking ESX-1 leads to poor granuloma formation 
[157], suggesting the role of this system in pathogenesis. Interestingly, while ESAT-6 alone 
inhibits IFN-γ production by CD4 T cells, ESAT-6/CFP-10 homodimers do not [147].  
TB10.4 is also essential for virulence and is in the subfamily of ESAT-6 like proteins 
[130, 158]. Over 70% of BCG vaccinees respond to this protein [130, 159]. Similar proteins to 
this that are immunodominant and recognized by BCG include Mtb32a and Mtb39a [160]. In 
LTBI patients, dominant CD4 targets are all contained in three antigenic islands [161]. This 
suggests that vaccination with only one or some of the antigens contained within will be 
ineffective. The myriad immunodominant antigens should be exciting for those wishing to 
developing vaccines. However, in a study that compared 21 strains of Mtb, most of the 491 
confirmed human CD4 and CD8 T cell epitopes are hyperconserved, i.e. conserved as well as 
housekeeping genes [162]. These data suggest that it is beneficial to Mtb for the host to mount a 
strong T cell response. Considering that one of those hyperconserved genes is ESAT-6, and that 
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ESAT-6 is critical for granuloma formation (at least in mice) [157], this also suggests that 
granuloma formation is beneficial as well. Protection of mice from Mtb challenge does not 
correlate with immunodominance by IFN- γ ELISPOT, suggesting that alternative antigens 
should be considered as well. Mice vaccinated with cryptic epitopes of ESAT-6 versus dominant 
ones show reduced bacterial burden [163]. Subdominant antigens in Mtb have indeed been 
identified. One such protein is Rv2660c, originally found to be expressed by Mtb under 
conditions of nutrient starvation and hypoxia [164]. CD4 T cells from LTBI patients respond to 
Rv2660c more than T cells from patients with active disease [165]. A report suggests that 
Rv2660c RNA may not be translated [166], but the translated protein has also been observed in 
BCG using mass spectrometry [167].  
1.7 CELLULAR IMMUNITY TO MTB 
What is known about protection from Mtb? There is a rich store of data from the last thirty years 
investing cellular mechanisms of immunity in murine, nonhuman primate, and human systems 
(Rev. in [168, 169]). CD4 T cells producing Th1 associated cytokines like IFN-γ and TNF take a 
central position in this canon, but other cell types and molecules have been shown to be just as, 
and potentially more, important. The strongest evidence that CD4 T cells are critical to immunity 
is that HIV infection greatly increases the risk of reactivation TB in humans with LTBI [170, 
171]. We have recapitulated these results in macaques, demonstrating that infecting LBTI 
macaques with SIV leads to 100% reactivation which correlates with early T cell depletion 
[172]. Interestingly, CD4 depletion by antibody only reactivates half of LBTI macaques 
suggesting both a spectrum of risk and that SIV is not simply depleting CD4 T cells in these 
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animals [58]. ESAT-6 specific CD4 T cells adoptively transferred to mice before Mtb challenge 
produce high levels of Th1 cytokines, but no protection is seen until 7 days p.i., highlighting the 
immense ability of Mtb to hide inside phagocytic cells [173]. CD4 T cells expand rapidly upon 
arrival at the granuloma to help contain Mtb [174], and may have assistance from memory 
lymphocytes residing in the tissue [167]. Direct recognition of macrophages by CD4 T cells is 
required for control of Mtb [175]. A CXCR3+ parenchymal CD4 T cell population has been 
identified that correlates strongly with protection against Mtb [176]. These cells produce less 
IFN-γ than their counterparts in circulation, and migrate rapidly to the lung parenchyma upon 
adoptive transfer. PBMCs from patients with active disease stimulated with Mtb produce more 
Th2 cytokines, while PBMCs from healthy controls produce more Th1 in response to Mtb, 
suggesting that Th2 is detrimental [177]. Mice that receive Th1 polarized cells mounted epitope 
specific protective responses, while mice that receive Th2 cells have lung fibrosis and more 
severe disease [178]. IL-4 has been implicated in TB disease in mice [179], but IL-4 mRNA is 
not observed in human granulomas [180]. Recent evidence hints that IL-4 may be present only 
within the context of helminthic co-infections [181]. The critical role of IFN-γ was demonstrated 
in KO mice, which markedly increased their susceptibility to Mtb challenge [182, 183]. IL-12 
from dendritic cells acts directly on CD4 to prime for IFN-γ production [184], and IL-12 
deficient mice were more susceptible than wild type mice [185]. Treating mice with exogenous 
IL-12 increases their survival and diminishes bacterial burden [186]. This does not occur in IFN-
γ KO mice, demonstrating that IL-12 is offering protection through IFN-γ. A case study of a 
baby with IFN-γ receptor deficiency who developed fatal BCG-induced disease complements the 
murine data [187]. Indeed, humans deficient in IL-12 receptor beta-1 chain have increased risk of 
TB disease [188], and a small deletion hotspot in human IFNGR1 is associated with dominant 
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susceptibility to mycobacterial infection [189]. Additional murine evidence depicts the essential 
role for IFN-γ produced by CD4 and its role in the CD8 response [190]. TNF also has a major 
role to play in cellular immunity, as in its absence a delay in the recruitment and activation of 
mononuclear cells occurs and leads to fatal BCG infection [191] or Mtb infection in mice [192]. 
The principal finding in humans is that anti-TNF therapy greatly increases the risk of reactivation 
TB in patients with LTBI [193]. We have also demonstrated that anti-TNF reactivates 50-75% of 
LTBI macaques [57].  IFN-γ dependent phagosome maturation in human macrophages is 
inhibited by TNF blockers [194]. Removing TNF may disturb the integrity of the granuloma in 
mice [195], likely through a reduction in inflammatory chemokines [196], although overt 
granuloma structural changes were not seen in macaques [57]. TNF blockade also interferes with 
the function of effector memory CD8 T cells by inducing their death through complement [197]. 
The expansion of γδ T cells is also stunted by anti-TNF [198].  
Clearly IFN-γ and TNF produced by CD4 T cells have important roles to play in TB. Is 
that the whole picture, though? IFN-γ levels in PBMCs and bronchoalveolar lavage (BAL) cells 
frequently correlate with poor outcomes [143, 199, 200]. IFN-γ accounts for only 30% of Mtb 
control observed in the murine lung, but about 80% of the control in the spleen [201]. Increasing 
IFN-γ in this model induces lethal pathology the lungs but increases protection in the spleen, 
suggesting that IFN-γ might control Mtb well in extrapulmonary sites but is not sufficient to do 
so in the lung, and is pathogenic in large quantities. CD4 T cells have been shown to protect 
mice independently of IFN-γ [202]. Antigen specific CD4 T cells that cannot produce IFN-γ nor 
TNF also can still protect mice from Mtb challenge [203, 204]. CD4 T cell independent 
protection can even be seen in a study where vaccination of CD4 KO mice still induces 
protection [205]. In contrast to these studies, transfer of IFN-γ deficient CD4 T cells to CD4 
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deficient mice was less protective than transfer of wild-type T cells [190]. Thus, IFN-γ and TNF, 
even CD4 T cells, are not the whole picture.  
What other putative cell types are associated with cellular immunity to Mtb? CD8 T cells 
have been shown to be important for protection against Mtb [206]. CD8 T cells can produce 
granulysin which kills Mtb directly [207]. Mice deficient in β2-microglobulin or MHC class I 
(and therefore CD8 T cells) were more susceptible than wild type mice [206]. Depletion of CD8 
in the chronic stage of Mtb infection in mice leads to increased bacterial burden, suggesting that 
CD8 are important for long term control [208]. Depletion in rhesus macaques challenged with a 
high dose of Mtb ablates the partial protection conferred by BCG in that model [209]. 
Unpublished studies from our own lab demonstrate that depletion of CD8 T cells prior to low 
dose infection of cynomolgus macaques leads to increased bacterial burden, while depletion 
during LTBI only reactivates a subset of animals. However, the role of CD8 T cells is still 
controversial as demonstrated in two vaccine studies in mice where elicitation of CD8 was either 
not protective [210] or was compensated for when absent [211].  
Regulatory T cells (Treg) have been implicated in TB pathogenesis, as depletion of these 
cells leads to a 10-fold reduction in Mtb in mice [212]. Contrary to those data, ICAM KO mice 
have fewer Treg cells due to aberrant signaling of transforming growth factor β (TGF-β) through 
SMAD3 [213], and these mice are more susceptible to Mtb challenge. In nonhuman primates, the 
frequency of Treg cells in PBMC decreases with Mtb challenge and increases in the airways 
[214]. LTBI macaques had higher Treg frequencies in PBMCs pre-challenge, while macaques 
with active TB had increased Treg cells in PBMC during challenge. It is likely that Tregs are 
important for controlling pathology, but also may impair clearance of the bacilli, and need more 
intensive study. The role of other so-called nonconventional T cells is just beginning to gain 
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appreciation. γδ T cells can lyse macrophages containing Mtb and are an early source of IFN-γ 
[215]. IL-17 production is dominated by γδ T cells [216], and these cells have shown the ability 
to generate recall responses following BCG and Mtb challenge in macaques [217]. Natural killer 
T cells (NKT) are present in humans with active TB in smaller numbers than in LTBI [218]. 
NKT may recognize glycolipids on BCG which can augment its efficacy [219]. Mucosa-
associated invariant T cells (MAIT) recognize Mtb antigens in patients with active TB [220]. 
CD1-restricted T cells, which recognize mycobacterial lipids, bind monomycolate and C32-
phosphomycoketide and are detected in PBMC of infected humans [221]. These T cells can 
produce IFN-γ and TNF, but do not vary in frequency between disease status and do not correlate 
with T cell responses to proteins [222]. MAIT cells are more prevalent in airways than in PBMC, 
and may play an early role in priming the immune response for pathogen elimination [223]. 
There is an underappreciated role for B cells in Mtb infection, which is not surprising 
since Mtb is typically an intracellular pathogen. There is some evidence that monoclonal 
antibodies against cell wall components of Mtb are protective [224]. The Mtb proteins ESAT-6, 
α-crystallin, and MSTA-10 are broadly recognized by antibodies from sera of macaques [225]. 
There is an early, transient antibody signature in LTBI macaques that stably increases in active 
TB and reactivation disease [226]. In humans, antibody levels increase with bacillary burden 
[226], but attempts to use antibody responses as biomarkers of disease have not yet been 
successful given the heterogeneity in responses in humans and macaques. B cells present 
primarily in clusters around the periphery of the granuloma and have germinal center-like 
properties [78]. B cells can regulate neutrophilia during Mtb infection and BCG vaccination by 
modulating the IL-17 response [227]. B cells readily produce pro- and anti-inflammatory 
cytokines, including IL-1β, IL-10, IL-17, IL-21, and TNF [228]. Stimulation of B cells from 
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human patients with LTBI via TLR-4 and 9 produces the greatest quantity of cytokine, and 
plasma cells (CD138+CD27-) from these individuals typically produce the most cytokines upon 
stimulation. Antibodies can be differentially glycosylated during post-translation modifications, 
and antibodies between active TB and LTBI have been recently found to have distinguishing 
patterns of glycosylation [229]. Antibodies from LTBI patients in this study had enhanced Fc 
effector profiles and were more effective at promoting intracellular killing of Mtb in 
macrophages.  
There are plenty of other cytokines and signaling entities that have been implicated to 
have a role in Mtb infection. IL-17 has been implicated in immunity to Mtb, especially when 
driven by IL-23 [230]. As previously mentioned, γδ T cells dominate production of IL-17 and 
can even generate recall to Mtb following BCG vaccination [216, 217]. IL-17 can recruit Th1 
cells, which are linked to BCG-induced protection in mice [231]. IL-17 boosted by BCG 
correlates to protection in cattle [232]. In one study, BCG-associated protection was IFN-γ 
independent but IL-17 dependent, mediated by CXCL13 induction to facilitate the localization of 
CXCR5+ T cells made in lymphoid structures near granulomas [233]. However, while 
potentially beneficial, IL-17 has also been linked to increased pathology and bacterial burden in 
the spleen, and may contribute to dissemination [234]. PBMCs from humans with active TB also 
express more IL-17 than LTBI patients [48]. IL-10 is another cytokine implicated in TB, with 
IL-10 mRNA detected in high levels in human TB lesions being mainly produced by 
macrophages [180]. Mtb is able to inhibit TNF-dependent apoptosis by inducing IL-10 
dependent secretion of soluble TNF receptor 2 from macrophages [235]. Mtb antigens can 
stimulate IL-10 production through TGF-β signaling [236]. Autocrine IL-10 production in 
macrophages induces an alternatively activated state that suppresses anti-Mtb effector 
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mechanisms without compromising T cell immunity [237]. IL-10 KO mice also have reduced 
bacterial burden in the lungs after challenge, preceded by an accelerated IFN-γ response in the 
lung via influx of CD4 T cells [234]. While IL-10 seems to contribute to Mtb pathogenesis, 
depletion of IL-10 185 days p.i. in mice leads to Mtb regrowth, essentially due to unchecked 
Th1-sponsored inflammation [238]. We have also shown that IL-17 and IL-10, when balanced, 
are the strongest correlate of sterilization within individual macaque lung granulomas [239]. 
Computational modeling supports this hypothesis [240]. Another immunoregulatory molecule, 
TGF-β, is produced in greater quantities from PBMC of active TB patients compared to LTBI, 
and can be localized in lung lesions [241, 242]. Mtb antigens can stimulate the production of 
TGF-β and IL-10 through TGF-β [241, 243]. BCG modified to express a peptide that blocks 
TGF-β confers additional protection in mice [244]. Mtb can directly stimulate monocytes to 
active TGF-β [245], and blocking TGF-β using siRNA improves TB disease in mice [246]. 
Nematode co-infection induces TGF-β which dampens the IFN-γ response, increasing the 
susceptibility of mice to Mtb challenge [247]. Not all immunoregulatory molecules are bad, 
though, as PD-1 KO mice are very susceptible to Mtb challenge, due to CD4-driven host 
inflammation and tissue destruction that does not reduce bacterial burden [248]. Type I 
interferon (IFN), while important for clearance of viruses, has been solidly demonstrated to be 
pathogenic in the context of Mtb infection. An association of bacterial hypervirulence with 
enhanced production of type I IFN has been demonstrated in the murine model, through 
suppression of Th1 [249]. In both murine and human cells, type I IFN is preferentially induced 
by Mtb in an ESX-1 dependent mechanism [250]. In a murine study utilizing intranasal 
instillation of poly(I:C), adjuvant driven type I IFN exacerbates TB disease [251]. A type I IFN 
gene signature was identified in patients with active TB in Indonesia where monocytes were 
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identified as the primary producers of this molecule [44]. The balance of type I and II IFN 
production determines the outcome of another mycobacterial disease—leprosy [252]. Induction 
of type I IFN leads to suppression of IL-1 and is detrimental for TB immunity [150]. IL-1 and 
PGE2 inhibit macrophage necrotic cell death [253]. Depletion of IL-1 promotes detrimental TB 
outcomes, whereas overproduction of IL-1 is beneficial [254]. IL-1 induces PGE2, which 
enhances the antimicrobial activity of macrophages and inhibits production of type I IFN [255].  
1.8 THE NEED FOR REAL CORRELATES OF PROTECTION 
There are currently no correlates of protection against TB. The main reason for this is that 
randomized, controlled clinical trials of effective vaccines are required to identify correlates 
[256], and there are no effective vaccines against TB. Instead, those in the TB field have sought 
to identify correlates of risk of active disease or LBTI. However, this is extremely misleading. 
LTBI is not protection, as those individuals still have a risk of developing active disease [23, 54]. 
In order to actually identify correlates, we will have to improve upon nature and confer 
something more potent that natural immunity against this disease. It is still worth an exploration 
of what is associated with disease or latency. One of the primary outcome measures in pre-
clinical and clinical trials of novel TB vaccines is the stimulation of IFN-γ, although this has 
never been shown to correlate with protection against Mtb infection [257, 258]. In fact, many 
studies suggest that IFN-γ correlates with active disease in human PBMCs [199], with pathology 
in cattle after BCG vaccination [143], and is higher in BAL cells from patients with active TB 
and drops after TB chemotherapy [200]. Protection against TB in mice conferred by BCG 
boosted by H1, a vaccine containing Ag85B and ESAT-6, does not correlate with IFN-γ 
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production in PBMCs [259]. Multifunctional T cells have been shown to correlate with 
protection in other infectious diseases where cellular immunity is important [260]. However, 
multifunctional Th1 cells in blood correlate with active TB in children [261], with active TB in 
adults [262], and with bacterial burden in macaques [263]. CD4 T cell production of IFN-γ, IFN-
γ/TNF/IL-2, and CD8 T cell production of IFN-γ do not correlate with risk of TB disease after 
BCG vaccination during the first two years of life [264]. A reduction in central memory CD4 T 
cells and increase in IL-17 were associated with active TB in adults [48]. AERAS 402, an 
experimental viral based vaccine, elicits robust cellular immune responses in macaques but these 
responses do not correlate with protection [265]. Transcriptional signatures are being 
investigated, but may be different between adults and children [266]. One study found 13 
molecules associated with protection in mice against TB shared between five experimental 
vaccines [267]. Another two studies found signatures including activated CD4 T cells associated 
with increased risk of TB disease [268, 269].  
1.9 NOVEL VACCINES FOR TB 
An effective vaccine for TB could target the disease at multiple stages. Therapeutic vaccines 
would act as host-directed therapy to ameliorate active disease. Post-exposure vaccination would 
target patients with LTBI and works to prevent active (transmissible) disease. The gold standard 
of TB vaccination would be a pre-exposure vaccine, one that prevents initial infection. However, 
since no correlates of protection to TB exist, a pre-exposure vaccination is a high bar to reach. A 
post-exposure vaccine would still be desirable since by preventing active disease, the 
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transmissible form of the disease is blocked, thereby halting transmission of Mtb. Currently, 
vaccines that target all three of these stages are in clinical development. 
 
Table 1: Vaccines utilized in this dissertation. 
 
 
 
 
 
 
Name Type Antigens Delivery Refs. 
BCG Live attenuated M. bovis (many) intradermal [132, 257, 270] 
M72 Protein subunit 
Live attenuated 
Mtb32a (Rv1196) 
Mtb39a (Rv0125) 
intramuscular 
aerosol 
[271-273] 
H56 Protein subunit ESAT-6 (Rv3875) 
Ag85B (Rv1886c) 
Rv2660c 
intramuscular 
 
[274-277] 
EB Live attenuated ESAT-6 (Rv3875) 
Ag85B (Rv1886c) 
intramuscular 
aerosol 
Experimental but similar to H1 
4ag Live attenuated ESAT-6 (Rv3875) 
Rv1733 
Rv2626 
RpfD 
intramuscular 
aerosol 
Experimental 
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The two main strategies in the vaccine field for TB are to replace BCG, or boost and/or 
broaden the immune response to BCG later in life. The majority of vaccines seeking to replace 
BCG are recombinant strains of BCG adjusted to be more immunogenic. These include strains of 
BCG that overexpress antigens (rBCG30, which overexpresses Ag85B [141, 278]), strains that 
express pore-forming toxins to allow escape to the cytosol for cross presentation of antigens 
(VPM1002 [279-281]), or strains that do both (AERAS 401 [282] and AERAS 422 [283], which 
was discontinued due to safety concerns [284]). Another approach has been to attenuate Mtb 
itself, by removing phoP and fadD26, which are major regulators of pathogenicity [285-288]. An 
attenuated Mtb strain lacking sigH has also been developed and shown efficacy in rhesus 
macaques [289]. There is a significant issue with this approach to new vaccines for TB. Since 
there can be no real replacement trial due to the partial efficacy of BCG, any vaccine must be 
given on top of BCG anyway, at least in most countries in the world. Thus boosting and/or 
broadening the immune response to BCG with heterologous vaccination is the more desirable 
strategy [290].  
The vaccine furthest along the path towards deployment in people is MVA85A, which 
contains Ag85A encoded in modified vaccinia Ankara. MVA85A was shown to be safe and 
immunogenic in adults [291], in adolescents and children [292], in BCG-vaccinated infants 
[293], and in HIV infected adults with active TB [294]. However, this vaccine completely failed 
to protect infants from either Mtb infection or TB disease [295], nor was it effective in HIV+ 
adults [296]. While this highlights the ability for clinical trials for novel TB vaccines to be 
effectively run [38], this failure should not have been surprising due to lack of efficacy in pre-
clinical models [286, 297]. This heterologous boost is now being tested through a new route of 
administration [298, 299]. Nevertheless, actual efficacy is not being assessed in pre-clinical 
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models, only peripheral immunogenicity. This approach is likely to fail as well, as peripheral 
recall responses have repeatedly been shown to not correlate with efficacy [264, 265, 295]. 
AERAS 402 is another viral vector heterologous boost that has been demonstrated to be safe and 
immunogenic in humans [300]. This vaccine did not increase protection in macaques delivered 
intramuscularly, despite generating potent immune responses to vaccine antigens [265]. This 
vaccine as well is now being investigated by different delivery routes [222, 301]. ID93 was 
developed as a heterologous protein fusion boost targeted against multidrug resistant Mtb and 
has been tested in mice and macaques [302, 303]. Administration of this vaccine during TB 
chemotherapy in mice and macaques has shown to improve clearance of Mtb over chemotherapy 
alone [303]. M72 is a fusion protein boost containing Mtb32a (Rv0125) and Mtb39a (Rv1196), 
two immunodominant Mtb proteins. This vaccine has been tested in mice [304, 305], guinea pigs 
[271], rabbits [306], macaques [273], and humans [272, 307-310]. H1 is another fusion protein 
vaccine, consisting of Ag85B and ESAT-6. This vaccine has also been tested in a variety of pre-
clinical models [311-313]. This vaccine induces long-lived central memory CD4 T cells that 
correlate with protection in mice, produce memory-associated cytokines (TNF, IL-2, or both), 
and have strong proliferative potential even after one year [314, 315]. The maintenance of 
memory is associated with Mtb control in this model, and these vaccine-specific cells can 
mobilize quickly from the LN to the lung [136, 316]. H1 has been shown to be safe and 
immunogenic in humans [317, 318]. H56, similar to H1 but includes Rv2660c, was developed as 
a multistage vaccine to engender protection against both primary TB and reactivation [274]. H56 
protects nonhuman primates from experimental reactivation with anti-TNF [275], induces a 
population of lung-homing CD4 T cells in mice [277], and is safe and immunogenic in human 
adults [276]. H4 and H28 are similar vaccines but utilize TB10.4 instead of ESAT-6 to avoid 
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confounding ESAT-6 based diagnostics. These vaccines have also been shown to be safe and 
immunogenic [315, 319]. However, ESAT-6 is responsible for most of the protection conferred 
in these vaccines, suggesting that vaccines moving forward need to contain that protein [320].  
1.10 FAILURE TO LAUNCH: THE NEED FOR NEW APPROACHES 
The fact that we now have 14 vaccines in clinical trials (for safety, immunogenicity, and 
protection) represents an enormous advance towards eradication of TB. However, significant 
roadblocks exist between where we are and the implementation of an efficacious TB vaccine. 
Three main problems are: 1) intramuscular boosting of BCG, and even intradermal 
administration of BCG, may not be the most effective routes of vaccination; 2) the vast majority 
of the vaccines in clinical trials have yet to demonstrate greater efficacy than BCG in pre-clinical 
models; and 3) the current endpoints for clinical trials are ineffectual and increase the length and 
cost of the trials.  
Evidence both old and new points to routes other than intradermal for BCG and 
intramuscular for heterologous boosting [321]. Old data in rhesus macaques vaccinated with 
intravenous BCG (1 mg) show significant resistance to Mtb challenge, with 57% of animals have 
no evidence of TB pathology 12 weeks p.i. and the rest exhibiting minimal disease [108]. 
Vaccination of rhesus macaques with aerosol BCG is not associated with adverse effects and 
protects the animals almost as well as intravenous BCG [109]. Intravenous BCG induces potent 
systemic and lung-resident CD4, CD8, and γδ T cell responses while aerosol BCG only induces 
those responses in the lung [322]. That being said, pulmonary administration of BCG induces 
higher frequencies of mucosal antibodies and γδ T cells in the lung compared to intravenous 
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BCG, which induces stronger peripheral responses [322]. Pulmonary “challenge” in TST+ 
humans with purified Mtb proteins leads to rapid expansion of T cells 48 hours later, suggesting 
that prior priming in the lung generates a memory pool capable of rapid response [323]. 
Intravenous Mtb challenge of mice leads to earlier production of Th1 in the lung [324]. 
Simultaneous intravenous/aerosol Mtb challenge in this model demonstrates early protection 
conferred by intravenous challenge to the lung challenge, suggesting that intravenous vaccination 
is a tractable strategy for control of Mtb, although perhaps difficult to implement on a wide scale, 
particularly in infants. LTBI patients have a 79% lower risk of developing active TB after 
reinfection versus uninfected individuals, hinting that prior Mtb infection in the lung generates 
local immunity to subsequent infection [325]. As previously mentioned, interference of NTM in 
BCG vaccination is seen as the major reason for lack of BCG efficacy [130, 131, 138]. Oral 
tolerance to NTM has been shown in a new study to interfere with intradermal BCG, but not 
BCG delivered by aerosol [326].  
Table 2: Adjuvants utilized in this dissertation 
Name Components Immunity Refs 
IC-31® antibacterial 11-mer peptide (KLKL5KLK) 
CpG motif (ODN1a) 
Th1/Th2 [327] 
CAF01 cationic liposome (DDA) 
glycolipid immunomodulator (TDB) 
Th1/Th17 [318, 328, 329] 
AS01E cationic liposome (DDA) 
glycolipid immunomodulator (TDB) 
Th1 [330] 
Ad5 replication-deficient human adenovirus 5 Th1 [331-333] 
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In addition to new routes of vaccination, dosing and adjuvants are also important to 
investigate. Repeated immunization has been shown to induce entry of immune cells into non-
lymphoid tissues [334]. Different adjuvants given with ID93 in mice produce different efficacy 
against Mtb challenge [335]. Different vectors or formulations of the same antigen direct the 
specificity of the adaptive response to target more or less protective epitopes [336]. For example, 
Ag85A delivered in Ad5 produces an IL-12 polarized response, while delivery in VSV induces 
more type I IFN [337]. Deliver of ID93 in two different TLR-4 agonists give slightly more 
protection against Mtb challenge in mice than having only one [338].  
New endpoints for pre-clinical and clinical trials will more effectively identify promising 
vaccine candidates reducing time and cost. As mentioned previously, PET-CT is an incredibly 
powerful tool to probe disease progression and efficacy of interventions in our human-like 
macaque model of TB [2]. High resolution CT is better than CXR at predicting active TB with a 
sensitivity of 96% versus 48% [339]. However, much of the strength of the modality comes from 
PET and the use of FDG as a probe, which incorporates into metabolically active cells. In the 
context of TB, FDG avidity in granulomas is likely conferred by macrophages, neutrophils, and 
activated lymphocytes [340]. Two different patterns of TB have been identified using PET: a 
pulmonary type more localized to the lung; and a lymphatic pattern associated with more intense 
systemic infection [341]. An increase in standard uptake values (SUV) of FDG in the thoracic 
LN occurs in household contacts who later have LTBI [342]. The maximal SUV in the lung can 
distinguish between active TB and old TB with 100% sensitivity and specificity using double 
phase PET imaging over 60 minutes [343]. Another case series has also suggested a role for PET 
to distinguish between active TB and LTBI [344]. In our cynomolgus macaque model, an early 
increase in the number of new lung granulomas and SUV predict development of active TB 
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[345]. LTBI human subjects with higher maximal SUV are at a higher risk of reactivation TB 
[346], and we have demonstrated the ability to assess risk of reactivation in macaques using PET 
[5]. PET can also be used to predict progression of HIV associated TB disease in humans [347]. 
In addition to probing disease, PET-CT has been used to investigate the efficacy of TB 
chemotherapy. The maximal SUV in LN and number of FDG-avid LN are higher in drug non-
responders [348, 349]. We have shown in cynomolgus macaques that PET-CT can evaluate drug 
efficacy [2, 350]. This technology was used to evaluate a new application of an antibiotic for 
multidrug resistant Mtb in humans [351], and the PET-CT data from that study matched our 
nonhuman primate data from a similar study [350]. Therefore, PET-CT is a robust means to 
assess TB interventions, and represents a potent and novel method to evaluate vaccine efficacy.  
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2.0  STATEMENT OF THE PROBLEM 
The World Health Organization estimates that there were 10.4 million new cases of TB in 2015 
and 1.8 million deaths, or almost 5,000 deaths every day, due to lack of an effective vaccine. 
This disease disproportionately affects the world’s poorest nations and will cost them $1-3 
trillion over the next decade. Many infants worldwide are vaccinated with BCG, but the vaccine 
has variable efficacy and does not protect against pulmonary infection, which is the most 
common form of TB. The immune responses necessary to protect against infection or disease are 
unknown, hindering the development of new vaccines. Many novel vaccine candidates are in 
development, but clinical trials are lengthy and expensive. There are no validated biomarkers for 
protection against active disease; clinical signs and symptoms are used as an endpoint measure 
instead, but can take months or years to appear.  
In this series of studies, we utilized both human-like (nonhuman primate, NHP) models 
of disease and novel vaccines to determine mechanisms of successful vaccine-induced immunity. 
Studying human TB is very challenging due to an inability to manipulate the system, accurately 
determine time, dose or strain of infection, and sample physiologic compartments besides blood. 
An animal model can overcome these obstacles. However, the most common model (murine) 
does not faithfully reflect disease progression or pathology observed in human TB. To meet this 
need, we have used one NHP model of disease (cynomolgus macaque), which presents with 
infection outcomes like humans—including latent infection—and the full spectrum of human 
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granulomas and pathology, as well as an NHP model that is more susceptible to active 
tuberculosis (rhesus macaque). The close similarity of disease to humans makes these models 
more translatable to human clinical studies than other models, while still being more tractable 
than studying actual humans. We utilized live serial PET-CT imaging, which allows us to track 
pathology and compare number and size of lesions, along with uptake of 18F-
fluorodeoxyglucose—interpreted as a general marker of inflammation. Using this advanced 
model system coupled with PET-CT, we have addressed the need for correlates of protection in 
the following aims: 
2.1 AIM 1: DETERMINE ABILITY OF PRIME-BOOST VACCINATION TO 
PROTECT AGAINST TUBERCULOSIS 
HYPOTHESIS: Prime-boost vaccination provides superior protection against tuberculosis 
compared to boost alone.  
Rhesus macaques were either unvaccinated, vaccinated with BCG, or primed with BCG 
and boosted with one of six vaccines. Outcomes were compared between these cohorts to 
evaluate the efficacy of prime-boost vaccination. Macaques were then partitioned by outcome to 
identify early markers predictive of outcome, and T cell signatures in lung-draining lymph nodes 
associated with improved outcome.  
 37 
2.2 AIM 2: CHARACTERIZE PROTECTION AGAINST REACTIVATION 
ENGENDERED BY VACCINATION 
HYPOTHESIS: Early events in lung granulomas and lymph nodes are associated with low 
apparent risk of reactivation disease. 
Cynomolgus macaques were either unvaccinated, vaccinated with BCG, or primed with 
BCG and boosted with H56:CAF01, previously shown to protect LTBI macaques from anti-TNF 
induced reactivation. Macaques were necropsied at six months post-Mtb challenge, and 
phenotypes associated with protection were characterized. This study was then repeated but 
macaques were necropsied at six weeks post-Mtb challenge. Outcomes at necropsy and 
immunological signatures in primary tissues were then identified that correspond to protection 
against reactivation. 
2.3 AIM 3: IDENTIFY PREDICTIVE MARKERS OF VACCINE EFFICACY 
HYPOTHESIS: PET-CT predicts vaccine efficacy early post-Mtb infection.  
Control macaques from a variety of past studies were utilized to develop a holistic 
outcome score. Macaques from AIM 1 and AIM 2 were then fit to this score. PET-CT and 
peripheral blood markers were then identified that correlated with outcome. 
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3.0  MODULATION OF INFLAMMATORY RESPONSE ASSOCIATED WITH 
IMPROVED OUTCOME IN THE RHESUS MACAQUE MODEL OF TUBERCULOSIS 
Data from this chapter will be incorporated with additional data from collaborators at the NIH 
NIAID Vaccine Research Center and subsequently published as a co-first author manuscript. 
3.1 ABSTRACT 
Tuberculosis (TB) is a major global health crisis. Vaccination with BCG fails to protect against 
pulmonary TB, the transmissible form of the disease, highlighting a desperate need for a new 
vaccine. The goal of this study was to evaluate prime-boost vaccination as a tractable strategy for 
combatting TB. BCG significantly reduces burden of TB in the lungs of rhesus macaques 
experimentally infected with Mycobacterium tuberculosis, the causative agent of TB. 
Recombinant human adenovirus 5 given after BCG greatly undermines the protection conferred 
by BCG. Macaques with lower lung inflammation assessed by PET-CT have better outcomes at 
the conclusion of the study. Lung-draining lymph nodes, but not lung granulomas, exhibited 
different frequencies of cytokine-producing T cells between better and worse outcomes. This 
study demonstrates the success of PET-CT as a predictive tool and presents a need to continue 
investigating routes of vaccination and types of regimens. 
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3.2 INTRODUCTION 
An estimated one billion people have succumbed to tuberculosis (TB) over the past two centuries 
[7]. Bacille Calmette-Guérin (BCG) was developed between 1908 and 1921 to curb the mortality 
inflicted by this disease [122, 352]. The deployment of this vaccine and industrialization of the 
western world greatly reduced the incidence of TB in the developed world [132, 353], but it still 
greatly impacts much of the rest of the world [7]. 100 million doses of this vaccine are given 
annually, protecting infants from the worst manifestations of TB but not protecting adolescents 
and adults from pulmonary infection and disease [7, 132]. A modern study of BCG efficacy in 
Norway demonstrates 60% efficacy at preventing TB disease for the first two decades of life 
declining to 40% in the second two decades [127]. Interestingly, in a study in human infants, 
BCG generates both high and low inflammatory responses, and neither correlate with risk for 
Mtb infection [264]. The primary new strategies that seek to bolster the waning immunity 
conferred by BCG are the replacement of BCG with a new live attenuated vaccine and boosting 
and/or broadening of the initial response to BCG [354]. Since BCG does confer partial efficacy 
to infants [132], any clinical trial cannot exclude BCG, which makes the replacement of BCG 
unlikely. Therefore, much of the attention of global health agencies is on this prime-boost 
strategy.  
Thirteen vaccine candidates are in clinical trials [355], and many more are in pre-clinical 
trials [356], all employing a variety of antigens and delivery systems. The lack of both an 
effective vaccine and complete natural clearance of Mycobacterium tuberculosis (Mtb; the 
causative agent) means that there are no correlates of protection against infection. Th1 and Th17 
type immunity have been shown in animal models and humans to a lesser extent to be important 
for control of Mtb (Rev. in [169]). Vaccination with BCG has been shown in humans to promote 
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Th1 cellular immunity [137]. Two subunit vaccines developed to boost and broaden the immune 
response to BCG are M72 and H56, both in human clinical trials [355]. M72 is composed of two 
proteins, Mtb32a and Mtb39a, and has been shown to enhance Th1 immunity in murine [305], 
guinea pig [271], rabbit [306], and cynomolgus macaques [273] as Mtb72F delivered in a variety 
of systems. This vaccine shows similar immunogenicity in humans as M72 delivered in AS01E 
[330], an adjuvant that elicits Th1 immunity through TLR4 [357]. H56 is composed of three 
proteins, ESAT-6/Ag85B/Rv2660c, and has been demonstrated to provide protection from Mtb 
infection pre- and post-Mtb exposure in the murine model [274], and protects cynomolgus 
macaques from anti-TNF induced reactivation [275]. H56 delivered in CAF01, a liposomal 
adjuvant designed to elicit Th1 and Th17 immunity [328], is thought to mediate protection 
through long-lived central memory CD4 T cells [315, 316] and by generating CD4 T cells that 
express lung homing markers and efficiently migrate to that site [277]. However, eliciting these 
responses in T cells in the blood through vaccination has yet to pan out to successful 
prophylaxis. To wit, the first novel human TB vaccine elicited strong recall responses in the 
blood and yet exhibited no efficacy in preventing Mtb infection in the lung [295]. Additionally, 
studies in human infants show that BCG elicits multifunctional CD4 T cells that are not 
associated with protection against active TB disease [264]. Our laboratory and others have 
demonstrated that T cell responses in the blood do not match those seen in the lung [239, 263], 
suggesting that a blood signature, unless correlated with outcome, is a poor measure in and of 
itself. This highlights the need for new outcome measures and tools to assess vaccine efficacy in 
pre-clinical models to downselect promising candidates to advance into humans. 
The goal of this study was to evaluate prime-boost vaccination as a tractable strategy in 
combatting TB. We sought to compare two routes of booster vaccination: subunit vaccination in 
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adjuvants delivered intramuscularly; and antigens encoded in non-replicative adenovirus vectors 
delivered intramuscularly and by aerosol. This is the first nonhuman primate study to directly 
compare intramuscular vaccination to intramuscular and aerosol vaccination, or to compare the 
same vaccine as a protein fusion or in a viral vector. This allowed us to compare both the ability 
of these systems to enhance the efficacy of BCG and to directly compare the routes of 
vaccination and antigens delivered. We also demonstrate the use of PET-CT as a powerful tool to 
assess outcome early after Mtb challenge, and highlight the role of the lung-draining lymph 
nodes (LN) as critical sites of immunity against TB. 
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3.3 RESULTS 
3.3.1 Humane endpoint as an outcome measure 
Table 3: Cohorts in study and vaccination schedules. This table describes the eight separate groups in this 
the study, along with number of macaques in each group (n), their prime vaccination, boosts including antigen and 
vehicle, and an abbreviated schedule with route information (see materials and methods for more detail concerning 
boosts, dosing, route, and the schedule). i.d.=intradermal. i.m.=intramuscular. aero=aerosol. 
 
 
 
 
Sixty-four rhesus macaques were utilized for this study (Table 3): unvaccinated controls 
(Control, n=12); macaques vaccinated with BCG Danish only delivered i.d. (BCG, n=8); 
macaques vaccinated with BCG boosted by protein subunit vaccines (H56 in adjuvant CAF01, 
n=6; M72 in adjuvant AS01E, n=8) delivered twice i.m.; macaques vaccinated with BCG 
boosted by a non-replicative human adenovirus 5 (Ad5) vector containing no antigen delivered 
Group n Prime Boosts Boost schedule 
1 12 PBS --- --- 
2 8 BCG (i.d.) --- --- 
3 8 BCG (i.d.) M72:AS01E Weeks 16 and 20 (i.m.) 
4 6 BCG (i.d.) H56:CAF01 Weeks 20 and 25 (i.m.) 
5 7 BCG (i.d.) Ad5(empty) Week 25 (i.m. and aero) 
6 8 BCG (i.d.) Ad5(M72) Week 20 (i.m. and aero) 
7 8 BCG (i.d.) Ad5(EB) Week 20 (i.m. and aero) 
8 7 BCG (i.d.) Ad5(4ag) Week 25 (i.m. and aero) 
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once i.m. and by aerosol as a control (BCG-Ad5(empty), n=7); and macaques vaccinated with 
BCG boosted by Ad5 containing three antigen sets (ESAT-6/Rv1733/Rv2626/RpfD, n=7; 
ESAT-6/Ag85B, n=8; M72, n=8) delivered once i.m. and aerosol. During vaccination, our 
collaborators at the NIAID Vaccine Research Center (VRC) collected immunologic data 
including bronchoalveolar lavage (BAL) cell responses to vaccine antigens, as well as responses 
from peripheral blood mononuclear cells (PBMCs). The rhesus macaques were transferred to us 
and then at 30 weeks post-BCG vaccination challenged with via bronchoscope with low-dose (8-
16 CFU) Mtb Erdman strain. 
 
Figure 5: A comparison of the percent of macaques in each group that reached humane endpoint before the 
conclusion of the study. Reaching human endpoint was determined by clinical criteria described in the materials and 
methods. Difference between the groups was assessed using the Mantel-Cox test with p value directly reported.  
 
The pre-determined endpoint of the study was 6 months post-infection, at which time 
animals were necropsied. Any animals reaching humane endpoints were necropsied earlier using 
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defined clinical criteria (see Materials and Methods). We observed significant differences in the 
numbers of macaques in each group who reached humane endpoint before the conclusion of the 
study (p=0.0045; Fig. 5). Two thirds (66.67%) of the control animals reached humane endpoint 
before the conclusion of the study. Vaccination with BCG improved general welfare of the 
macaques, with only about a third (37.5%) reaching humane endpoint before 6 months. Boosting 
BCG had variable impact upon this outcome measure, from 25% (BCG+M72:AS01E) to 66.67% 
(BCG+H56:CAF01) reaching humane endpoint before 6 months. Boosting BCG with empty 
Ad5 greatly increased the macaques’ susceptibility to Mtb, as none of the animals reached the 
end of the study.  
3.3.2 BCG confers protection against TB disease 
We first assessed the ability of BCG to protect rhesus macaques using our outcome measures: 
Figure 6: A comparison of control macaques to BCG vaccinated macaques. Each dot represents one 
animal and bars represent medians. Comparisons were done using the Mann-Whitney test with p values reported.  
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i.e. total bacterial burden in the lung and lymph nodes (LN), extrapulmonary pathology observed 
grossly, and total lung inflammation assessed by PET, where total lung inflammation is the sum 
of all image voxels of FDG-avid lung pathology. Previously published data have shown variable 
effects of BCG on protection in macaques, although several of these studies used high dose Mtb 
challenge [286, 358]. We show that BCG does induce some level of protection against disease 
progression following low dose challenge (Fig. 6). Compared to unvaccinated animals, there was 
a significant reduction in total CFU in the lungs (nearly 100-fold, p=0.0091), but not in the 
thoracic lymph nodes. We also observed a significant reduction in extrapulmonary involvement 
(p=0.0231), and in lung inflammation (p=0.0328). This protection was associated with 
significant increase of IFN-γ ELISPOT responses to culture filtrate protein (CFP, pan-
mycobacterial) before challenge, and a trend towards lower responses after challenge (Fig. 7).  
Figure 7: Antigen-specific IFN-γ responses to CFP (pan-mycobacterial stimulation) before challenge or 
six weeks post-challenge between control macaques to BCG vaccinated macaques. Each dot represents one animal 
and bars represent medians. Comparisons between the groups were done using the Mann-Whitney test with p 
value reported. SFU=spot forming units.  
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BCG was not effective at preventing establishment of infection, as determined by similar 
numbers of lung granulomas in unvaccinated and BCG vaccinated animals at 4 weeks post-
infection (Fig. 8). However, BCG vaccinated macaques have fewer lung granulomas than 
controls at 8 weeks (p=0.0306), 12 weeks (p=0.0301), and 16 weeks (p=0.0477) after Mtb 
challenge. BCG vaccinated macaques also have less total lung inflammation p.i. at 4 weeks 
(p=0.0026), 8 weeks (p=0.0099), and 20 weeks (p=0.0304). At 4 weeks p.i., we observed fewer 
involved LN by PET (p=0.0089). Thus, BCG is at least partially effective in this model system.  
Figure 8: PET-CT markers from challenge until necropsy between control macaques to BCG vaccinated 
macaques. Each line represents one animal. Comparisons of markers between groups was done using the Mann-
Whitney test (* indicates significant difference) with p values reported in the text. Left Time points with significant 
difference were 4, 8, and 20 weeks p.i. Center Time point with significant difference was 4 weeks p.i. Right Time 
points with significant difference were 8, 12, and 16 weeks p.i. 
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3.3.3 Protein fusions do not improve BCG-induced protection 
We next sought to assess the impact of boosting BCG with protein fusions containing Mtb and/or 
BCG antigens on outcomes in specific compartments of the rhesus macaques. Neither M72 or 
H56 protein fusions in adjuvants was effective at boosting BCG-induced protection using these 
outcome measures (Fig. 9). Surprisingly, a trend towards increased lung bacterial burden with 
protein boost was observed (top left).  There was no effect on LN bacterial burden or lung 
inflammation, but there was a trend towards decreased extrapulmonary pathology with 
M72/AS01E boost (bottom left).  
Figure 9: A comparison of BCG vaccinated animals to animals vaccinated with BCG and protein subunit 
vaccines delivered in adjuvant. Each dot represents one animal, and bars represent medians. Comparisons were done 
using Dunn’s multiple comparisons. None of the comparisons were statistically significant. The values for the 
controls are shown for comparison but were not included in the statistical analysis. 
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There was no difference in early IFN-γ ELISPOT responses between any of the cohorts (Fig. 
10). There was additionally no difference in amounts of inflammation in the lung by PET 
between the groups (Fig. 11).  
Figure 10: Antigen-specific IFN-γ responses to vaccine antigen peptide pools (indicated above) before 
challenge or six weeks post-challenge between BCG vaccinated macaques and BCG and protein subunit vaccines 
delivered in adjuvant. Each dot represents one animal and bars represent medians. Comparisons between the groups 
were done using the Kruskal-Wallis test (KW, left) or the Mann-Whitney test (right). None of the comparisons were 
statistically significant. SFU=spot forming units.  
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An increased number of lung granulomas was observed at 4 and 8 weeks p.i. in the 
BCG+H56:CAF01 group versus the BCG+M72:AS01E group (p=0.0125 and p=0.0078 
respectively), and versus BCG alone at 4 weeks p.i. (p=0.0263). BCG+M72:AS01E vaccinated 
macaques had fewer inflamed or necrotic LN by PET than BCG vaccinees at 8 weeks p.i. 
(p=0.0302). Thus, these two different protein fusions were ineffective at boosting BCG-induced 
protection in this model. 
Figure 11: PET-CT markers from challenge until necropsy between BCG vaccinated macaques and 
BCG and protein subunit vaccines delivered in adjuvant. Each line represents one animal. Comparisons of 
markers between groups was done using Dunn’s multiple comparisons test (* and # indicate significant 
difference) with p values reported in the text. Center Time point with significant difference was 8 weeks p.i.  
Right Time points with significant difference were 4 and 8 weeks p.i. 
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3.3.4 Adenoviral vectors do not improve protection conferred by BCG 
Next, we assessed the ability of a viral vector to boost BCG-induced protection. As a control, we 
administered empty Ad5 to BCG-vaccinated animals. Surprisingly, this empty viral vector 
significantly increased the bacterial burden in the lung (p=0.0072) and the total lung 
inflammation by PET (bottom right, p=0.0554), compared to BCG alone. While not statistically 
significant, boosting with Ad5 containing antigens seemed to partially rescue the increase in lung 
bacterial burden and total lung inflammation. We also observed a trend towards addition 
protection over BCG alone against extrapulmonary pathology, particularly in the Ad5-
Figure 12: A comparison of BCG vaccinated animals to animals vaccinated with BCG and antigens 
delivered in Ad5. Each dot represents one animal, and bars represent medians. Comparisons were done using 
Dunn’s multiple comparisons and p values are directly reported. The values for the controls are shown for 
comparison but were not included in the statistical analysis. 
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Ag85B/ESAT6 group (bottom left). There was no effect on lymph node bacterial burden. Our 
collaborators at the VRC have shown that Ad5-containing Mtb antigens delivered i.m. and by 
aerosol leads to high levels of Mtb-specific CD4 and CD8 T cells in the lungs (Fig. 13). 
Although some macaques have as many as 20% of memory CD4 and 50% of memory CD8 
responding to vaccine antigens, none of the animals have improved outcomes, suggesting that 
even strong recall in the BAL is not sufficient for vaccine-induced protection. Recall responses 
to various vaccine antigens were observed by IFN-γ ELISPOT with some significant differences 
Figure 13: Frequency of memory T cells in BAL fluid that produce cytokines in response to vaccine-
specific antigen peptide pools in macaques receiving an Ad5 boost by aerosol. Top panels are CD4 T cells and 
bottom panels are CD8 T cells. Responses to vaccine antigens are split by each antigen, e.g. M72 by its two 
antigens Mtb32a and Mtb39a, indicated underneath and grouped by vaccine regimen. Each dot represents one 
animal and bars represent medians. Data collected by our collaborators at the NIAID VRC. 
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between cohorts (Fig. 14). There was no difference during challenge between the vaccine 
regimens for most of the PET-CT markers (Fig. 15). Macaques vaccinated with 
BCG+Ad5(empty) had significantly more granulomas than BCG (p=0.0183), BCG+Ad5(EB) 
(p=0.0047), and BCG+Ad5(M72) (p=0.0027) at 4 weeks p.i., and those same groups at 8 weeks 
p.i. (p=0.0384, p=0.0072, and p=0.0026 respectively). Thus, the delivery of antigens via the Ad5 
viral vector, even when up to 4 antigens were incorporated into the viral vector, was ineffective 
at boosting BCG-induced protection, and in fact was detrimental in several compartments.  
Figure 14: Antigen-specific IFN-γ responses to vaccine antigen peptide pools (indicated above) before 
challenge or six weeks post-challenge between BCG vaccinated macaques and BCG and antigens delivered in 
Ad5. Each dot represents one animal and bars represent medians. Comparisons between the groups were done 
using the Kruskal-Wallis test (KW) and Dunn’s multiple comparisons with p values reported. SFU=spot forming 
units.  
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Figure 15: PET-CT markers from challenge until necropsy between BCG vaccinated macaques and BCG 
and antigens delivered in Ad5. Each line represents one animal. Comparisons of markers between groups was done 
using Dunn’s multiple comparisons (* # + indicate significant difference) with p values reported in the text. Right 
Time points with significant difference were 4 and 8 weeks p.i. 
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3.3.5 Direct comparison of protein vs viral vectored vaccines 
This study provided the opportunity to compare the ability of protein vs viral vector boost using 
the same antigens, namely M72. Direct comparison of M72 protein to adenoviral vector, as 
boosts to BCG showed no differences, with the exception of a trend hinting that delivery of 
protein in adjuvant by i.m. gave slightly better protection against extrapulmonary pathology (Fig. 
16, bottom left, p=0.0928). There was no difference between these routes of administration in 
PET-CT markers during challenge as well (Fig. 17). We also compared the protein H56 in 
adjuvant to Ad5-EB; these share two antigens (Ag85B and ESAT6), but H56 also contains the 
protein Rv2660c [274]. No difference was observed between the protein and adenoviral vaccine 
Figure 16: A comparison of BCG and protein subunit vaccines delivered in adjuvant with BCG and 
antigens delivered in Ad5. Each dot represents one animal, and bars represent medians. Comparisons were done 
using the Mann-Whitney test and p value was directly reported. 
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here either, in any of our outcome measures at necropsy.  BCG+Ad5(EB) vaccinated macaques 
had fewer lung granulomas at 4 weeks p.i. (p=0.0188) and 8 weeks p.i. (p=0.0097) than 
BCG+H56:CAF01 vaccinees. Thus, we did not find major differences between protein or 
adenoviral-vectored vaccines as boosts to BCG in this model, with neither type of vaccine 
improving upon BCG vaccination.  
Figure 17: PET-CT markers from challenge until necropsy between BCG and protein subunit vaccines 
delivered in adjuvant with BCG and antigens delivered in Ad5. Each line represents one animal. Comparisons of 
markers between groups was done using the Mann-Whitney test (* indicates significant difference) with p values 
reported in the text to specifically compare the two regimens with M72, and to compare the regimens with H56 
and EB. Right Time points with significant difference were 4 and 8 weeks p.i. 
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3.3.6 Stratifying outcome of macaques based on quantifiable measures 
The data we have presented thus far, while not showing an appreciable improvement in outcome 
using any of the prime-boost strategies, demonstrate a wide spectrum of outcomes within each 
cohort, with some macaques doing very well and others doing quite poorly (Fig. 18). 
 
Figure 18: Radiologic examples of spectrum of TB disease in rhesus macaques. Representative PET-
CT scans from 1-3 days prior to necropsy. The left two panels are examples of rhesus macaques with better and 
worse outcomes from the control cohort, and the right two panels are examples of macaques with better and worse 
outcomes from among the vaccinated cohorts.  
 
Instead of using vaccination as a proxy for improved outcome, a cluster analysis could be used to 
separate the macaques in this study into groups based upon similarity of overall outcome. Then 
correlates of improved outcome, and immune responses at necropsy associated with better 
outcomes, could be identified regardless of vaccine regimen. A cluster analysis groups data 
points (in this case macaques) together into clusters based upon parameters (here, outcomes at 
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necropsy) so that members of one group are more similar than those of other groups. K-means 
clustering [3] uses the variability in parameters (outcomes at necropsy) to plot data points 
(macaques) on a subspace and then identifies the most likely way to generate k clusters based on 
those points. Using gross pathology and bacterial burden at necropsy with k=3, k-means 
clustering was utilized to identify three groups separated by their variability in outcomes at 
necropsy (Fig. 19, top). How exactly, though, are these three groups separated by variability in 
outcome? We used principal components analysis (PCA) to explore how each of the outcome 
measures contributed to the generation of these three groups. K-means clustering creates a space 
known as the cluster centroid subspace on to which the clusters are mapped, which has been 
Figure 19: Partitioning the macaques in the study based on outcome. Using the outcomes in previous 
figures, the macaques were partitioned into three major groups using k-means clustering [3]. The top plot contains 
the three clusters generated by this tool, colored according to outcome: worse (red), middle (blue), and better 
(green). Each dot represents one animal. The bottom left panel contains eigenvalues for each principal component 
(PC). The bottom right table contains loading values for each significant PC. These PCs are indicated in the top 
graph, i.e. PC1 as “worse outcome” and PC2 as “LN” versus “lung”.  
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shown to be identical to the subspace spanned by principal components in PCA [359]. The 
centroid subspace here was then mapped to a PCA subspace to identify the relationships between 
outcome measures (i.e. pathology and CFU) that are separating the animals into three groups. 
Using the Kaiser rule, which dictates that only components with eigenvalue greater than one 
significantly impact variability [4], two principal components (PC) were identified as significant 
(Fig. 19, bottom left). PC1 represents the x-axis of the clustering subspace. The loading values 
indicate how strongly each outcome impacts the variability due to that component (Fig. 19, 
bottom right) [360]. Since PC1 contains loading values that are mostly all strongly positive, this 
likely indicates that PC1 represents outcome holistically (“worse outcome”). Thus, the more 
positive along the x-axis the macaque is, the worse all the outcome measures are, and vice versa. 
PC2 represents the y-axis of the clustering subspace, and has positive loading values for 
outcomes associated the lung, and negative loading values for outcomes associated with LN and 
other extrapulmonary sites, suggesting that when disease is more severe in one of those 
compartments it is less severe in the other (“LN” versus “lung”). The clusters are arranged left to 
right, or along the x-axis (PC1; overall outcome), suggesting that red represents macaques with 
worse outcomes (n=15), blue macaques in the middle of the spectrum (n=24), and green 
macaques with better outcomes (n=23). Thus, k-means clustering was used to partition the 
macaques into three groups based on quantifiable outcome measures at necropsy, and PCA was 
used to demonstrate that overall outcome drives the differences between the clusters and balance 
of TB in the lungs or in the LN and extrapulmonary sites drives the differences within the 
clusters. K-means clustering and PCA are tools that can therefore be used in vaccine studies with 
lots of variability in outcome to tease out the factors that drive the variability and separate 
subjects by outcome, regardless of treatment cohort.  
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Control animals belong to each of these three groups in relatively similar numbers (Fig. 
20). Vaccinated animals, with the exception of BCG boosted by empty Ad5, have relatively 
fewer animals with worse outcomes. However, boosting with empty Ad5 resulted in no animals 
with “better” outcomes, and nearly 60% of this group was in the worse outcome category. An 
interesting trend emerged in this analysis of outcome in the prime-boost cohorts, where boosting 
BCG either increased the number of macaques having a middle outcome (BCG+Ad5(4ag)) or 
increased the number of macaques both having better and worse outcomes (BCG+Ad5(EB)). 
Thus, vaccination in general reduces the incidence of the worst TB disease outcomes. 
3.3.7 Early control of host inflammation correlates with improved outcome 
We have demonstrated that we can sort the animals from this study into categories by worse, 
middle, or better outcomes (Fig. 20). Using the IFN-γ ELISPOT data (Fig. 7, 10, 14) before and 
Figure 20: These graphs display the percentage of each study group (i.e. vaccine regimen) that belong to 
each outcome. 
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after Mtb challenge after stimulation with CFP (pan-mycobacterial), ESAT-6, and CFP-10 (both 
Mtb specific), we sought for differences at these early time points in recall response of macaques 
with better and worse outcomes. There was no significant difference in IFN-γ prior to challenge 
between the two groups of outcomes (Fig. 21, top panels). Six weeks post-Mtb challenge, the 
macaques that would later have better outcomes had significantly fewer T cells in blood that 
produced IFN-γ in response to mycobacterial stimulations (Fig. 21, bottom panels). These data 
indicate that increased peripheral responses to Mtb antigens after infection correlate with poor 
outcome. This is likely due to Mtb proliferation early in monkeys that are not controlling 
infection, resulting in stimulation of T cell responses.  
We also utilized PET-CT markers similar to above (Fig. 8, 11, 15, 17) to see whether we 
Figure 21: Early suppression of peripheral IFN-g response associated with improved outcome. The top 
panels are IFN-g ELISPOT responses from PMBCs two weeks before Mtb challenge, and the bottom panels are 
responses six weeks post-Mtb challenge. Each dot represents one animal, and bars represent medians. Comparisons 
were done using the Mann-Whitney test with p values directly reported. SFU=spot forming units. 
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could distinguish between better and worse outcomes early post-infection. Total lung 
inflammation as determined by PET at 8 and 12 weeks p.i. was significantly higher in the 
animals with worse outcomes (Fig. 22). Macaques with worse outcomes also exhibited more 
FDG-avid LNs at 8 weeks p.i., and formed more granulomas between 4-12 weeks p.i., indicating 
dissemination of infection (Fig. 22). These data suggest that modulation of lung inflammation 
early is related to control of TB disease. Early reduced IFN-γ responses and PET-assessed 
inflammation could be useful as indicators of vaccine effectiveness, and this is explored further 
in chapter 5. 
Figure 22: Less inflammation in the lung and LNs early corresponds to better outcomes. The top panels 
are PET-CT markers at 8 weeks post-Mtb infection and the bottom panels are PET-CT markers at 12 weeks post-
Mtb infection. Each dot represents one animal, and bars represent medians. Comparisons were done using the 
Mann-Whitney test with p values directly reported. 
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3.3.8 Modulation of T cell activity in the LN, but not lung granulomas, associated with 
improved outcome 
At necropsy, we assessed T cell function in individual lung granulomas and lung-draining LNs. 
There was no difference in CD3+ T cell function in cells from lung granulomas from animals 
with better outcomes versus worse outcomes (Fig. 23). T cells from lung-draining LNs either 
received no exogenous stimulation (Fig. 24A; i.e. were only stimulated by Mtb antigens already 
present in the LN at necropsy) or were stimulated with PDBU and ionomycin (P&I) to assess 
capabilities of cytokine production (Fig. 24B). There were lower frequencies of cytokine-
Figure 23: Immunologic differences in cytokine-producing T cell frequencies from lung granulomas 
between animals with better and worse outcomes. For the bar graphs, the bars represent interquartile ranges and 
the thick line represents the median. Comparisons were done using the Mann-Whitney test. For the pie graphs, the 
dark portion of the central pie represents single cytokine-producing T cells and the white portion represents 
multifunctional T cells. Comparisons of pie graphs was done using a permutation test as previously described [6]. 
None of the comparisons (Mann-Whitey or permutation) were statistically significant.  
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producing T cells that were multifunctional, single functional, or producing any cytokine at all in 
LNs from macaques with better outcomes (Fig. 24A). These LNs also had lower frequencies of T 
cells producing IFN-γ, interleukin-2 (IL-2), and tumor necrosis factor (TNF) (Fig. 24A). LNs 
from macaques with better outcomes contained relatively lower frequencies of T cells producing 
Figure 24: Immunologic differences in cytokine-producing T cell frequencies from LNs between animals 
with better and worse outcomes. For the bar graphs, the bars represent interquartile ranges and the thick line 
represents the median. The pound sign indicates a significant difference between the outcomes using the Mann-
Whitney test. For the pie graphs, the dark portion of the central pie represents single cytokine-producing T cells and 
the white portion represents multifunctional T cells. Comparisons of pie graphs was done using a permutation test as 
previously described [6]. A These T cells were not exogenously stimulated with Mtb antigens. B These T cells were 
stimulated with phorbol 12, 13-dibutyrate and ionomycin. 
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IL-2 and higher frequencies of T cells producing interleukin-6 (IL-6) (Fig. 24A). These LNs also 
contained relatively more multifunctional T cells than LNs from animals with worse outcomes 
(Fig. 24A). While on their own LNs from animals with better outcomes have lower frequencies 
overall of cytokine-producing T cells (Fig. 24A), LNs from both groups of macaques were 
equally capable of making the same frequencies of cytokine-producing T cells (Fig. 24B). LNs 
from both groups were also equally capable of producing most cytokines in this study, with the 
exception of TNF, of which the LNs from macaques that fared better were capable of making 
higher frequencies of TNF-producing T cells (Fig. 24B). LNs from macaques with better 
outcomes contained relatively lower frequencies of T cells capable of making IFN-γ and 
relatively higher frequencies of T cells capable of making TNF (Fig. 24B). These LNs also 
contained relatively higher frequencies of T cells capable of being multifunctional (Fig. 24B). 
These data highlight the overall immune responses that are associated with control of Mtb in this 
model system.   
3.4 DISCUSSION 
The goal of this study was to assess whether boosting BCG by a variety of strategies was capable 
of conferring additional protection against Mtb challenge in a nonhuman primate (rhesus) model 
of TB. Rhesus were chosen due to their increased susceptibility to developing TB, and we 
reasoned that this model would provide a good option for identifying protective regimens. We 
demonstrated that with the selection of therapeutics utilized in this study that boosting BCG with 
subunit protein vaccines in adjuvant or with antigens encoded in an Ad5 viral vector did not 
provide any additional protection on top of BCG. BCG on its own did provide appreciable 
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protection to Mtb challenge. We then partitioned the macaques in this study by outcome, 
demonstrated the powerful ability of PET-CT to distinguish between good and bad outcomes 
early post-infection, and identified immune signatures in lung-draining LNs associated with 
relative protection against TB.  
When comparing the different types of vaccines in this study, BCG gave the best 
protection against Mtb challenge in our model, although many of these animals still presented 
with disease. None of the vaccine regimens prevented infection. BCG so far is the only TB 
vaccine with demonstrated efficacy against any manifestation of tuberculous disease in humans, 
albeit not against pulmonary TB [132]. In this study, boosting BCG did not provide additional 
protection from disease. These data are mirrored in human studies, where a BCG antigen 
(Ag85B) delivered in modified vaccinia Ankara (MVA) failed to provide additional protection 
from BCG [38]. Another goal of this study was to determine whether lung-targeted vaccination 
was efficacious in boosting BCG, and more efficacious than vaccination administered only by 
i.m. While both of these questions resulted in generating moot answers, interestingly a control 
group (BCG boosted by empty Ad5) provided a strong, albeit negative, signal. Ad5 has been 
shown to elicit strong T cells responses, especially type I interferon responses via its shaft 
protein [331], which are detrimental to successful immunity to TB infection [42, 252, 361]. 
Indeed, the monkeys in this study had strong T cell responses in the lungs following Ad5-antigen 
vaccination. This could explain the increase in susceptibility in this study, but also suggests that 
immune polarization in the lung could either break, or potentially make, protection to TB. 
Vaccine systems that promote type I interferon should therefore not be utilized for tuberculosis, 
and systems that instead promote immunity shown to be efficacious against Mtb, e.g. Th1 and 
Th17 [169], should be investigated within the context of the lung. Once an ideal delivery system 
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is chosen, the antigens or attenuated organism delivered should then be picked. BCG’s efficacy 
in this study would suggest that live vaccines should be of particular interest [362], including 
BCG delivered to the lungs or intravenously, which has been mildly investigated [108, 109, 363].  
One of the major gaps in vaccine development for TB is the desperate need for new 
outcome measures. Current clinical trials for efficacy typically use two endpoints: isolating Mtb 
from a study subject or a clinical diagnosis of TB [295]. These endpoints can take months to 
years to appear, or never at all, and the diagnostic methods are not the most sensitive and are in 
need of improvement [364]. In this study we demonstrate the use of statistical methods to 
partition animals by outcome [3], allowing one to explore factors associated with variability in 
outcome. BCG in this study reduced the number of rhesus macaques having the worst TB 
outcomes, a phenotype that is mirrored in the efficacy of BCG preventing the worst outcomes 
(e.g. Pott’s disease and meningitis) in human infants [132]. While boosting BCG does not appear 
to provide additional protection in this study, an interesting phenotype was observed when 
looking at how many macaques belonged to each outcome for each vaccine. Boosting BCG 
appeared to have one of two effects: either more animals had a middle outcome, with fewer 
having a better or worse outcome, e.g. BCG+Ad5(ESAT-6/Rv1733/Rv2626/RpfD); or more 
animals had better and worse outcomes, e.g. BCG+Ad5(M72). Since these vaccines were 
delivered the same way using the same vehicle, this suggests that the difference in phenotype is 
linked to the antigens delivered. This argues for potentially combining antigens from multiple 
vaccines into one boost, or for utilizing live attenuated mycobacterial vaccines that contain these 
and potentially more antigens.  
We have previously illustrated the potency of PET-CT as a cutting-edge tool to assess TB 
disease at serial time points to predict disease outcome [345], to evaluate chemotherapeutic 
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efficacy [2, 350], and to determine risk of reactivation disease [5]. Here we show that early 
mitigation of lung and LN associated inflammation by PET is associated with improved 
outcomes in the rhesus macaques. Further work will continue to develop PET-CT as a predictive 
tool and novel outcome measure for pre-clinical vaccine efficacy studies for TB vaccines. In T 
cells from primary tissues at necropsy, differences immunologically between better and worse 
outcomes were observed not in lung lesions but in lung-draining LNs. The two strongest loading 
factors for the “overall outcome” component in our k-means clustering were gross pathology in 
the lung and number of LN with viable bacteria. These outcomes are both highly suggestive of 
dissemination, since lung pathology captures number and spread of lesions and number of 
involved LNs is evidence of trafficking of Mtb. Thus, the difference in dissemination in these 
animals is associated with divergent T cell phenotypes in the lung-draining LNs, not in T cells 
from lung lesions. These data generate two potential hypotheses: the difference in T cell 
phenotype could be responsible for control of dissemination of TB disease; or control of disease 
could be exerted through other means, leading to more of a memory phenotype rather than 
effector phenotype in the LN as a result. Further work in our laboratory will seek to test these 
hypotheses for improvement of TB vaccines moving forward. 
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3.5 MATERIAL AND METHODS 
3.5.1 Animals 
The Institutional Animal Care and Use Committee of the University of Pittsburgh approved all 
experiments. The animals were housed and maintained in accordance with standards established 
in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.  
Vaccination. Rhesus macaques (Macaca mulatta) imported from China and in the United 
States for at least a year were used for these studies (N=64). Before study start, animals were 
screened for cross-reactivity to mycobacterial antigens by ELISPOT and for neutralizing 
antibodies to Ad5 in their serum. Animals with a neutralizing titer of 16 or lower were 
considered negative. Animals were pair housed during immunization at Bioqual (Rockville, MD) 
and randomized into study groups (Table 3). Group 1 (control) was not vaccinated. Groups 2-8 
were vaccinated at week 0 with BCG Danish (2-8*105 CFU in 0.1 mL) from Statens Serum 
Institut (Copenhagen, Denmark) by the intradermal route (i.d.). Group 3 was boosted at weeks 16 
and 20 with M72 (Mtb32A/Rv0125/PepA and Mtb39A/Rv1196/PPE18) in adjuvant AS01E by 
the intramuscular route (i.m.) [272, 330]. Group 4 was boosted at week 20 by M72 in replication-
deficient recombinant human adenovirus 5 (Ad5) (1*1010 viral particles per route) by both i.m. 
and aerosol using the eFlow rapid nebulizer (4 µm drop size; PARI, Starnberg, Germany). Group 
5 was boosted at week 20 by ESAT-6 and Ag85B in Ad5 by both i.m. and aerosol. Group 6 was 
boosted at week 25 with empty (i.e. no Mtb antigens) Ad5 by both i.m. and aerosol. Group 7 was 
boosted at week 25 with ESAT-6, Rv1733, Rv2626, and RpfD in Ad5 by both i.m. and aerosol. 
Group 8 was boosted at weeks 20 and 25 with H56 (ESAT-6/Ag85B/Rv2660c) in adjuvant 
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CAF01 by i.m. [276, 318]. Animals were transferred to the University of Pittsburgh at week 24, 
quarantined for 6 weeks, and transferred to an ABSL-3.  
Challenge. Animals were challenged with 8-16 CFU in 2 mL volume per animal of 
Erdman strain Mycobacterium tuberculosis (Mtb) via bronchoscope. Animals were clinically 
monitored and examined daily, including: appetite, weight, erythrocyte sedimentation rate 
(ESR), activity, gastric aspirate, and coughing. These signs were utilized as criteria in 
determining if an animal qualified as meeting human endpoint before the conclusion of the 
study. 
Necropsy. The macaques in this study were euthanized approximately 6 months (24-28 
weeks) after Mtb challenge. All animals were euthanized with an intravenous overdose of 
sodium pentobarbital (Beuthanasia) and maximally bled. At necropsy each animal was examined 
grossly for pathology. Using our published scoring system [65], the total amount of pathology 
was recorded from each lung lobe (number and size of lesions), LN (size and extent of necrosis), 
and extrapulmonary compartments (number and size of lesions). A pre-necropsy PET-CT scan 
was used as a “map” for identifying and finding each lesions in the lungs. Each individual lesion 
in the lung and all thoracic LNs identified were excised and mechanically homogenized to create 
a single cell suspension. Portions of the suspensions were spread on 7H11 agar (Difco) and 
incubated at 37°C with 5% CO2 for 3 weeks. CFU were then counted from these plates and used 
to both quantify individual lesion bacterial burden and—when summed together—the total 
bacterial burden for the animal [239, 365]. Portions of these suspensions were also used for 
multiparameter flow cytometry (see below), and the remained was stored at -80°C. 
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3.5.2 PET-CT scans and analysis 
PET-CT scans were performed using a microPET Focus 220 preclinical PET scanner (Siemens 
Medical Solutions) and a clinical eight-slice helical CT scanner (Neurological Corp.) as 
previously described [2, 350]. 18F-fluorodeoxyglucose (FDG), a non-specific marker of 
inflammation, was utilized as the probe for PET. Serial PET-CT scans were performed between 
2 and 24 weeks post-Mtb infection, and before necropsy. OsiriX viewer, an open-source PACS 
(Picture Archiving and Communication System) workstation and DICOM (Digital Imaging and 
Communications in Medicine) image viewer, was used for scan analyses as previously described 
[350]. Briefly, a region of interest (ROI) was segmented which encompassed all lung tissue on 
CT and was then transferred to the co-registered PET scan. On the PET scan, all image voxels of 
FDG-avid pathology (SUVmax > 2.3) were selected and summated resulting in a total SUVmax 
value.  To account for basal metabolic FDG uptake in the animal, the total SUVmax was 
normalized to resting muscle resulting in a total lung inflammation value. Individual granulomas 
as seen on CT were counted in each scan to enumerate them longitudinally. Number of FDG-
avid LN is a full count of any LN visible by PET with SUV > 5 normalized to resting muscle.  
3.5.3 ELISPOT 
Heparinized blood was drawn from study macaques at time points pre-Mtb challenge (two weeks 
prior to Mtb challenge) and post-Mtb challenge (six weeks after). Peripheral blood mononuclear 
cells (PBMCs) were isolated using the standard Percoll gradient isolation (GE Healthcare) and 
washed with sterile PBS. ELISPOT for IFN-γ was performed as previously described [115]. 
Briefly, 96-well opaque multiscreen immunoprecipitation filtration plates (Merck 
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Millipore) were hydrated, washed, and coated with 7.5 µg/mL of anti-human/nonhuman 
primate IFN-γ (GZ-4: Mabtech) for 2 hours at 37°C with 5% CO2. Plates were then blocked 
with complete RPMI containing 10% human AB serum for 2 hours at 37°C with 5% CO2. Each 
stimulation condition was performed in duplicate. Medium only was used as a negative control, 
and phorbol dibutyrate/ionomycin (P&I) and anti-CD3 were used as positive controls. CFP and 
peptide pools of H56 vaccine antigens (ESAT-6, Ag85B, Rv2660c) were used at 10 µg/mL. 
PBMCs were then added, and the plate was incubated for 48 hours at 37°C with 5% CO2. The 
plate was then washed and detection antibody (7-B6: Mabtech) was added at 2.5 µg/mL and 
incubated for 2 hours at 37°C with 5% CO2. The plate was washed and streptavidin-conjugated 
horseradish peroxidase was added at a 1:100 dilution and incubated for 45 minutes at 37°C with 
5% CO2. The plate was washed and then developed using AEC substrate. The plate was dried 
overnight and read using an ImmunoSpot analyzer (Cellular Technologies Limited). 
3.5.4 Flow cytometry on primary tissue samples 
Data collection. Single cell suspensions of individual lung granulomas obtained at necropsy 
were incubated in brefeldin A (GolgiStop, BD Biosciences) for 2 hours at 37°C with 5% CO2. 
Single cell suspensions of individual lung-draining LNs obtained at necropsy were either 
incubated in brefeldin A for 2 hours at 37°C with 5% CO2, or incubated with phorbol 12,13-
dibutyrate (PDBU) and ionomycin for 3.5 hours in the presence of brefeldin A at 37°C with 5% 
CO2. The cell suspensions were then stained for viability (Invitrogen), surface, and intracellular 
markers. Surface markers included: CD3 (SP34-2: BD Biosciences); CD11b (ICRF44: BD 
Biosciences); and CD20 (2H7: eBiosciences). Intracellular markers included: IFNγ (B27: BD 
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Biosciences); TNF (MAB11: BD Biosciences); IL-2 (MQ1-17H12: BD Biosciences); IL-17 
(eBio64CAP17: eBiosciences); IL-10 (JES3-9D7: eBiosciences); and IL-6 (MQ2-6A3: BD 
Biosciences). Data acquisition was performed using a LSR II (BD Biosciences) and the 
resulting data were gated and quantified using FlowJo (Version 9.9.3; Treestar Inc.).  
Gating. Singlet cell populations were separated first using forward scatter area and 
height. Live cells were then gated, followed by the lymphocyte population based upon size. 
CD11b+ and CD20+ cells were then removed from this population, and remaining CD3+ 
cells were selected. Gates for each of the six cytokines were used to quantify individual 
production. The Boolean gating tool was then utilized to determine the combinations in 
which the six cytokines were produced.  
3.5.5 Statistics 
Graphics and statistics in all figures except 18-19 and 23-24 were created using Prism 
(Graphpad). In these figures where indicated: comparisons of time to human endpoint were done 
using the Mantel-Cox test; comparisons of two groups were performed using the Mann-Whitney 
test; and comparisons of three groups were done using Dunn’s multiple comparisons. Graphics 
and statistics in the other part of figure 19 were generated using JMP (SAS). K-means clustering 
was utilized to partition the animals by outcome (k=3). Analysis and presentation of flow 
cytometric data in figures 23-24 was performed using SPICE (Ver. 5.23; 
https://exon.niaid.nih.gov/spice/) [6]. Comparisons of frequency of cytokine-producing CD3 T 
cells between outcomes were performed using the Mann-Whitney test. Comparisons between 
profiles of relative Boolean cytokine expression (pie graphs) were done using a permutation test 
as previously described [6].  
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4.0  BCG+H56:CAF01 LIMITS HOST INFLAMMATION AND BACTERIAL 
DISSEMINATION IN A NONHUMAN PRIMATE MODEL OF TUBERCULOSIS 
This chapter is adapted from the manuscript in submission: DiFazio RM, Maiello P, Myers AJ, 
Rodgers MA, O’Malley M, Tomko J, Frye LJ, Fillmore D, Agger EM, Andersen P, Lin PL, and 
Flynn JL. BCG+H56:CAF01 limits host inflammation and bacterial dissemination in a 
nonhuman primate model of tuberculosis.  
4.1 ABSTRACT 
The experimental tuberculosis (TB) subunit vaccine H56 was previously shown to boost the 
effects of the currently licensed vaccine (BCG) to protect non-human primates (NHPs) infected 
with Mycobacterium tuberculosis (Mtb) from reactivation disease. The goal of this study was to 
determine which aspects of Mtb infection are influenced by this vaccine. Cynomolgus macaques 
received no vaccine, BCG only, or BCG boosted by H56 in CAF01, an experimental liposomal 
adjuvant. A combination of BCG with H56:CAF01 prevented early dissemination of lung 
granulomas after low dose Mtb challenge, substantially reduced lung inflammation, as measured 
by PET-CT, and limited infection of mediastinal lymph nodes (LNs). We then repeated the 
experiment and necropsied animals at 5-6 weeks post infection to examine the early local 
responses that confer protection. NHPs vaccinated with BCG+H56:CAF01 had significantly less 
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disease early in LNs than unvaccinated controls. T cells from the LNs of the vaccinated animals 
also had differential cytokine expression compared to controls. This study provides new insights 
into which aspects of Mtb infection are modulated by BCG+H56:CAF01 vaccination and is the 
first described use of PET-CT to evaluate vaccine efficacy in the macaque model of TB. 
4.2 INTRODUCTION 
Tuberculosis (TB) was responsible for 10.4 million new cases and 1.8 million deaths worldwide 
in 2015. Over 95% of TB deaths occur in developing countries, disproportionately affecting 
those in poverty [23]. This highlights a critical need for new interventions. Approximately 43 
million lives were saved between 2000 and 2014 through TB chemotherapy [23]. The drug 
regimen for TB, although lengthy and complex, can ablate infection, but studies suggest that 
previously infected and treated persons are actually at an increased risk for TB disease [366]. 
The introduction of a new effective vaccine, along with optimization of current tools and 
increased health coverage and social protection, would improve the 2% annual decline in TB 
incidence to 17% [367]. All of these factors highlight the need for a vaccine or other therapeutic 
measures to gain control over this disease.  
Individuals with active TB disease spread the infection via aerosolized droplets 
containing Mycobacterium tuberculosis (Mtb), the causative agent [368]. About 30% of people 
exposed to these droplets become infected [369]. In the infected population, approximately 10% 
will develop active TB while the other 90% will have an asymptomatic infection, known as 
latent TB infection (LTBI) [35]. Those with LTBI have a 10% per lifetime risk of later 
developing active (reactivation) TB [325]. Since approximately 2.3 billion people have LTBI [7], 
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this represents a massive pool of potential cases of active TB. Preventing infection or 
reactivation with a vaccine would have a major effect on the disease spread. There are no 
validated immunological correlates of protection against TB. Despite this, most vaccines in 
development against TB are specifically selected for immunogenicity and tested in murine 
models [257]. The MVA85A vaccine, the first new vaccine for TB tested in humans, was 
developed along these guidelines and was shown to have no efficacy against prevention of 
infection or disease [38, 295], highlighting the need for new endpoints of TB protection. These 
new endpoints should be tied to TB outcomes that are expected to be important for pathogenesis 
of TB. This could include bacterial burden in lungs, inflammation, dissemination of Mtb within a 
host, and involvement of mediastinal lymph nodes. Inflammation is responsible for most of the 
host-directed damage caused by Mtb [169, 370], and its limitation by a vaccine will likely limit 
disease and could limit transmission. Dissemination within a host, both within the lung and 
outside of the lung to other tissues, represents a lack of control and can lead to the most severe 
forms of TB disease [12]. Mediastinal lymphadenitis is among the most common forms of 
extrapulmonary TB and represents a niche for bacterial replication and growth [12, 371, 372]. 
Evaluating bacterial burden and immune function in these pathologies in humans is impractical.  
While the murine model is the most commonly used animal model of TB, it fails to 
replicate the most essential aspects of the disease, namely human-like pathology and disease 
progression or latent infection [106]. Our lab has pioneered the use of the cynomolgus macaque 
non-human primate (NHP) model, which faithfully replicates all aspects of M. tuberculosis 
infection, pathology and disease [107, 373]. We can accurately assess bacterial burden and 
pathology in our model at necropsy [65, 239, 365], and use serial PET-CT imaging to track 
infection trajectory and inflammation [107, 374]. This technology matches similar data from 
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humans [347, 350], highlighting its translational capabilities. However, it has not been 
previously used to assess TB vaccines in a quantitative fashion.  
H56, a protein subunit vaccine, was designed to boost and broaden the immune response 
to BCG [274]. BCG is the only licensed vaccine for TB, which protects infants from severe TB 
disease but has variable efficacy in adolescents and adults [132, 375]. H56 is composed of three 
proteins: Ag85B, which is expressed in BCG; ESAT-6, which is expressed in Mtb but deleted in 
BCG; and Rv2660c, which is highly expressed by Mtb under various nutritional and oxidative 
stress conditions in vitro [274]. Thus, H56 was designed as a multistage vaccine for pre- and 
post-exposure administration to prevent both acute disease after infection and reactivation of 
LTBI, as described in the murine model system [274, 320]. We previously published that 
cynomolgus macaques vaccinated with BCG + H56:IC31® are protected from reactivation TB 
induced by anti-TNF antibodies [275]. NHPs protected from reactivation had very little to no 
Mtb in their thoracic LNs, a striking finding as most unvaccinated animals, as well as those 
vaccinated with BCG alone, had several LNs with viable bacteria [5]. In the current study, we 
vaccinated and challenged NHPs to characterize the protection conferred by BCG and H56. We 
sought to use our PET-CT technology to investigate differences between vaccinated and control 
animals. We then performed early necropsies post-challenge in vaccinated animals to identify 
immunological and physiological mechanisms of protection.  
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4.3 RESULTS 
4.3.1 Immune responses pre- and post-challenge 
Twenty cynomolgus macaques were either unvaccinated (N=6), vaccinated with BCG Danish 
only (N=4), or received BCG Danish followed by two injections of H56 in CAF01 (N=10) (Fig. 
25, top), a liposomal adjuvant designed to elicit Th1 and Th17 cellular immune responses [318, 
328]. These animals were then challenged with low dose Erdman strain Mtb and necropsied 5-6 
months post-infection. During challenge, PET-CT was used to assess extent of infection, 
inflammation, and disease severity.  
Throughout the study, immunogenicity was assessed by IFN-γ ELISPOT and multicolor 
flow cytometry. Significantly more IFN-γ producing PBMCs responding to CFP, a pool of 
secreted proteins that elicit pan-mycobacterial responses, were observed in BCG/H56 
Figure 25: Chapter 4 study design. The top figure represents the six-month study. Of the 20 macaques used 
for this portion of the study, 6 were unvaccinated controls, 4 received BCG only, and 10 received BCG and 
H56:CAF01. The bottom figure represents the six-week study. Of the 12 macaques used for this portion of the 
study, 6 were unvaccinated and 6 were vaccinated with BCG and H56:CAF01.  
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vaccinated macaques compared to BCG only at two weeks pre-Mtb challenge (p=0.0118; 
Fig. 26), and in BCG/H56 vaccinated macaques compared to controls one and two weeks 
post-Mtb challenge (p=0.0381, p=0.0195 respectively). No significant differences by ESAT-
6 specific ELISPOT responses between the groups were observed. A significant increase in 
Ag85B specific responses was observed in BCG/H56-vaccinated animals compared to those 
vaccinated with BCG only one week after the first H56 boost (p=0.0131). Stimulation with 
Rv2660c produced a significant, albeit small, difference between BCG/H56 and BCG only at 
Figure 26: Antigen-specific IFN-γ responses to CFP (pan-mycobacterial stimulation) and peptide pools 
from H56 antigens in unvaccinated (control), BCG only, and BCG/H56 vaccinated macaques were determined by 
ELISPOT (depicted as spot-forming units (SFU) per 200,000 cells). Each line represents one animal. Green (BCG 
only) and blue (BCG/H56) wedges denote vaccinations, while the red wedge denotes Mtb challenge. Asterisks 
denotes significant difference between either two groups by Mann-Whitney (pre-challenge) or three groups by 
Dunn’s multiple comparisons (post-challenge) with p values in the text. Medium background responses were 
subtracted from each antigen-specific result.  
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four weeks pre-Mtb challenge (p=0.0325).  
When examining pre-challenge responses by flow cytometry, we observed that H56 
significantly boosted the macaques’ ability to produce cytokines (IFN-γ, TNF, IL-2, or IL-17) 
in non-naïve CD4 T cells one week after each boost compared to BCG only (p=0.0412, 
p=0.0338 respectively), determined using potent non-specific stimulation (phorbol 
dibutyrate and ionomycin (P&I); Fig. 27). A higher frequency of non-naïve T cells from 
BCG/H56 vaccinated macaques produce cytokines after ESAT-6 stimulation one week after 
the first H56 boost (p=0.0104). A significantly higher frequency of non-naïve T cells in 
Figure 27: Frequencies of memory CD4 T cells producing IFN-γ, TNF, IL-2, or IL-17 in response to 
phorbol dibutyrate and ionomycin (P&I) or peptide pools of H56 vaccine antigens were determined using 
multicolor flow cytometry. Each line represents one animal. Green (BCG only) and blue (BCG/H56) wedges 
denote vaccinations, while the red wedge denotes Mtb challenge. Asterisks denotes significant difference between 
either two groups by Mann-Whitney (pre-challenge) or three groups by Dunn’s multiple comparisons (post-
challenge) with p values in the text. Medium background responses were subtracted from each antigen-specific 
result.  
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these animals also respond to Ag85B one week after the first H56 boost (p=0.0277) and 
two weeks pre-Mtb challenge (p=0.0411). Responses to Rv2660c were significantly higher 
in BCG/H56 vaccinated macaques four weeks pre-Mtb challenge (p=0.0371). Upon further 
dissection of responses just before Mtb challenge, non-naïve CD4 T cells from control 
animals were mostly only capable of being terminally differentiated IFN-γ+ effector cells 
(Fig. 28), while CD4 T cells from BCG/H56 vaccinated macaques were more capable of 
being multifunctional and displaying memory phenotypes (IL-2+ alone or with other 
Figure 28: Boolean combinations of frequencies of memory CD4 T cells pre-Mtb challenge producing 
IFN-γ, TNF, IL-2, or IL-17 in response to P&I or peptide pools of H56 vaccine antigens were determined using 
multicolor flow cytometry. Each bar displays the mean response, and error bars represent SEM. Medium 
background responses were subtracted from each antigen-specific result.  
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cytokines). Non-naïve CD4 T cells from BCG only macaques produced only single cytokines 
in response to vaccine antigens (Fig. 28), and none to ESAT-6, which is not in BCG. 
Responders to vaccine antigens in BCG/H56 vaccinated animals exhibited 
multifunctionality and more robust memory phenotypes, including ones previously 
associated with protection in this family of vaccines (IL-2+, IL-2+TNF+; Fig. 4, top right) 
[136, 315]. We also observed a vaccine antigen-responsive population of IL-2+IL-17+ CD4 
T cells that are likely memory CD4 T cells generated by CAF01, which was designed to elicit 
Th1 and Th17 type responses [328].  
4.3.2 Vaccination prevents dissemination of granulomas in the lung 
We reported previously that cynomolgus macaques with LTBI have fewer granulomas than those 
with active disease [65], and that the formation of new granulomas in the early phase of infection 
(3-6 weeks) is associated with development of active disease months later [345].  
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Mtb infection of cynomolgus macaques results in the full spectrum of infection 
outcomes, as can be seen in the variability in lung pathology of unvaccinated controls at 
necropsy (Fig. 29A), with two of the six control animals exhibiting minimal disease. In contrast, 
most of the vaccinated animals had minimal lung pathology at necropsy (Fig. 29A). As in our 
previously published study [275], BCG/H56 did not protect all macaques, since 2 of the 10 
vaccinated animals had lung pathology similar to unvaccinated controls. Discordant with the 
Figure 29: Vaccination prevents dissemination of granulomas in the lung. For all graphs, each dot 
represents one animal and bars represent medians. Comparisons were done using Kruskal-Wallis (KW), and if 
KW<0.05, Dunn’s multiple comparions with p values directly reported. A Total amount of gross pathology in the 
lung observed at necropsy. B The total bacterial burden from lung granulomas in each animal enumerated from 
plates spread at necropsy. C Number of additional new granulomas in the lung of each animal that formed 
between 4 and 12 weeks p.i. D Median size of lung granulomas at 4 weeks p.i.  
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pathology scores, the median total bacterial burden in the lung among the three groups was 
similar, although one BCG vaccinated and several of the BCG/H56 vaccinated animals had 
relatively low lung bacterial burdens (Fig. 29B). Serial PET-CT scans showed that animals 
vaccinated with BCG/H56 formed fewer new lung granulomas than control animals after 4 
weeks post-infection (although not statistically significant) (Fig. 29C), indicating a reduction in 
dissemination in most BCG/H56 monkeys, a phenotype associated with control of disease [345]. 
The majority of BCG/H56 vaccinated animals have a median lung granuloma size of less than 2 
mm (median=1.725 mm), while the median size of lung granulomas from control animals is 
about twice as large (median=3.55 mm; Fig. 29D). Thus, vaccination seems to limit lung 
pathology through prevention of dissemination and spread in that compartment, not necessarily 
by reducing lung bacterial burden. 
4.3.3 H56 in CAF01 limits pathology and bacterial burden in the mediastinal lymph 
nodes 
In our previous study, BCG/H56 vaccinated animals with asymptomatic infection were protected 
from anti-TNF-induced reactivation disease and had completely sterile LNs, except for one 
animal with one LN that contained viable bacteria [5, 275]. This phenotype is strikingly different 
than what is typically seen in our NHP model, suggesting that control of Mtb in the mediastinal 
LNs is important for protection against reactivation. We sought to further explore this 
compartment in our current study. The median necropsy score (summary of gross pathology) in 
LNs for the animals vaccinated with BCG/H56 was half that of control animals (Fig. 30A), an 
indication of substantially less grossly visible involvement. The median of total CFU in the LN 
compartment was 20-fold lower in BCG/H56 vaccinated animals (820 CFU) compared to 
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unvaccinated animals (16960 CFU; Fig. 30B). The median number of thoracic LN with 
culturable Mtb per animal was 4 for unvaccinated animals, and 3.5 for BCG only vaccinated 
Figure 30: H56 in CAF01 limits pathology and bacterial burden in the mediastinal lymph nodes. For A-
C, each dot represents one animal and each bar represents a median, and comparisons were done using the 
Kruskal-Wallis test (KW). A The amount of pathology (necropsy score) observed at necropsy in the LN 
compartment. B The total bacterial burden in the LNs determined by summing the plated CFU of all LN in each 
animal. C Number of LNs at necropsy with viable bacteria, i.e. CFU+. Historical data show that 4-5 LN are 
typically CFU+ at necropsy. D Stacked graphs representing the proportions of LNs containing total bacteria 
(CEQ; live and dead) and/or live bacteria (CFU). LN that lack both CEQ and CFU likely never had Mtb or Mtb 
was quickly killed upon arrival (CEQ-CFU-, green). Having CEQ but not CFU suggests that Mtb grew in the LN 
but were killed (CEQ+CFU-, red). The limit of detection for CEQ is about 1000, so LN without CEQ but with 
CFU usually means that the CEQ was below this limit (Unreliable CEQ, CFU+, hashed). In support of this, the 
CFU in these LN are usually below 1000 as well. LNs with both CEQ and CFU have viable bacteria and a total 
count of organisms (CEQ+CFU+, blue). A comparison of CEQ-CFU- proportions of LNs was done using Fisher’s 
exact test. 
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animals, but only 1.5 in BCG/H56 vaccinated animals (Fig. 30C). This suggested that either 
H56:CAF01 prevents Mtb from reaching the LN compartment in most monkeys, or provides an 
immunologic environment that can kill Mtb that establish and are growing in the LN. To assess 
these possibilities, we compared the chromosomal equivalents (CEQ) of Mtb in all thoracic LN 
from the monkeys in each group. We previously showed that CEQ represents a total bacterial 
count in granulomas or lymph nodes that includes live and dead Mtb, since Mtb DNA persists in 
granulomas for many months [5, 86]. Having neither CEQ nor CFU (CEQ-CFU-) in a LN 
suggests that Mtb bacilli never reached that tissue, or are rapidly killed. The percentage of CEQ-
CFU- LNs was significantly different among the study groups (p=0.0391), with 27.5% more LNs 
with no sign of current or previous Mtb infection in BCG/H56 animals compared to controls 
(Fig. 30D). CEQ-CFU- LNs also display no microscopic pathology or inflammation. These data 
together suggest that BCG/H56 is substantially limiting productive dissemination to the LN 
compartment.  
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4.3.4 H56 in CAF01 reduces lung inflammation and apparent risk of reactivation 
determined by PET-CT 
Serial PET-CT imaging was pioneered by our laboratory in the nonhuman primate (NHP) model 
of TB as a quantitative and translational means of assessing the extent of disease during Mtb 
challenge [350, 374]. Using this tool, we observed striking differences in both spread of TB and 
Figure 31: Qualitative comparisons of 3D PET-CT renderings at the conclusion of the study. 3D scan 
renderings were generated for two animals from each group to illustrate the impact of each vaccine on overall 
inflammation, or FDG avidity. Panels in the top row showcase the worst animal in each study cohort. Panels in the 
bottom row include the middle animal in each group. Worst and middle here are determined by total lung 
inflammation, quantified and graphed in Figure 32A.  
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host inflammation (FDG avidity) in these macaques by the conclusion of this study (Fig. 31). 
BCG/H56 limits both the most severe cases of TB compared to BCG alone and controls (Fig. 31, 
top), and well as limiting the median amount of total lung inflammation (Fig. 31, bottom). The 
total lung inflammation (in standard uptake values; SUV) was quantified to visualize these 
differences between groups (Fig. 32A). BCG alone (median=1611) conferred about a 6.5-fold 
decrease in lung inflammation compared to controls (median=10482) by the end of the study. 
Boosting with H56:CAF01 (median=265) decreased lung inflammation by another 6 fold, a 
decrease in inflammation of 40 fold compared to controls.  
Figure 32: H56 in CAF01 reduces risk of reactivation disease determined by PET-CT. We have 
previously published that two PET-CT endpoints, low total lung inflammation and lack of sites of extrapulmonary 
involvement, predict low to no risk of reactivation disease [5]. A Total lung inflammation (standard uptake values; 
SUV) was plotted for all macaques at the conclusion of the study (6 months p.i.). Each dot represents one animal 
and bars represent medians. Comparisons between the groups was done using the Kruskal-Wallis test (KW). B 
Total lung inflammation was plotted for only the animals with LTBI in each group. Each dot represents one animal 
and bars represent medians. Open circles represent animals that have sites of extrapulmonary involvement by PET-
CT. The dashed line represents the cutoff for high or low total lung inflammation. C The percentage of macaques 
in each group that either had clinically-determined active TB (grey) or LTBI (purple). Animals with LTBI were 
then further subdivided by risk as determined in Fig. 4B. Comparisons of percentage of low risk LTBI animals 
between groups was done using Fisher’s exact test with the p value reported directly.  
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We recently published that PET-CT imaging parameters can be used to predict risk of 
reactivation disease induced by TNF neutralization in NHPs with LTBI six months or more after 
challenge [5]. Specifically, low total lung inflammation and lack of extrapulmonary sites of 
infection predict low to no risk of reactivation disease with 92% sensitivity and specificity. In 
that study, 50% of cynomolgus macaques classified as LTBI were at low risk of reactivation 
following anti-TNF antibody treatment. Using clinical measures as previously described [65], 
50% of the unvaccinated and BCG only animals in this study would be classified as LTBI six 
months p.i. (n=3 and n=2, respectively), while 70% of BCG/H56 vaccinated animals had LTBI 
(n=7), similar to our previous study [275]. Using our published criteria for risk of reactivation on 
only the macaques with LTBI (Fig. 32B), one animal from the unvaccinated and one from the 
BCG only groups were at low risk, while 6 of the 7 (87.5%) BCG/H56 vaccinated animals with 
LTBI were classified as low risk for reactivation TB, a significant difference (p=0.04; Fig. 32C). 
These data are supported by our earlier findings that BCG boosted with H56 prevented 
reactivation induced by anti-TNF treatment [275], in which 0 of 4 LTBI BCG+H56:IC31® 
monkeys reactivated, while 3 of 4 BCG-only vaccinated animals reactivated. Together these data 
suggest that H56:CAF01 works to stabilize inflammation in the granulomas and lungs, and that 
maintenance of this low level of inflammation is important for long-term control of disease and 
prevention of immune-compromise induced reactivation.  
4.3.5 Vaccination mitigates lung inflammation early post-infection 
We then used serial PET-CT to investigate early differences in inflammation post-challenge that 
could be associated with the protection conferred by BCG/H56. Most of the unvaccinated 
animals experimentally infected with Mtb in this experiment had elevated total levels of FDG 
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avidity in lungs early, peaking around 4-6 weeks post-infection (p.i.) and maintaining high levels 
for the duration of challenge (Fig. 33A). Animals vaccinated with BCG only showed a wide 
range of lung inflammation, with one animal having very low FDG avidity in the lungs (Fig. 
Figure 33: H56 in CAF01 mitigates lung inflammation early post-infection. A Total lung SUV of FDG 
was divided by the resting muscle SUV and plotted over time for controls (red), BCG only (green), and BCG/H56 
(blue). Each dot represents a time point. Asterisks represent time points (3 and 4 weeks) post-infection where the 
BCG/H56 vaccinated animals are significantly different than the controls by Dunn’s multiple comparisons. P 
values are reported in the manuscript. For B-E, all data are from 4 weeks p.i. and comparisons between groups 
were done using Dunn’s multiple comparisons. B Total lung inflammation at 4 weeks p.i. Each dot represents one 
animal and bars represent medians. C FDG SUV per lung granuloma at 4 weeks p.i. Each dot represents one 
granuloma and bars represent medians. D The sum of the maximum LN SUV at 4 weeks p.i. Each dot represents 
one LN and bars represent medians. E The number of FDG-avid LNs (SUV>2.3) at 4 weeks p.i. Each dot 
represents one animal and bars represent medians.   
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33A). The cohort vaccinated with BCG/H56 had significantly reduced FDG avidity compared to 
the unvaccinated controls at 4 weeks p.i. (p =0.0141; Fig.  33A-B). We then investigated this 
early time point (4 weeks p.i.) further. The reduction in lung FDG avidity occurs early at the 
level of individual granulomas (Fig. 33C). Lung granulomas from control animals are more FDG 
avid than those from vaccinated animals at 4 weeks post-infection (Fig. 33C). The total 
inflammation of thoracic LN (sum of maximum LN SUV) (Fig. 33D) and the number of FDG 
avid LNs are significantly less in BCG/H56 vaccinated animals compared to controls (Fig. 33E).  
4.3.6 H56 in CAF01 prevents mediastinal lymph node pathology early post-infection 
The evidence presented thus far suggests that BCG/H56 provides long-term protection, as 
evidenced by reduced lung inflammation, minimal dissemination, and limited thoracic LN 
involvement. However, to assess the early events that contribute to this protection is difficult 
since these necropsies were performed 5-6 months after infection. Our previous data and the 
literature support that early events are crucial to infection outcome in natural infection [115, 345, 
376]. In this current study, the mitigation of lung inflammation and reduction of dissemination in 
vaccinated animals was observed as early as four to six weeks (Fig. 29; Fig. 33). To address 
these early events, including LN involvement, we repeated the study but performed the 
necropsies earlier, at 5-6 weeks post-infection, focusing on unvaccinated and BCG/H56 
vaccinated animals (n=6 per group; Fig. 25, bottom).  
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Grossly visible lung pathology and total lung bacterial burden were similar between the 
two groups (Fig. 34), suggesting that later control of inflammation is not associated with early 
bacterial control in the lungs. Early total lung inflammation (FDG avidity) was lower in 
BCG/H56 vaccinated animals than controls, along with the sum of maximum LN SUV and 
number of FDG-avid LNs (Fig. 35), similar to the first cohort of animals. There was pronounced 
early infection control in the LN of BCG/H56 vaccinated animals. The necropsy score of LNs 
Figure 34: Bacterial burden in the lung early post-infection does not correspond to vaccination. 
Comparisons were done using the Wilcoxon rank-sum test. A The total amount of gross pathology observed in the 
lung compartment at necropsy in the early animals. Each dot represents one animal and bars represent medians. B 
The total bacterial burden from all lung granulomas plated at necropsy. Each dot represents one animal and bars 
represent medians. C The CFU from all granulomas excised at necropsy. Each dot represents one granuloma and 
bars represent medians. 
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was significantly reduced in the vaccinated macaques (Fig. 36A), and the median total CFU in 
LNs (870 CFU) was almost 300-fold lower than LNs from control animals (250550 CFU; Fig. 
36B). The LN with the highest number of Mtb bacilli in each vaccinated macaque (median=310 
CFU), with one exception, had 600-fold fewer bacteria than the LN with the highest Mtb burden 
from control animals (median=188000 CFU; Fig. 36C). LNs with neither CEQ nor CFU (CEQ-
CFU-) were more prevalent from BCG/H56 vaccinated versus control animals (Fig. 36D), 
Figure 35: Radiological data from the second set of animals. These graphs demonstrate that the limited 
PET-CT data from the short course of animals (Fig. 25, bottom) match the radiological data from the long course 
(Fig. 33). These data include total lung inflammation graphed over the limited time points with an asterisk 
representing significant difference (A), total lung inflammation at 3 weeks p.i. (B), the sum of the maximum LN 
SUV (C), and the number of FDG-avid LN (SUV>2.3). D. Each line/dot represents one animal and bars represent 
medians. Comparisons were performed using Wilcoxon rank-sum tests. 
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confirming that BCG with H56 prevents early Mtb dissemination to or growth within the LN 
compartment. These early infection data support the longer-term studies, both showing a 
reduction in inflammation early and protection from LN infection by BCG/H56.  
Figure 36: H56 in CAF01 prevents mediastinal lymph node pathology early post-infection. For A-C, 
each dot represents one animal and bars represent medians, and comparisons were performed using the Wilcoxon 
rank-sum test. A The amount of pathology observed at necropsy specifically in the LN compartment. B The total 
bacterial burden in all LN excised at necropsy. C The highest value for CFU in a LN for all animals in each 
cohort. D Stacked graphs representing the proportions of LNs containing total bacteria (CEQ; live and dead) 
and/or live bacteria (CFU). Group comparisons of CEQ-CFU- LNs were done using Fisher’s exact test. See 
legend of Figure 30D for interpretations of each LN phenotype. 
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4.3.7 Mediastinal lymph nodes exhibit differential cytokine production in BCG/H56-
vaccinated animals but not in lung granulomas 
In our previous work, multicolor flow cytometry on excised and homogenized individual 
granulomas at necropsy identified T cell cytokine profiles associated with sterilized granulomas 
[239]. We used this same technology to identify early immune responses associated with 
vaccine-induced protection seen six months post-infection. All mediastinal LNs, both involved 
and uninvolved, were excised at necropsy, homogenized to create single cell suspensions, and 
then assayed by flow cytometry to elucidate immune function. There was a trend of lower 
frequencies of cytokine producing T cells in the vaccinated animals, most prominently observed 
in the percentage of any cell producing cytokines and in single functional T cell cytokine 
production (Fig. 37A). Lower frequencies of T cells from LNs of vaccinated animals produce 
interferon gamma (IFN-γ; p=0.047) and significantly higher frequencies of T cells produce 
tumor necrosis factor (TNF; p=0.018; Fig. 37B). When using a permutation test to compare the 
profiles of cytokine production from LNs, significant differences were observed between the 
unvaccinated and vaccinated groups of macaques.  
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 Figure 37: Mediastinal lymph nodes exhibit differential cytokine production in BCG/H56-vaccinated 
animals. These graphs represent flow cytometric data on primary tissue from early (5-6 weeks p.i.) necropsies 
from LNs. A Total cytokine production was measured in absolute numbers (% of CD3) for the production of any 
of the six cytokines (ANY), production of two or more cytokines (Multi), and production of only one cytokine 
(Single). Bars represent medians and boxes represent interquartile ranges. B Individual cytokine production was 
measured in relative numbers (percent of total production). Bars represent medians and boxes represent 
interquartile ranges. Pound signs indicate a significant difference between the two groups by Wilcoxon rank-sum 
test. C Profile of cytokine expression visualized from Boolean gating data into pie charts with arcs. Each wedge of 
the pie represents a single or multiple cytokine producing T cell population, and each arc represents a cytokine 
being produced alone or with other cytokines. Comparisons were performed using a permutation test as previously 
described [6].  
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Both cohorts had similar relative frequencies of multifunctional (center pie, white) to single 
functional (center pie, black) T cells (Fig. 37C). Within the multifunctional populations, 
however, BCG/H56 vaccinated animals had a higher relative frequency of IFN-γ+TNF+ T cells, 
Figure 38: These graphs represent flow cytometric data on primary tissue from early necropsies from 
lung granulomas. A Total cytokine production was measured in absolute numbers (% of CD3) for the production 
of any of the six cytokines (ANY), production of two or more cytokines (Multi), and production of only one 
cytokine (Single). Bars represent medians and boxes represent interquartile ranges. B Individual cytokine 
production was measured in relative numbers (percent of total production). Bars represent medians and boxes 
represent interquartile ranges. Pound signs indicate a significant difference between the two groups by Wilcoxon 
rank-sum test. C Profile of cytokine expression visualized from Boolean gating data into pie charts with arcs. 
Each wedge of the pie represents a single or multiple cytokine producing T cell population, and each arc 
represents a cytokine being produced alone or with other cytokines. Comparisons were performed using a 
permutation test as previously described [6].  
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while control animals had a higher relative frequency of IL-6+IL-10+IL-17+ T cells (Fig. 
37C). Within the single functional populations, control animals had a higher relative 
frequency of terminally differentiated IFN-γ+ T cells, while BCG/H56 vaccinees had higher 
relative frequencies of IL-6+, IL-10+, IL-17+, and TNF+ T cells in their LNs (Fig. 37C). In 
lung granulomas from early necropsies, there was no difference in total frequencies of T cells 
producing cytokines (in any combination) between vaccinated and control macaques (Fig. 38A). 
Similarly, there was no difference in relative production of any of the individual six cytokines 
examined (Fig. 38B). We applied a permutation test to compare the profiles of cytokine 
production between the cohorts, and again there was no difference (Fig. 38C). This corresponds 
to the fact that bacterial burden in the lung granulomas is similar between the cohorts (Fig. 34C).  
4.4 DISCUSSION 
The goal of this study was to identify correlates and mechanisms of protection in macaques 
vaccinated with BCG and H56, an experimental fusion protein boost. We showed previously in 
our NHP model, which faithfully replicates TB in humans [107], that BCG boosted by H56 
protects against reactivation TB [275]. The estimated 2.3 billion people with LTBI [7] represent 
an enormous reservoir of potential reactivation TB. Active disease is the transmissible form, so 
by blocking active or reactivation TB, one can prevent transmission of Mtb and stop the spread 
of TB. Therefore, a vaccine that may not prevent infection but blocks disease, like BCG with 
H56, is crucial to the fight against TB. This study sought to identify which aspects of M. 
tuberculosis infection are influenced most strongly by BCG/H56. 
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In this study, animals vaccinated with both BCG and H56:CAF01 had significantly less 
total lung inflammation than animals vaccinated with BCG only or no vaccine as measured by 
PET-CT and reflected in the lung pathology score. The reduced inflammation was apparent at 
the individual granuloma level early; in addition, the granulomas from BCG/H56 vaccinated 
animals were smaller than those from control animals. Many of the clinical signs and symptoms 
of TB are caused by excessive host inflammation, so that lower total lung inflammation is 
associated with better control of disease [169, 370]. In other work performed by our laboratory 
[5], we established that PET-CT could be used to determine risk of reactivation disease using our 
model with TNF neutralization as an inducer of reactivation. Using this technology, we 
confirmed that most (87.5%) of the BCG/H56 vaccinated animals with LTBI are at low risk of 
reactivation, which corroborates our earlier data on H56 preventing anti-TNF induced 
reactivation [275]. In comparison, 17% of the unvaccinated and 25% of the BCG-only 
vaccinated animals with LTBI in the current study would be categorized as low risk of 
reactivation. Vaccination with BCG and H56:CAF01 could reduce total lung inflammation by 
either reducing the bacterial burden or modulating the host response to Mtb. We show here that, 
surprisingly, this decrease in lung inflammation was not associated with a change in lung 
bacterial burden, suggesting that this vaccine regimen is modulating the host immune response 
against Mtb. However, in our recent study [5], risk of reactivation determined by total lung 
inflammation was associated with lower bacterial burden in the lung. None of the animals in that 
study were vaccinated, suggesting that natural protection against reactivation disease is 
associated with control and reduction of Mtb, while BCG/H56 induced protection is associated 
with modulation of the host immune response. Host inflammation therefore is an important 
correlate of protection against reactivation disease, and modulating host immunity to Mtb either 
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through vaccination or host-directed therapy delivered specifically to the lungs or LN might be a 
tractable new therapeutic for eliminating reactivation disease in TB.  
In this model of TB, BCG does confer some protection against Mtb challenge [275], as it 
does in humans [127, 132]. However, BCG alone does not protect against anti-TNF induced 
reactivation, while boosting with H56 does [275]. Where does H56 work to protect macaques 
from reactivation disease? How is the protection engendered by BCG/H56 different than BCG 
alone? Vaccination with BCG prevents pathology in the lung and restricts the size of granulomas 
early p.i. Surprisingly, this protection does not correspond to a decrease in bacterial burden in the 
lung. Boosting with H56 does not improve these specific outcomes, suggesting that the 
protection seen in the lung is generated by BCG. Dissemination within the lung, i.e. formation of 
new granulomas within the first few weeks after establishment of infection, is associated with 
eventual development of active TB [12]. While a few macaques in the control and BCG only 
groups naturally resisted dissemination of lung lesions, most BGC/H56 vaccinated animals were 
protected from dissemination, with the number of new granulomas after establishment being 0-1 
for the majority of animals. Additionally, the median score for lung pathology in BCG/H56 
vaccinated animals is nearly the same for macaques necropsied at both six weeks and six months, 
while the median score for lung pathology at six months in controls is three times higher than at 
six weeks p.i., indicating further dissemination in the absence of vaccination. In the mouse 
model, vaccination with H56:CAF01 generates vaccine specific T cells that efficiently and 
preferentially home to the lung parenchyma from the LNs [277], suggesting that these cells are 
responsible for the protection observed against dissemination of Mtb in the lung.  
Host inflammation is a major driving factor of poor disease outcome in TB [169, 370]. 
We and our colleagues have shown that a decrease in lung inflammation, as determined by total 
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FDG avidity in the lung, correlates with successful TB chemotherapy in active TB in macaques 
and humans [2, 350, 351] and low risk of reactivation disease in monkeys with LTBI [5]. In our 
previous study with BCG/H56 vaccination [275], we observed that LNs from vaccinated animals 
that did not reactivate when treated with anti-TNF therapy were all completely sterile, except for 
one animal with one CFU+ LN [5]. This suggested that LNs were an important compartment for 
BCG/H56 induced protection against reactivation disease. The more detailed analysis in the 
current study showed that 80% of BCG/H56 vaccinated animals have less pathology and lower 
bacterial burden in the LN than the median of the control or BCG only groups. The control and 
BCG only groups have a median of four LNs with viable bacteria, while a majority of BCG/H56 
vaccinated animals have two or fewer involved LNs, with quantitative PCR data suggesting that 
mycobacteria never productively disseminated to these LNs in the first place. These data together 
demonstrate that, while BCG confers some protection in the lungs, H56 works to boost 
protection specifically in the LN compartment.  
Since early events post-infection are thought to be the most critical in determining TB 
outcome [115, 345, 376], we investigated vaccine induced protection at 5-6 weeks post-infection, 
to see whether control of Mtb in the LN compartment was still a phenotype strongly associated 
with BCG/H56 vaccination. Indeed, at early time points animals vaccinated with BCG/H56 had 
significantly less involvement of LNs as compared to controls. There are two possibilities for the 
reduction in CFU+ LN in vaccinated animals: prevention of dissemination to the LN or improved 
killing of bacteria that establish and grow in the LN. Our CEQ analysis supports the former 
possibility—that the vaccine not only limits dissemination within the lung, but also to the 
thoracic LNs, as CEQ were not detected in most of the LN in the BCG/H56 vaccinated animals. 
There was no difference in control of Mtb in the lungs of vaccinated and unvaccinated animals at 
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either time point, further corroborating the hypothesis that early control of Mtb in the LN 
generates vaccine-induced protection from reactivation TB later on. However, the CEQ data are 
also consistent with the possibility that Mtb do disseminate to the LNs but are immediately 
killed, resulting in CEQ that are below detectable limits. While the reduction in lung granuloma 
dissemination would support that dissemination to LN is also impaired, there isn’t an appreciable 
difference in the early immune responses of the lung granulomas. In contrast, there were 
differences in early immune responses between the LNs from control and vaccinated animals, 
which may support immediate killing in the LNs. This would indicate that vaccination results in 
T cells that reside in thoracic LNs and are capable of preventing bacterial growth in that 
compartment. In any event, BCG/H56 clearly has a strong protective effect on the thoracic LNs. 
LNs are the most common site of extrapulmonary TB in both humans and non-human primates 
[371], and are known to be an important niche for disease and potentially a reservoir for 
infection and disease persistence [372]. New adjuvants are being developed to deliver antigen to 
the LN and stimulate immune responses in that compartment [377, 378]. A vaccine that 
specifically targets the LN, perhaps using new technology, would represent an important new 
therapeutic for TB.  
The ability to investigate the immune responses in individual lesions is incredibly 
powerful and unique to our model system. In this study, we have utilized these techniques to 
identify immune responses that are associated with protection from reactivation. Just as there is a 
striking difference in bacterial burden early in the LN, there is a difference in cytokine profiles 
early post-infection in the LN of BCG/H56 vaccinated animals compared to controls. This 
cytokine profile is most likely a consequence of TB control and diminished bacterial replication 
in vaccinated animals. That this immunological difference is seen early is significant because 
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early events are likely influential in outcome of TB [376]. IFN-γ, while important for control 
of Mtb via macrophages [379], is detrimental in excess and may be responsible for TB-
induced pathology [201]. We have shown that having a small pool of IFN-γ-producing T 
cells, not a lack nor excess, is associated with bacterial clearance in lung granulomas [239]. 
Single producing IFN-γ T cells are short-lived, terminally differentiated effector cells [380], 
and are associated with a lack of control of TB in murine models [176, 201]. T cells that 
produce TNF, IL-2, or both are central memory cells [380]. TB-specific central memory cells 
are associated with protection against Mtb challenge in mice [136], and are observed in 
mice vaccinated with H56:CAF01 [274, 277, 320]. Control animals have a greater relative 
frequency of IL-6+IL-10+IL-17+ triple producing T cells, while BCG/H56 vaccinated 
animals have greater relative frequencies of those three cytokines being singly produced 
and IFN-γ+TNF+ double producing T cells. IFN-γ+TNF+ T cells are uniquely poised to home 
from LNs to non-lymphoid organs [381], and both cytokines are more efficient at killing 
Mtb in macrophages than either alone [88]. IL-6+, IL-10+, and IL-17+ single producing T 
cells could be more efficient at migration from the LNs to the lung parenchyma as well. 
Indeed, one of the main phenotypes of this vaccine is generation of a potent lung-homing T 
cell population [277]. Thus, LNs from BCG/H56 have a greater relative frequency of central 
memory cells and smaller relative frequency of terminally differentiated cells than control 
animals early p.i. In general, frequencies of T cells producing IL-6, IL-10, and IL-17 are 
similar to frequencies of T cells producing IFN-γ and TNF. Mtb-specific T cells can control 
infection in a IFN-γ/T-bet independent manner [203], and there is mounting evidence for 
the importance of these other cytokines in TB disease [169, 361]. Taken together, these 
immune responses correlate with the reduction in bacterial burden in the LN at early time 
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points and may be contributing to the protection from reactivation disease that is seen 
later in the course of infection. This warrants further investigation into this phenotype of 
protection to further demonstrate mechanistically that this leads to protection. These data 
can thus be utilized to inform future vaccine design to aid in the development of a 
successful therapeutic to combat TB.  
4.5 MATERIALS AND METHODS 
4.5.1 Animals 
The Institutional Animal Care and Use Committee of the University of Pittsburgh approved all 
experiments. The animals were housed and maintained in accordance with standards established 
in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.  
Vaccination and challenge. Cynomolgus macaques (Macaca fascicularis) imported from 
China and in the United States for at least a year (Valley Biosystems) were used for these studies 
(n=32). For the six-month study (Fig. 25): control animals received no vaccination (n=6); BCG 
only animals were vaccinated with 0.1 mL BCG Danish (SSI) intramuscularly (n=4); BCG and 
H56:CAF01 animals were primed with 0.1 mL BCG Danish intramuscularly followed by two 
doses of the vaccine H56 (Ag85B-ESAT6-Rv2660c; 50 μg) formulated with CAF01 (625 μg 
dimethyldioctadecyl-ammonium (DDA) and 125 μg trehalose-6,6-dibehenate (TDB)) at weeks 
10 and 14 after BCG priming (n=10). Originally, even groups (n=10) were planned for just 
control and BCG+H56:CAF01. The unequal group resulted from the need to capture PET-CT 
and outcome data from animals vaccinated with BCG alone, data that we lacked at the outset of 
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the study. Thus, we decided to split the control group to include this important and relevant 
control. For the six-week study: control animals received no vaccination (n=6); BCG and 
H56:CAF01 animals were primed with 0.1 mL BCG Danish intramuscularly followed by two 
doses of the vaccine H56 (50 μg) formulated with CAF01 (625 μg DDA and 125 μg TDB) at 
weeks 10 and 14 after BCG priming (n=6). All animals in the study were then challenged at 22 
weeks post-BCG priming with 8-24 CFU in 2 mL volume per animal with virulent Erdman strain 
Mtb via bronchoscope. For the six-month study, macaques were determined to have active or 
latent TB by necropsy using clinical and microbiologic signs [65].  
Necropsy. For the six-month study, macaques were euthanized approximately 22-24 
weeks post-Mtb challenge, except for an early necropsy warranted by clinical condition (n=1, 
BCG only group). For the six-week study, macaques were euthanized 5-6 weeks post-Mtb 
challenge. All animals were euthanized with an intravenous overdose of sodium pentobarbital 
(Beuthanasia) and maximally bled. At necropsy each animal was examined grossly for 
pathology. Using our published scoring system [65], the total amount of pathology was recorded 
from each lung lobe (number and size of lesions), LN (size and extent of necrosis), and 
extrapulmonary compartments (number and size of lesions). A pre-necropsy PET-CT scan was 
used as a “map” for identifying and finding each lesion in the lungs. Each individual lesion in the 
lung and all thoracic LNs identified were excised and mechanically homogenized to create a 
single cell suspension. Portions of these samples were spread on 7H11 agar (Difco) and 
incubated at 37°C with 5% CO2 for 3 weeks. CFU were then counted from these plates and used 
to both quantify individual lesion bacterial burden and—when summed together—the total 
bacterial burden for the animal [239, 365]. Portions of these samples were also used for 
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multiparameter flow cytometry (see below), and the remainder was stored at -80°C for other 
assays, including assessing chromosomal equivalents (CEQ; see below).  
4.5.2 Peripheral blood immune response assays 
Heparinized blood was drawn from study macaques at time points pre-Mtb challenge (weeks 0, 
2, 4, 6, 10, 11, 12, 14, 15, 16, 18, and 22 weeks post-BCG) and post-Mtb challenge (weeks 1, 2, 
3, 4, 6, 8, 12, 16, and 22). Peripheral blood mononuclear cells (PBMCs) were isolated using the 
standard Percoll gradient isolation (GE Healthcare) and washed with sterile PBS [115].  
ELISPOT. ELISPOT for IFN-γ was performed as previously described [115]. Briefly, 
96-well opaque multiscreen immunoprecipitation filtration plates (Merck Millipore) were 
hydrated, washed, and coated with 7.5 µg/mL of anti-human/nonhuman primate IFN-γ 
(GZ-4: Mabtech) for 2 hours at 37°C with 5% CO2. Plates were then blocked with complete 
RPMI containing 10% human AB serum for 2 hours at 37°C with 5% CO2. Each stimulation 
condition was performed in duplicate. Medium only was used as a negative control, and phorbol 
dibutyrate/ionomycin (P&I) and anti-CD3 were used as positive controls. CFP and peptide pools 
of H56 vaccine antigens (ESAT-6, Ag85B, Rv2660c) were used at 10 µg/mL. PBMCs were 
then added, and the plate was incubated for 48 hours at 37°C with 5% CO2. The plate was 
then washed and detection antibody (7-B6: Mabtech) was added at 2.5 µg/mL and incubated 
for 2 hours at 37°C with 5% CO2. The plate was washed and streptavidin-conjugated horseradish 
peroxidase was added at a 1:100 dilution and incubated for 45 minutes at 37°C with 5% CO2. 
The plate was washed and then developed using AEC substrate. The plate was dried overnight 
and read using an ImmunoSpot analyzer (Cellular Technologies Limited).  
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Flow cytometry. PBMCs were stimulated with peptide pools of H56 vaccine antigens 
used at 10 µg/mL for 1 hour at 37°C with 5% CO2, and then 5 hours in the presence of brefeldin 
A (Golgistop, BD Biosciences). Medium only was used as a negative control, and P&I was used 
as a positive control. The cells were then stained for surface and intracellular markers. Surface 
markers included: CD3 (SP34-2: BD Biosciences); CD4 (L200: BD Biosciences); CD45RA 
(5H9: BD Biosciences); and CD27 (0323: eBiosciences). Intracellular markers included: IFN-γ 
(B27: BD Biosciences); TNF (MAB11: BD Biosciences); IL-2 (MQ1-17H12: BD Biosciences); 
and IL-17 (eBio64CAP17: eBiosciences). Data acquisition was performed using a LSR II (BD 
Biosciences) and the resulting data were gated and quantified using FlowJo (Version 9.9.3; 
Treestar Inc.).  
Gating. Singlet cell populations were separated first using forward scatter area and 
height. The lymphocyte population was then gated based upon size. CD3+ cells were 
selected, and CD45RA and CD27 were then used to remove naïve T cells. Gates for each of 
the four cytokines were used to quantify individual production. The Boolean gating tool 
was then utilized to determine the combinations in which the six cytokines were produced.  
4.5.3 PET-CT scan analysis 
PET-CT scans were performed using a microPET Focus 220 preclinical PET scanner (Siemens 
Medical Solutions) and clinical eight-slice helical CT scanner (Neurological Corp.) as previously 
described [2, 350]. 18F-fluorodeoxyglucose (FDG), a non-specific marker of inflammation, was 
utilized as the probe for PET. Serial PET-CT scans were performed at 2, 3, 4, 6, 8, 12, and 16 
weeks post-Mtb infection, and before necropsy. OsiriX viewer, an open-source PACS (Picture 
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Archiving and Communication System) workstation and DICOM (Digital Imaging and 
Communications in Medicine) image viewer, was used for scan analyses as previously described 
[350]. Briefly, a region of interest (ROI) was segmented which encompassed all lung tissue on 
CT and was then transferred to the co-registered PET scan. On the PET scan, all image voxels of 
FDG-avid pathology (SUVmax > 2.3) were selected and summated resulting in a total SUVmax 
value.  In order to account for basal metabolic FDG uptake in the animal, the total SUVmax was 
normalized to resting muscle resulting in a total lung inflammation value [5]. Individual 
granulomas as seen on CT were counted in each scan to enumerate them longitudinally. SUV per 
lung granuloma was calculated as previously described [345]. The maximum SUV per LN was 
ascertained from the PET scan and was normalized to resting muscle.  These values (one for 
each lymph node per monkey) were then summed to create the outcome measure. Number of 
FDG-avid LN is a full count of any LN visible by PET with SUV > 5 normalized to resting 
muscle.  
4.5.4 Flow cytometry on primary tissue samples 
Data collection. Single cell suspensions of individual lung granulomas and LNs obtained at 
necropsy were incubated in brefeldin A (GolgiStop, BD Biosciences) for 2 hours at 37°C with 
5% CO2. The cell suspensions were then stained for viability (Invitrogen), surface, and 
intracellular markers. Surface markers included: CD3 (SP34-2: BD Biosciences); CD11b 
(ICRF44: BD Biosciences); and CD20 (2H7: eBiosciences). Intracellular markers included: IFN-
γ (B27: BD Biosciences); TNF (MAB11: BD Biosciences); IL-2 (MQ1-17H12: BD 
Biosciences); IL-17 (eBio64CAP17: eBiosciences); IL-10 (JES3-9D7: eBiosciences); and IL-6 
(MQ2-6A3: BD Biosciences). Data acquisition was performed using a LSR II (BD 
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Biosciences) and the resulting data were gated and quantified using FlowJo (Version 9.9.3; 
Treestar Inc.).  
Gating. Singlet cell populations were separated first using forward scatter area and 
height. Live cells were then gated, followed by the lymphocyte population based upon size. 
CD11b+ and CD20+ cells were then removed from this population, and remaining CD3+ 
cells were selected. Gates for each of the six cytokines were used to quantify individual 
production. The Boolean gating tool was then utilized to determine the combinations in 
which the six cytokines were produced.  
4.5.5 Chromosomal equivalents (CEQ) 
Following necropsy, tissue homogenates were re-suspended in 1xPBS and stored at -80C.  M. 
tuberculosis genomes were extracted from thoracic lymph node and lung samples as previously 
described [5, 86]. Following DNA extraction and concentrations measurement, quantification of 
chromosomal equivalents (CEQ) of M. tuberculosis was performed using real-time PCR as 
previously described [5, 86].  
4.5.6 Statistics 
For the six-month study, comparisons between groups were performed using the Kruskal-Wallis 
test with Dunn’s multiple comparisons test. For the six-week study, comparisons between groups 
were performed using the Mann-Whitney (Wilcoxon rank-sum) test for non-parametric values. 
Comparison of CEQ and CFU phenotypes between groups was performed using Fisher’s exact 
test. With the exception of the flow cytometric data, all graphics and statistics were created using 
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Prism (Graphpad). Analysis and presentation of flow cytometric data was performed using 
SPICE (Ver. 5.23; https://exon.niaid.nih.gov/spice/) [6]. Comparisons between absolute and 
relative cytokine expression were performed using the Wilcoxon rank-sum test. Comparisons 
between profiles of Boolean cytokine expression (pie graphs) was done using a permutation test 
as previously described [6].  
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5.0  PET-CT IMAGING PREDICTS VACCINE EFFICACY IN NONHUMAN 
PRIMATE MODELS OF TUBERCULOSIS 
Data from this chapter will subsequently be published in a first author manuscript. 
5.1 ABSTRACT 
Tuberculosis (TB) is a major global health concern, disproportionately affecting the world’s 
poorest nations. Many new vaccines for TB are in development, but clinical and pre-clinical 
trials are lengthy and expensive. New outcome measures are needed accurately reflect disease 
status, and markers need to be identified that can quickly predict these outcomes. The goal of this 
study was to develop a holistic, single measure in a non-human model of TB and identify 
surrogates that accurately predict this measure. Quantifiable outcome measures were used to 
create a factor-weighted score, resulting in one comprehensive number that reflects outcome. 
PET-CT markers by two months after challenge can be used to accurately predict outcome 
months later at necropsy. Putative blood signatures collected pre-challenge were identified that 
predict outcome. These tools should be further developed for use in modern vaccine evaluation 
to expedite the deployment of a novel TB therapeutic. 
 111 
5.2 INTRODUCTION 
There are two main challenges in vaccine deployment: development and testing. Many novel 
vaccines have been developed for TB and are in various stages of pre-clinical and clinical trials 
[356, 382, 383]. This begs the question: how does one down-select a putative candidate? Thus 
far, only one new large-scale efficacy trial has been performed for a novel TB vaccine [295], 
using either isolation of Mycobacterium tuberculosis (Mtb; the causative agent) or clinical 
diagnosis of TB as the main outcome [38]. Unfortunately, there are some significant pitfalls to 
using these outcomes. A clinical diagnosis of TB may take years or decades after the initial 
phase of infection [23]. In addition, TB cases can be culture negative, and such studies can be 
particularly difficult in infants. These outcomes also produce a binary outcome—active disease 
and latent TB infection—which has been shown to poorly reflect the true nature of tuberculosis, 
which is a spectrum of disease featuring everything from well-controlled latency, to subclinical 
disease, mild disease, and fulminant TB [55, 56]. This highlights a critical need for new outcome 
measures that reflect this spectrum and capture all aspects of TB disease.  
Blood correlates of TB outcome have been investigated in humans in attempts to develop 
a useful biomarker. Some studies show specific cellular immune responses that correlate with an 
outcome in the context of BCG vaccination [131, 268, 384], while some demonstrate that 
responses of hypothesized importance, e.g. production of IFN-γ, do not correlate with TB 
outcome [264]. Studies like these have led some in the field to question the reliance on a 
handful of immune effector molecules for an especially complex disease like TB [257]. 
Other studies have identified profiles of gene expression and/or cellular responses that 
correlate with outcome in adolescents and adults, years after BCG vaccination [42, 268, 
269]. However, for a real correlate of protection, an effective vaccine for tuberculosis is 
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needed [256], creating a catch-22 in the process of trying to develop such a vaccine. All the 
studies performed to date sought to correlate a host response to binary TB outcome [385], 
which will not capture the heterogeneity in TB disease, highlighting the need for novel, 
modern outcome measures. Our lab has pioneered the use of live positron emission 
tomography (PET)-computed tomography (CT) imaging to accurately describe and model 
outcomes for TB chemotherapy studies [2, 350]. PET-CT is highly translatable, with data 
from non-human primates (NHPs) matching data from humans in a variety of applications 
[350, 386, 387]. PET-CT can also be utilized as a tool for predicting clinical outcome [345] 
and risk of reactivation disease in latency [5]. However, since clinical outcome is binary, 
PET-CT for vaccine efficacy is merely a correlate of risk. It is unknown if PET-CT correlates 
to a continuous outcome of disease, which would mechanistically demonstrate 
inflammation measured by PET-CT as a correlate of protection. Certainly, PET-CT would 
not be used as a routine determinant of disease, but could lead to more tractable 
biomarkers that could be used in humans. 
The goals of this study were two-fold: to create a composite score that weights 
quantifiable outcome criteria to properly reflect their contribution to the overall outcome of each 
animal; and to identify markers, using PET-CT and flow cytometry, that are predictive of the 
composite score. Composite standardized scores have been used to great success in education 
and psychology [388]. Briefly, variables such as outcome measures are normalized to fit a 
Gaussian distribution then standardized, e.g. transformed into a z-score. Principal components 
analysis (PCA) can be utilized to assess relative contributions of each measure to overall 
variability [389], determining whether weighting of the measures is necessary. This technique 
has been used to create overall scores for diseases like chronic obstructive pulmonary disease 
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[390] and reduced 149 questions in a health questionnaire to the widely used and verified SF 36 
[391]. Many types of models exist to use variables to forecast an outcome. The simplest is 
standard least squares (SLS), more commonly referred to as multiple regression, in which 
coefficients of the regression model can be used to infer importance to variability in outcome 
[392]. Danger arises when many parameters are used to construct models, as overfitting may 
occur, which means that the model is highly predictive of its own data but responds poorly to 
novel data. Cross validation techniques have been developed to overcome overfitting [393]. In 
this study, we used SLS models to construct predictive models of outcome score based upon 
PET-CT data early after Mtb, and peripheral immune data before challenge. These responses will 
be further vetted and developed in future studies.  
5.3 RESULTS 
The goal of this study was to create a score that would combine the quantifiable outcome data 
from macaques at necropsy into a single number that represents the spectrum of outcomes, and 
then to build models that use PET-CT and peripheral blood data to predict before and early after 
Mtb challenge outcomes 20-24 weeks later. In this dissertation, 96 macaques were utilized to 
study various aspects of TB vaccinology. The 64 rhesus macaques from chapter 3 and the 32 
cynomolgus macaques from the long study in chapter 4 were combined with 28 control 
cynomolgus macaques from other studies (Table 4) [5, 345, 350, 365].  
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Table 4: List of macaques utilized in the modeling study. 
n Species Use in this study Refs 
12 Rhesus Control animals to standardize score Chapter 3 
52 Rhesus Vaccinated animals for comparison Chapter 3 
6 Cynomolgus Control animals to standardize score Chapter 4 
28 Cynomolgus Additional controls from other studies [5, 345, 350, 365] 
14 Cynomolgus Vaccinated animals for comparison Chapter 4 
12 Cynomolgus Short-course animals to test PET-CT model Chapter 4 
 
5.3.1 Standardized score summarizes outcomes in one continuous metric 
The first step was to develop a continuous score that neatly incorporated outcomes at necropsy 
into a single metric that reflected the spectrum observed in TB outcomes [55, 56]. Rather than 
having to build multiple predictive models for each outcome, e.g. a model for bacterial burden in 
the lung, a model for pathology in LN, etc., predictive models will only have to forecast this one 
metric that captures all outcome measures. How best to build a holistic outcome score? A 
standardized score, or z-score, is used frequently in many different scientific fields, especially in 
psychology and the social sciences, to combine different quantitative outcomes of various scales 
and units [388]. A z-score essentially takes a distribution of data and centers it using a mean and 
standard deviation, so that a value of zero represents the mean and each integer on the scale 
represents values a standard deviation higher (positive) or lower (negative) than the mean. Our 
scoring systems for gross pathology and bacterial burden have wildly different scales, and using 
a standardized score would facilitate the combination of these data. All of the macaques selected 
for this study could be used to create the score, but their score values would not be very 
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informative since this combines control and treatment group animals. For example, by 
standardizing each measure (e.g. lung bacterial burden) to all macaques, an animal at zero would 
represent the mean of all animals included, and an animal at -1 would have an outcome one 
standard deviation better than the mean of all animals, which is not very informative. On the 
other hand, by standardizing each measure to the control macaques, an animal at zero would 
Figure 39: Construction of a holistic, continuous outcome score. A Example of transformation and 
standardization of one outcome measure. Raw total CFU data for the lung (blue) are first log10 transformed (red) to 
fit those data to a normal, or Gaussian, distribution. The transformed data are then standardized to a z-score (green), 
so that the mean is zero and each integer is a standard deviation. B Eigenvalues for the principal components of the 
five necropsy outcome measures. C The macaques utilized for this study on a principal component space. Only one 
component was significant as determined by the Kaiser rule, i.e. eigenvalue>1 [4]. Each dot represents either one 
rhesus macaque (red) or one cynomolgus macaque (blue). D The loading values for the main principal component, 
and the percent of the total component each outcome represents.  
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represent the mean of the controls only, and an animal at -1 would have an outcome one standard 
deviation better than controls, thus displaying the impact of a treatment over controls.  
We therefore planned to use the mean and standard deviation of only the control animals 
to standardize each necropsy outcome, allowing the score values to be more informative by 
depicting the magnitude of difference between treatment and control macaques. Gross pathology 
in the lungs, in the lymph nodes (LN), and in other extrapulmonary sites (EP) and total bacterial 
burden in the lung and LN were chosen as the five main quantifiable and objective outcome 
measures as these summarized the data collected at necropsy. The raw values for these five 
outcomes were first transformed to a normal distribution to aid in modeling (Fig. 39A). The data 
were then standardized to the 46 control macaques (12 rhesus and 34 cynomolgus) to create 
unitless measures all on the same scale that could then be combined into one holistic metric.  
The next question was whether to weight each of the five main standard scores before 
combining them. If each standardized outcome contributes to the variability in overall outcome 
equally (i.e. has equal weight), then the five standard outcomes should be weighted by 0.2 since 
each contributes 20% to total outcome. However, if some outcomes contribute to the variability 
in overall outcome more, they should be weighted more to reflect that, e.g. if lung bacterial 
burden contributes to 50% of the variability it should be weighted by 0.5. To address this 
question, we utilized principal component analysis (PCA) to determine the extent to which each 
outcome measure contributed to the overall variability. The Kaiser rule dictates that only 
principal components (PC) that have an eigenvalue greater than one significantly contribute to 
variability [4]. Of the PC eigenvalues (Fig. 39B), only the first PC (PC1) was above one, 
suggesting that only PC1 significantly explained variability in macaque outcomes. PC1 
explained 70.2% of the variability in outcome (Fig. 39C), and most of the rhesus (red) and 
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cynomolgus (blue) macaques overlap in this vector subspace. The loading values for each PC 
indicate how strongly each outcome impacts the variability due to that component [360]. The 
loading values for all five outcomes are very similar and each contributes approximately 20% to 
the principal component (Fig. 39D), suggesting that the outcomes do not need to be weighted 
since they contribute almost equally.  
5.3.2 Using the outcome score to compare controls to vaccinated macaques 
The five control-standardized outcomes were then averaged to create the overall outcome score 
(Fig. 40), where zero represents the mean of the controls and each integer represents a standard 
deviation better (negative) or worse (positive) than control macaques. To provide an example of 
the output, macaques were grouped by the chapter of this dissertation in which they were 
studied. There was no statistical difference between any of the vaccinated macaques and 
Figure 40: Comparisons of outcome scores between cohorts from the other studies in this dissertation. Each 
dot represents one animal and bars represent means and standard deviation. Left, Outcome scores from the rhesus 
macaques in chapter 3. Dunn’s multiple comparisons were used to compare each vaccine regimen to controls 
specifically, and to compare each BCG boost regimen to BCG. None of the comparisons were statistically different. 
Right, Outcome scores from the cynomolgus macaques in chapter 4. Dunn’s multiple comparisons were used to 
compare the groups, and no statistical difference was found. 
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controls, nor between any of the prime-boost cohorts and BCG, in the animals from chapter 3 
(Fig. 40, left). These scores fit well with the what was demonstrated in that study, which is that 
none of the vaccines significantly protect rhesus macaques from TB. Most of the treatment 
groups, with the exception of BCG+Ad5(empty), have a difference in outcome score of about 0.5 
from the rhesus controls, which based upon the z-score means about a 20% improvement. There 
was no difference in the cynomolgus macaques from chapter 4 by comparing all three cohorts 
(Fig. 40, right). However, BCG was severely underpowered in this comparison. Excluding BCG 
and using Welch’s t test to compare control and BCG+H56:CAF01 only yields a p value of 
0.0153. The mean outcome score of the BCG+H56:CAF01 vaccinees was about -0.8, which 
indicates that these animals on average had outcomes better than 78.8% of all control macaques. 
Thus, this outcome score represents a single metric that captures the spectrum of outcomes in the 
macaques and facilitates overall comparisons between cohorts.  
5.3.3 Early PET-CT markers robustly predict outcomes 
The second step of this study was to build models that integrate early serial PET-CT markers (4-
12 weeks p.i.) to predict later outcomes (24+ weeks p.i.). There were four quantifiable PET-CT 
outcome measures in this study using the PET probe 18F-fluorodeoxyglucose (FDG), a 
nonspecific marker for inflammation [374]. The first is the number of FDG-avid thoracic lymph 
nodes (LNs), which are inflamed LNs visible by PET. The second is the total amount of FDG 
uptake in the lungs, interpreted as total lung inflammation. The third is the number of new lung 
granulomas visible by CT that appear after 4 weeks p.i. Four weeks p.i. is the earliest reliable 
count of granulomas in the lungs following infection. The fourth is the number of sites of 
extrapulmonary (EP) involvement apparent by PET or CT. We first correlated each PET-CT 
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marker at each time point to the outcome to elucidate the individual influences of the 
radiological markers (Fig. 41, top panel). The number of FDG-avid LN was the most robust 
predictive PET-CT marker, followed by total lung inflammation. The ability of each of these 
markers to predict outcome score increased as the macaques progressed in their respective 
studies. At each of the early time points p.i. investigated, backwards stepwise parameter 
selection was used to pick one or more of the four PET-CT markers to create the most predictive 
regression model of outcome with the lowest amount of residual error compared to other models 
(Fig.  41, bottom panel, dotted line). To capture the dynamics of these markers over time, each 
Figure 41: Predictive models of efficacy using serial PET-CT markers. The top panel represents models at 
each of three time points. The models on the dotted line only use PET-CT data from that particular time point. The 
models on the solid line use PET-CT data from that time point and potentially the time points prior. The bottom panel 
depicts each PET-CT marker directly correlated to the outcome score at each time point. 
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marker at 8 and 12 weeks p.i. had its 4 week value subtracted to determine the change over time. 
These new markers were then added to the original ones at each time point to create a cumulative 
model at each time point (solid line). The most predictive time point was determined to be 12 
weeks p.i., which robustly predicted the outcome score at 20-24 weeks p.i. (R2=0.7828; Fig. 42).  
5.3.4 PET-CT model predicts likely long-term outcomes of short-term studies 
Data from cynomolgus macaques in chapter 4 offered an opportunity to test the robustness of 
PET-CT’s predictive ability. The twenty macaques in that study used to build the model were 
challenged and necropsied 24 weeks later (Fig. 43, left). However, to investigate early events 
associated with protection from reactivation TB, twelve macaques (unvaccinated or BCG/H56 
vaccinated, see chapter 4) were challenged and necropsied 5-6 weeks later. To test the PET-CT 
model, we took PET-CT data from those macaques necropsied early and entered them into the 
Figure 42: The most robust PET-CT predictive model, at 12 weeks p.i. The actual outcome scores (y-
axis) fit to the outcome scores predicted by the PET-CT model (x-axis). Each dot represents one animal and the 
line is of best fit.  
 121 
model to predict the outcomes of those macaques had they gone to 20-24 weeks p.i. (Fig. 43, 
right). The predicted outcome scores fell well within the range observed in the long-term vaccine 
study, and there were no significant differences between the actual and predicted distributions of 
scores using an equivalency test. These data suggest that early PET-CT markers robustly predict 
subsequent TB outcomes.  
5.3.5 Peripheral blood markers correlate with outcome score 
The final step in this study was to build models that used flow cytometric data from peripheral 
blood mononuclear cells (PBMC) before challenge to predict outcomes months after challenge. 
While immunologic data was not available from all of the macaques used to build this model, 
flow cytometric data on PBMCs were available from 40 of the rhesus macaques in chapter 3 and 
all of the cynomolgus macaques from chapter 4. Since the goal of this final step was to identify 
vaccination-specific immune signatures, all control macaques were first excluded. A signature 
Figure 43: PET-CT model predicts outcome for a separate cohort of animals. Each dot represents the 
outcome score for one macaque, and bars represent means and standard deviation. The two cohorts of macaques on 
the left (ACTUAL) were necropsied at six months post-Mtb challenge, and the scores are from the data collected at 
necropsy. The two cohorts of macaques on the right (PREDICTED) were necropsied at six weeks post-Mtb 
challenge, and the scores were generated from the predictive models in Fig. 41.  
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independent of any particular TB vaccine is more useful than signatures for each individual 
vaccine, so rather than using PBMC responses to non-vaccine antigens (e.g. responses to H56 in 
M72 vaccinees), only vaccine-specific response were used (e.g. response to M72 in M72 
vaccinees) and were compared equally across groups. Vaccine antigen-specific responses from 
PBMCs were then subset by lineage (CD4 or CD8) and by cytokine expression (producing any 
or all interferon-γ (G), IL-2 (2), or tumor necrosis factor (T)). Five time points before Mtb 
challenge were chosen, using immune responses from before BCG, two time points after BCG, 
and a time point after each boost (if boosted at that time point). Thus, these predictive models 
were built using cytokine production by T cells from vaccinated animals in response to antigen 
stimulation to whichever vaccine regiment they received at relevant time points before challenge. 
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Figure 44: Predictive models of efficacy using peripheral T cell markers. A Backwards stepwise selection 
was used to build models of vaccine antigen-specific peripheral immune responses that predict outcome score. The 
blue line represents the overall R2 (coefficient of determination) at each time point. The red line represents the R2 
adjusted for the number of parameters included by using the degrees of freedom (number of terms). The green line 
represents the R2 for k-fold validation models. B Breakdown of the T cell markers that contribute to the predictive 
models at each time point. The subsets of T cells are on the y axis, with lineage (CD4 or CD8) and cytokine 
production (G=IFN-γ; 2=IL-2; T=TNF; ANY=any combination of those three cytokines) denoted. The length of each 
bar represents the strength of the contribution of that marker to the model, measured by log10 of the p value. Markers 
whose bars are on the left are associated with improved (lower) outcome score while markers whose bars are on the 
right are associated with worsened (higher) outcome scores.  
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Backwards stepwise selection of these T cell responses was used to build predictive regression 
models at each pre-challenge time point (Fig. 44A). Any or all the T cell markers were used at 
each time point and the robustness of the model (coefficient of determination, or R2) was plotted 
(blue line). One major problem with regression models is overfitting, which means that a model 
is created that fits predictive markers to an outcome very well but poorly predicts new data 
entered into the model [392]. Overfitting usually occurs when too many irrelevant parameters 
(predictive markers) are entered into a model. To avoid overfitting in this study, two means of 
validation were used: the R2 adjusted for degrees of freedom (R2adj, red), or the number of 
parameters used in each model; and k-fold cross validation (R2k-fold, green), which randomly 
subsets the data into k partitions and in turn builds a model using k-1 partitions and tests it 
against the remaining one [393]. The adjusted R2 combats overfitting by penalizing the model 
every time a new parameter is added, i.e. the more T cell signatures used the more the R2 is 
penalized (decreased). Cross-validation is even more stringent by repeatedly constructing models 
and fitting data set aside against the model, thus continually testing the ability of the model to 
react to new data.  
Essentially, the closer the three R2 values are to one another, the more robust the model, 
and validation R2 values (red and green) that are much lower than the main one (blue) hint at 
overfitting or inaccurate models. The models early post-BCG and after the second boost have the 
highest main R2 (blue) and relatively similar validation R2 values (red and green). This suggests 
that vaccine antigen-specific responses are most reliably predictive of outcome score early post-
BCG vaccination and after secondary boosting of BCG (Fig. 44A).  
We then sought to elucidate the specific cytokine responses at each time point that 
significantly contribute to the models. We determined the p value of each immune marker in its 
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relationship to the model and log10 transformed the data, keeping it negative if it contributed to a 
lower (better) outcome score and making it positive if it contributed to a higher (worse) outcome 
score (Fig. 44B). Thus we have demonstrated the ability of peripheral T cell responses to predict 
outcome before Mtb challenge, and have identified putative markers that will be vetted and 
further developed in subsequent studies.  
5.4 DISCUSSION 
The goal of this study was to create a holistic outcome score and to construct models that can 
accurately forecast the score before or early post-Mtb challenge. The development of a broad 
score would allow for macaques between many different studies to be compared to one another, 
and would be the first step in pursuit of predictive markers (Fig. 45). Between Mtb challenge and 
necropsy, radiological data are collected that robustly predict outcome and can abbreviate the 
length of a pre-clinical study. Before challenge, during vaccination, blood markers can be 
identified that can more easily be translated to clinical studies. This study has presented a metric 
that combines five different outcome measures into one score. This score is based upon a z-score, 
which is unitless and allows different continuous measures to be combined. In this study, instead 
of using the mean and standard deviation of all the macaques, the outcomes were standardized to 
the controls. This allows for more meaningful statements to be made about the different study 
cohorts. Thus, the control animals should have a mean of zero and standard deviation from -1 to 
1. If a vaccination group has a mean of -1, that means the group overall did one standard 
deviation better than controls, or better than about 84% of controls. This score may be 
standardized to any control, so that comparisons could be made directly to BCG only vaccinated 
 126 
macaques instead, for example in a study examining prime-boost efficacy. This score is also 
continuous, and while providing more power and less type I error, also reflects the natural 
spectrum of outcomes in TB [55, 56].   
This study features predictive models that utilize early PET-CT data to robustly predict 
outcome much later. These models were used to predict outcomes in separate cohorts of 
macaques for which there were PET-CT data but not outcome data. The predicted values not 
only fit well with actual outcome scores six months p.i. but are not statistically different from 
one another. This provides more evidence to the robustness of PET-CT as a predictive tool. PET-
CT thus should be further developed as a pre-clinical instrument to abbreviate the process of 
down-selecting vaccine candidates to move into human trials. The most protected macaques 
included in this study were at a low risk of reactivation disease, which had been previously 
shown using that vaccine [275] and shown using a PET-CT metric [5] in Chapter 4. This 
Figure 45: Approach for building predictive models of vaccine efficacy. The blue arrow represents the 
temporal direction of the study, which begins with vaccination and ends with outcome determined at necropsy. The 
step was to build an outcome score (OUTCOME) which encapsulates the various outcome measures into a single 
continuous score. The next step was to build a model that utilized PET-CT markers (RADIOLOGY) after Mtb 
challenge to predict outcome. The final step was to build a model that incorporated various CD4 and CD8 T cell 
cytokine profiles (IMMUNOLOGY) to predict outcome. 
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protection was apparent both in total lung inflammation and in the LN. The best PET-CT 
associated predictors were related to both of those markers. However, the best vaccine would be 
one that prevents initial establishment of Mtb, as evidenced by prevention of granuloma 
formation. A vaccine that accomplishes this does not yet exist, but we have provided evidence 
that a vaccine with this protective phenotype could be identified very quickly using PET-CT, 
most likely by 4 weeks post-Mtb challenge, thus greatly expediting pre-clinical trials.  
At the end of the study we used peripheral blood markers collected before Mtb challenge 
to build predictive models of outcome score. These models were not as robust as the models 
using PET-CT markers, but are more translatable to human clinical trials since they are linked to 
immune responses following vaccination and not radiological responses following Mtb infection. 
The most robust of these pre-infection models were early after BCG vaccination and after the 
secondary boosting of BCG immunity. We then identified the immune markers in each model 
that contributed to its robustness the most. These T cell responses were all vaccine antigen-
specific, and thus were technically recalled by a variety of different antigens. However, the goal 
was to identify signatures that were vaccine-independent and correlative of protection against 
TB. Thus, these markers could theoretically be applied to any novel TB vaccine trial. Most of 
these cytokine markers were present in CD4 T cells, which makes sense since most TB vaccines 
are designed to elicit immunity in those cells [356]. Most of these markers only appear at one 
time point, while others are significantly associated with outcome at multiple time points. 
Production of IFN-γ and TNF by CD4 T cells is mostly associated with poor outcome scores. IL-
2 and TNF production, associated with central memory T cells [380], is very strongly associated 
with improved outcome scores early after BCG vaccination. The production of all three 
cytokines together by CD8 is associated with poor outcome scores early during vaccination, but 
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slowly becomes associated with improved outcome over the course of vaccination. CD4 T cells 
that make any cytokine (ANY) exhibit similar associations with outcome scores, suggesting 
dynamic associations peripherally with protection. More macaques are needed to vet these 
observations and further develop peripheral blood markers as a signature of vaccine-engendered 
protection.  
5.5 MATERIALS AND METHODS 
5.5.1 Animals 
The Institutional Animal Care and Use Committee of the University of Pittsburgh approved all 
experiments. The animals were housed and maintained in accordance with standards established 
in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.  
The animals utilized for this study were primarily studied in chapters 3 and 4 of this 
dissertation, and extensive descriptions of vaccinations, Mtb challenge, and necropsy procedures 
can be found in this section of those chapters, as can data on PET-CT data and peripheral blood 
responses using flow cytometry. Data on additional controls have been published [5, 345, 350, 
365].  
5.5.2 Outcome score 
Raw data on gross pathology from the lung, LN, and EP and total bacterial burden from the lung 
and LN were imported from those earlier studies into JMP (SAS). Discrete count data (necropsy 
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score) were transformed using a square root transformation to a Gaussian (normal) distribution, 
and continuous data (CFU) were transformed using a log10 transformation. These five outcomes 
were then standardized using the prototypical z-score: 
 
where x is an outcome value for a macaque, µ is the mean of the population, and σ is the 
standard deviation. For this study, the mean and standard deviation utilized for each outcome 
measures were of only the control animals to compare the treatment groups to them. These five 
z-scores were then averaged together without weight, since they equally impact the variability on 
outcome (see results).  
5.5.3 PET-CT models 
PET-CT data from the macaques at 4, 8, and 12 weeks p.i. was imported and transformed to 
Gaussian distributions using a square root transformation for count data (FDG-avid LN, # of new 
granulomas, # of sites of EP) and a log10 transformation for continuous data (total lung 
inflammation). Backwards stepwise parameter selection was used to pick one or more of these 
measures at each time point. The model with the highest R2 and lowest residual error (AICc) was 
selected as the best for each time point. For the components, each PET-CT marker was 
correlated to outcome score and R2 was then reported. These models were saved as formulae for 
subsequent prediction of outcome scores. PET-CT data from the twelve short-course macaques 
in Ch. 4 was imported and transformed as above. These data were then entered into the 
appropriate formulae to calculate predicted outcome score. 
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5.5.4 Immunology models 
Rhesus and cynomolgus macaque peripheral blood data were matched, and five shared time 
points and sixteen shared T cell markers emerged. Vaccine antigen-specific responses were used 
for the model, e.g. response to peptide pools of H56 antigens for H56 vaccinees, responses to 
M72 antigens for M72 vaccinees, etc. Thus, there were sixteen potential markers at each time 
point. Backwards stepwise parameter selection was to pick one or more of each marker at each 
time point. The model with the highest R2 from the k-fold cross validation models was selected 
as the best model for each time point (k=4). For each model, p values were reported to measure 
the significance of the association between the selected markers (one or more of the sixteen) and 
the outcome scores. These p values were then log10 transformed and reported. Transformed p 
values were all negative, but those with an association to poor outcome were made positive for 
clarity in presentation.  
5.5.5 Statistics  
All statistics and data presentation were done in JMP (SAS) and Prism (Graphpad). Comparisons 
were done using Welch’s t test and the Holm-Šídák test in Prism to compare the outcome scores. 
JMP was used to build SLS or multiple regression models, to create the outcome score, to test 
the actual and predicted outcome scores using an equivalency test, and to perform correlations 
where described in this study. 
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6.0  IMPLICATIONS OF THIS DISSERTATION 
6.1 PROTECTION ENGENDERED BY BCG AND BCG/H56 
In all the studies performed in the course of this dissertation, a wide spectrum of 
outcomes was observed. These data add to the growing body of evidence that tuberculosis (TB) 
is not merely two distinct binary outcomes, but rather a spectrum from well-contained latency to 
fulminant disease [55, 56]. In the rhesus macaque model of TB, BCG arguably provided the best 
protection against low dose Mycobacterium tuberculosis (Mtb) challenge. BCG vaccinated 
rhesus macaques exhibited a lower bacterial burden in the lung, reduced extrapulmonary 
pathology visible at necropsy, and less total lung inflammation by PET.  This cohort of animals 
also had reduced evidence of TB disease using PET-CT markers at early time points. BCG here 
appears to work at the level of some sterilizing immunity in the lung and prevention of 
dissemination to extrapulmonary sites. However, the LN compartment seems to be neglected by 
this vaccination, as there was no difference in bacterial burden in the LN between control 
macaques and those vaccinated with BCG. These data are similar to data from BCG in 
cynomolgus macaques from this dissertation. BCG vaccinated cynomolgus macaques exhibited 
less gross pathology in the lungs at necropsy than control macaques, albeit without reducing 
bacterial burden in the lung. This BCG vaccinated cohort also had animals with smaller median 
lung granuloma sizes, lower FDG SUV per lung granuloma, and lower total lung FDG avidity at 
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early time points post Mtb challenge. Interestingly, some LN protection is also seen early by 
PET-CT in this cohort, as macaques in it had fewer FDG-avid LN and lower summations of 
maximal LN SUV than control macaques. That being said, by necropsy later in the study, no 
protection in the LN compartment was observed for BCG vaccinated animals. These data 
together with the rhesus data suggest that BCG confers some protection from TB by working 
early in the lung and LN, but not maintaining protection within the LN compartment. This lack 
of long-lasting effect in the LN compartment could be one explanation for the incomplete 
protection conferred by BCG, as the data in this dissertation strongly demonstrate that LN are 
critical for protection against TB disease. Although BCG does not protect against pulmonary 
infection in humans later in life, BCG does protect infants from severe manifestations of TB 
disease which are typically extrapulmonary in nature [132]. This dissertation has provided some 
evidence that BCG is protective in rhesus macaques against extrapulmonary TB, which is thus 
supported by these observations in humans.  
The fact that BCG is a live vaccine might explain why it does confer such potent initial 
immunity to TB, as live vaccines typically engender more robust immunity [394]. None of the 
vaccines used to boost BCG conferred protection beyond BCG, and none of them were live. 
There are live vaccine candidates in clinical trials [356]. These were developed to replace BCG, 
but their ability to boost BCG has yet to be investigated. That being said, revaccination with 
BCG has already been explored and shown to instill no additional protection against TB [138]. 
The fact that none of the experimental vaccines could increase protection against TB beyond 
BCG additionally suggests that either they are inadequate or that they should be investigate using 
alternative routes of vaccination. Boosting BCG with empty Ad5 not only removed the 
protection conferred by BCG but made the macaques more susceptible to Mtb challenge than 
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completely unvaccinated controls. Ad5 induces type I interferon (IFN) responses which have 
been demonstrated to be detrimental to anti-TB immunity [150, 255]. The Ad5 vector was 
replication deficient, though, and thus was not replicating when the macaques were challenged. It 
is possible that the vector polarized the cells in the lung and thus reacted later to Mtb challenge 
differently. Immunization of mice with poly(I:C), which also induces type I IFN, leads to worse 
TB outcomes after Mtb challenge [251]. These data suggest that viral vectors, or any adjuvant 
that stimulates type I IFN, should not be used in vaccination against TB. Though these were the 
macaques vaccinated via aerosol and i.m., the aerosol route of vaccination should not be ignored. 
Other adjuvants and delivery systems that are more successful through other routes could be 
investigated by aerosol. A similar sentiment should be applied towards the strategy of prime-
boost vaccination. It still represents a highly tractable approach to TB vaccination, as there is 
evidence for its efficacy in cynomolgus macaques, and should continue to be investigated and 
developed in that nonhuman primate model.  
Although the evidence in the rhesus macaque model does not paint prime-boost in a 
favorable color, boosting BCG with H56 in CAF01 reduces the risk of reactivation disease in 
cynomolgus macaques, like our previous data utilizing IC31® [275]. The protection conferred by 
H56 appears to be orchestrated in the lymph nodes (LN). This compartment has emerged as 
pivotal to TB outcome, and will be discussed in depth in the next section. The protection against 
disease observed in BCG vaccinated rhesus macaques appeared to be mostly in the lungs, by 
both bacterial burden and total lung inflammation. This implies that different vaccines might 
work through different routes, and confer different types of protection. Perhaps, to achieve 
optimal protection against TB, multiple types of vaccine need to combined to stimulate immunity 
in all relevant physiological compartments. After these studies, a “home-run” vaccine has yet to 
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emerge. None of the vaccines in this dissertation prevented infection or fully prevented active 
TB disease. The data contained within highlight a major gap that continues to exist in TB 
vaccinology, which is not knowing the best route of vaccination. Too much of the efforts of the 
field have been expended on identifying antigens that could be utilized in a vaccine without 
completely understanding where and how these antigens should be administered to a host to 
protect it from TB. We have a vaccine that demonstrates some quantity of efficacy against TB 
(BCG), and this represents a powerful tool to probe the various routes and vehicles for vaccine 
administration. Once the best route is identified, the could be systematically tested to determine 
which construct engenders the best protection from TB. These studies therefore highlight the 
need for both investigation of novel vaccines and delivery of promising candidates through 
alternative routes.   
6.2 LYMPH NODES ARE A CRITICAL SITE OF MTB INFECTION 
In both nonhuman primate models, the LN compartment played an extremely critical role in 
determining the ability of a macaque to resist TB disease. Rhesus macaques that completed the 
study in this dissertation with better outcomes had LN with T cell cytokine profiles that were 
significantly different that those from LN of rhesus macaques with worse outcomes. This 
difference in immune profile was not observed in lung granulomas from these two different 
groups of animals. Since outcome in that study was determined independently of treatment 
group, this suggests that having a beneficial T cell signature in the LN is broadly important for 
protection against TB disease, and further suggests that the LN exert considerable influence over 
eventual outcome. Protection against reactivation TB with BCG/H56 in cynomolgus macaques 
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was elucidated further by demonstrating that early post-Mtb infection there is a reduction in 
bacterial burden and more CEQ-CFU- LN, or LN where Mtb did not establish infection. These 
data all highlight the critical role that LN play in determining TB outcome.  
This dissertation thus adds to the theory that LN could be the epicenter of TB, not the 
lung. Even before Mtb was identified as the causative agent of TB [17], it was observed that 
primary lung infection is not a prerequisite for the development of pulmonary TB [395]. The 
clear majority of bacterial burden is in the LN, not the lung. This was observed in most of the 
nonhuman primates in this dissertation, apart from those animals with especially severe lung 
disease, e.g. TB pneumonia. In humans, it has also been noted that there is “a difference in tissue 
susceptibility…provided by the freer multiplication of the bacillus in the lymph nodes draining a 
site of primary infection than in the infected site itself.” [396]. Only after systemic immunity 
against TB is mounted are pathological responses recorded in the lung [75]. In all routes of Mtb 
or M. bovis infection observed, the LN eventually become a stronghold for mycobacteria. In the 
classic route, pulmonary exposure to Mtb in humans and nonhuman primates leads to infection 
of the lung-draining LN [12, 111], as does pulmonary exposure to M. bovis in cattle [397]. 
Ingestion of M. bovis by cattle leads to lymphatic spread from a primary gut infection to 
mediastinal or tracheobronchial LN, with or without pulmonary disease [398, 399]. Intratonsilar 
inoculation of M. bovis in cattle leads to initial colonization of the tonsils or medial 
retropharyngeal LN with subsequent spread to the lung-draining LN [400]. Lymphatic 
endothelial cells have been demonstrated to be a replicative niche, in which autophagy either 
promotes or restricts the growth of Mtb based on the activation profile of the cell [401]. In 
addition to the role of the LN as a preferred replicative niche, we have demonstrated the clear 
role of the LN as a key player in reactivation TB. In experimental reactivation with anti-TNF, the 
 136 
first signs of reactivation appeared in the LN which exhibited satellite lesions forming from 
established granulomas, which were not apparent in the macaques that did not reactivate [57]. 
CD4 depletion of LTBI macaques induces reactivation that is associated with lower CD4 counts 
in the LN [58]. Both this dissertation and a previous study also highlight the LN as a protected 
site in macaques with a low risk of reactivation TB engendered by BCG/H56 vaccination [275]. 
This body of evidence thus suggests that not only are the LN a critical site of Mtb infection, but 
that they should be targeted by therapeutics, especially those that seek to block TB disease 
specifically.  
6.3 A NEW FRAMEWORK FOR PRE-CLINICAL MODELS 
The rhesus macaque model exhibits pathology like that of human infants, while we have clearly 
demonstrated that the cynomolgus macaque model is incredibly similar TB of adolescents and 
adults [107]. Interesting, this dissertation has provided evidence that BCG confers a decent 
amount of protection to rhesus macaques against disease and no protection against clinical TB in 
cynomolgus macaques. These data are like the data in humans that suggest that BCG protects 
infants, but not adolescents or adults [132]. Therefore, this dissertation could begin to provide a 
framework for future pre-clinical models. Rhesus macaques could be used for pre-exposure 
vaccines, in which prevention of infection is the endpoint, and cynomolgus macaques used for 
post-exposure vaccines, in which prevention of clinical disease is the endpoint. H56 vaccination 
data in this dissertation provides a neat example for this framework. H56 was developed as a 
multistage vaccine useful for both pre- and post-exposure TB [274]. That being said, there is a 
lack of strong evidence that this vaccine prevents infection. In this dissertation, BCG/H56 
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vaccination does not prevent initial granuloma formation in cynomolgus macaques and has no 
efficacy beyond BCG in rhesus macaques. There is evidence, though, in this dissertation and 
published that BCG/H56 reduces the risk of reactivation TB [275], and is thus efficacious as a 
post-exposure vaccine. This was observed not in the rhesus macaque model but the cynomolgus 
macaque model.  
A new outcome score was developed in this dissertation that is holistic and captures all 
the outcomes at necropsy into a single number. This score is relatively easy to build from a set of 
controls, and since it is standardized to a normal curve, it is relatively easy to interpret. This 
score can be standardized based on any control. For example, if the study’s aim is to compare 
boosting BCG prime to prime alone, the BCG group can serve as the base for the outcome score. 
This score also is the most amenable way to build predictive models. Few models can predict 
multiple outcome variables simultaneously, and models that predict continuous variables are 
decidedly more powerful than those that predict binary outcomes. Thus, this continuous outcome 
score serves both needs. One of the major limitations of this score, however, is the masking of 
the various individual outcomes of TB infection and disease, such as compartmental outcomes 
(lung or LN or EP). This dissertation has demonstrated a very clear role for the LN in association 
with the eventual outcome of TB disease. The better outcomes of rhesus macaques in the prime-
boost study had a differential T cell signature in the LN but not in lung granulomas. BCG/H56 
vaccinated cynomolgus macaques had a reduced apparent risk of reactivation TB by PET-CT 
which was associated with protection in the LN, as these macaques had similar bacterial burden 
in the lung as control macaques. This distinction between protection in these divergent sites is 
essentially lost in a holistic outcome score as all of the different outcomes are merged into a 
single number. If the question is simply modeling the overall outcome of a macaque, this is of no 
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consequence. However, if the LN are a critical compartment of special interest for a study, then 
the outcome score may not be the best tool to build models or answer other questions. However, 
this challenge is easily overcome as models can be built directly to bacterial burden or pathology 
in the LN. These two outcomes could even be combined in a “LN outcome score” using the 
methodology laid out in this dissertation, and predictive models using immunological markers or 
PET-CT based markers could be built to this instead. Instead of a “one size fits all” mentality, 
the tools developed in this dissertation should be applied flexibly to suit the appropriate research 
question. If the goal of a therapeutic is to prevent disease, LN are the likely target and outcome 
scores and predictive markers can be adjusted accordingly. However, if a novel vaccine that 
prevents initial infection is under scrutiny, the lung is the likely site for this protection to occur, 
and again, the outcome score and predictive markers can be manipulated to accommodate this 
alternative (and preferred) research objective.  
This dissertation demonstrates a clear role for PET-CT imaging in predicting vaccine 
efficacy. This technology has displayed a clear role in assessing efficacy of TB chemotherapy [2, 
350, 351]. We now have evidence that this technology may be applied successfully to pre-
clinical vaccine studies to shorten them and increase their power. The immediate implication of 
the research in this dissertation around this cause is the ability to drastically condense pre-clincal 
vaccine trials in cynomolgus macaques. This represents an immediate savings in research dollars 
that can be spent to procure additional macaques to increase power, new reagents or additional 
procedures to investigate cellular and molecular responses, among many other things. This 
powerful tool using the framework provided by this dissertation should hopefully hasten 
successful pre-clinical candidates from the nonhuman primate model into clinical trials for 
humans. However, a nasty problem still awaits any new (or old) therapeutic candidate that dare 
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arrive at this stage. The endpoints currently used in human trials are sadly antiquated and greatly 
contribute to the cost and length of these trials. PET-CT may be a robust means of predicting 
vaccine efficacy in nonhuman primates, but its use in humans for clinical trials is dubious. PET-
CT is expensive at the large scale and exposes individuals to potentially high doses of radiation. 
Additionally, this technique is powerful as a tool after Mtb challenge, which means that within 
the context of human trials, cohorts of patients would need to be vaccinated and then wait to 
become infected with Mtb, their infection status would need to be precisely known temporally 
which is currently extremely difficult to determine, and then the predictive model would be 
applied. Thus, for clinical trials, PET-CT is neither the most practical nor feasible means of 
assessing vaccine efficacy. One of the goals of this dissertation was to identify peripheral 
immune markers that were predictive of vaccine efficacy as well. This additional tool would 
represent a much more attractive means of measuring vaccine efficacy in human cohorts as blood 
is easily sampled, they are not exposed to many other risks by this means of sampling, and this 
occurs after vaccination but before Mtb challenge, thus reducing the length and ultimate cost of a 
clinical trial. This dissertation contains predictive models of TB outcome that utilize vaccine 
antigen specific T cell cytokine responses. These models are not nearly as robust as the PET-CT 
predictive models, but bring two extremely important concepts to the table. The first is simply 
the idea that peripheral blood signatures can be used to predict TB outcomes. The second 
concerns the fact that the signatures were identified across all vaccines. This is significant 
because a signature should not be vaccine specific but rather vaccination specific, meaning that 
the goal of research in this field should be to identify one set of blood markers that would predict 
success or failure against any novel TB vaccine, as having to develop separate sets of markers 
for each vaccine going into trials would be pointless. This would represent a significant advance 
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in other ways. If such markers could be identified, markers that predict protection conferred by 
any vaccination regardless of target disease could potentially be identified. These data would 
also suggest a common immune “theme” to TB protection, which would shed light on the basic 
immunology of protective immunity to TB. Thus, the continued development of a blood 
signature that is predictive of vaccine efficacy and TB outcome should be of the utmost 
importance in the field of TB vaccinology.  
6.4 FUTURE DIRECTIONS FOR THESE FINDINGS 
One of the things this dissertation highlighted was the importance of model selection. Earlier it 
was posited that rhesus macaques are more appropriate as a pre-exposure model, and 
cynomolgus macaques should be used for post-exposure studies. Thus, future pre-clinical trials 
using nonhuman primates should be designed with this framework in mind. This dissertation also 
demonstrated the need to focus on route of vaccination. The best route of vaccination necessary 
to protect against TB should be identified first, with the actual antigens or vaccine chosen after. 
BCG demonstrated efficacy in the rhesus macaques suggesting that it would be worthwhile to 
test alternative routes of vaccination with this vaccine. Intravenous and aerosol BCG have been 
shown to provide superior protection to Mtb challenge in rhesus macaques versus intradermal 
BCG [108, 109]. These routes have not been investigated in the model that more closely 
resembles the target demographic for novel TB vaccination (cynomolgus macaque), and thus 
future studies should investigate intravenous and aerosol BCG in the cynomolgus macaque 
model. Of special interest should be an intravenous prime that utilizes repeated aerosol boosts to 
attract memory T cells to the site of initial infection of Mtb to act as a pre-exposure vaccination 
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regimen. Any post-exposure vaccination should be designed to target the LN as this 
compartment has been shown to be critical for protection against reactivation TB. As previously 
mentioned, the most susceptible rhesus macaque cohort was the one receiving empty Ad5, 
suggesting that adjuvants or vectors that induce type I IFN should not be utilized in subsequent 
studies. The LN compartment should continue to be investigated to both understand how it might 
be functioning as the epicenter of TB disease and its role in reactivation TB. PET-CT should 
continue to be developed for pre-clinical vaccine trials. This dissertation and other published 
research demonstrate the ability of PET to assess risk of reactivation TB, which will be useful for 
evaluating post-exposure vaccines. CT can identify granulomas as the form, and thus could very 
rapidly identify cohorts of macaques in which early granuloma formation is suppressed by a 
vaccine candidate. Future work will also seek to validate the peripheral immune biomarkers 
identified in this dissertation. Data from more vaccines should be collected for this, as a 
universal signature of vaccine-induced protection would be the most useful tool in quickly 
evaluating efficacy in humans during clinical trials. Finally, although it is a bit outside the scope 
of this dissertation, I wish to express the continued hope for additional TB work in the form of 
ending poverty in developing nations. TB is mainly a social disease, and poverty-associated 
factors increase the likelihood of infection and progression to active disease [8]. The associated 
expenses and lost income due to illness can impede TB care, deepen impoverishment, and 
increase the risk of adverse outcomes and recurrence. Social protection interventions in the 
future can be TB specific [402]. In countries that are now developed, it has been shown that 
increased spending on social protection decreases the prevalence, incidence, and mortality of TB 
[353]. I sincerely hope that these tools, in combination with new therapeutics, will receive the 
funding and attention they deserve, and remain optimistic that TB may one day be eradicated.   
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APPENDIX A 
ACTIVE TRANSFORMING GROWTH FACTOR-β IS ASSOCIATED WITH 
PHENOTYPIC CHANGES IN GRANULOMAS AFTER DRUG TREATMENT IN 
PULMONARY TUBERCULOSIS  
This chapter is adapted from the original publication: DiFazio RM, Mattila JT, Klein EC, 
Cirrincione LR, Howard M, Wong EA, Flynn JL. Active transforming growth factor-β is 
associated with phenotypic changes in granulomas after drug treatment in pulmonary 
tuberculosis. Fibrogenesis and Tissue Repair. 2016. 9(6).  
A.1 ABSTRACT  
Tuberculosis (TB) chemotherapy clears bacterial burden in the lungs of patients and allows the 
tuberculous lesions to heal through a fibrotic process. The healing process leaves pulmonary scar 
tissue that can impair lung function. The goal of this study was to identify fibrotic mediators as a 
stepping-stone to begin exploring mechanisms of tissue repair in TB. Hemotoxylin and eosin 
staining and Masson’s trichrome stain were utilized to determine levels of collagenization in 
tuberculous granulomas from non-human primates. Immunohistochemistry was then employed 
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to further interrogate these granulomas for markers associated with fibrogenesis, including 
transforming growth factor β (TGFβ), α-smooth muscle actin (αSMA), phosphorylated SMAD-
2/3, and CD163. These markers were compared across states of drug treatment using one-
way ANOVA, and Pearson’s test was used to determine the association of these markers 
with one another. Active transforming growth factor β (TGFβ) and α-smooth muscle actin 
(αSMA) were present in granulomas from primates with active TB disease. These 
molecules were reduced in abundance after TB chemotherapy. Phosphorylated SMAD-2/3, 
a signaling intermediate of TGFβ, was observed in greater amounts after one month of 
drug treatment than in active disease, suggesting that this particular pathway is blocked in 
active disease. Collagen production during tissue repair is strongly associated with TGFβ in 
this model, but not with CD163+ macrophages. Tissue repair and fibrosis in TB that occurs 
during drug treatment is associated with active TGFβ that is produced during active disease. 
Further work will identify mechanisms of fibrosis, and work towards mitigating lung impairment 
with treatments that target those mechanisms. 
A.2 BACKGROUND 
With 10.4 million new cases and 1.8 million deaths annually worldwide, tuberculosis (TB) is one 
of humanity’s greatest health threats [7]. Granulomas, the pathologic hallmark of TB, are well-
circumscribed organized collections of host immune cells that form in response to the inhalation 
of aerosols containing Mycobacterium tuberculosis (Mtb)—the causative agent of TB. Although 
granulomas can function to kill or contain Mtb, they can also serve as a niche for growth and 
persistence of the organism [59, 60, 403]. Granulomas often feature a necrotic center and are 
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thus dubbed as necrotizing or caseous, while granulomas lacking this necrosis are said to be non-
necrotizing. Granulomas feature epithelioid macrophages, elongated cells with larger nuclei, 
surrounded by other macrophages and lymphocytes [69]. Bacteria can be found in epithelioid 
macrophages and in caseum [69]. Uncontrolled replication leads to dissemination of the bacteria 
and formation of new granulomas. However, some granulomas can restrain bacterial 
dissemination or even develop locally sterilizing immunity. As a result, these granulomas are 
often fibrotic and can contain a calcified core (referred to as fibrocalcific lesions) [404].  A 
mixture of necrotizing and collagenous lesions is typical of secondary pulmonary tuberculosis 
and is referred to as fibrocaseous disease [404, 405]. Although the host factors that lead to 
control or dissemination of a single granuloma are unclear, we have demonstrated that various 
types of granulomas and outcomes exist within a single non-human primate, similar to humans 
[86, 404].  
Tissue fibrosis can result from a wound healing response that includes fibroblast 
activation and recruitment, production of extracellular matrix materials, and distortion of the 
normal tissue architecture. The most common extracellular matrix component is collagen I, 
which is the most fibrous form of collagen and represents about 84% of the collagen produced by 
fibroblasts [406]. Fibrosis can be caused by a local inflammatory response and fibrosis-related 
pathogenesis is associated with dysfunction of many organs, including lungs, liver, and kidneys 
[407-409]. Transforming growth factor-β (TGFβ) is the main cytokine implicated in 
fibrogenesis, although other cytokines are implicated, including TNF, IL-6, IL-10, IL-13, and IL-
17 [410-415]. TGFβ is produced in a latent form (L-TGFβ) and can be activated through the 
plasmin protease pathway, CD36 and thrombospondin (TSP), reactive oxygen and nitrogen 
species, hypoxia, low pH, and matrix metalloproteases [416]. Active TGFβ utilizes type 1 and 2 
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TGFβ receptors, signaling through a variety of intermediaries, including phosphorylated 
SMAD-2/3 [417]. Through these intermediaries, TGFβ stimulates differentiation of fibroblasts 
into myofibroblasts that then produce alpha-smooth muscle actin (αSMA), a key indicator of and 
contributor to fibrotic pathogenesis [418]. TGFβ has been observed and measured in pulmonary 
fibrosis and, in the lung, is produced by alveolar macrophages, fibrocytes, and lung epithelial 
cells [419-422]. Alveolar macrophages from humans with pulmonary fibrosis display an 
alternatively activated (M2) phenotype, and induction and maintenance of M2 macrophages is 
critical to pathology in pulmonary fibrosis [423]. M2 macrophages are also major producers and 
activators of TGFβ [421].  
Although several types of pulmonary fibrosis have been characterized and studied, 
fibrosis in tuberculosis is not well understood. Significant pulmonary impairment was observed 
in 59% of patients with TB disease [424], half of whom had less than 50% of their original 
forced vital capacity [424]. This loss of pulmonary function resulted in 177 subjects losing 1189 
disability adjusted-life years [425]. Lung function does not improve over the course of 
chemotherapy [426], and this chronic impairment increases incrementally with the number of TB 
episodes experienced in a progressive manner [426]. The main course of treatment for post-
tuberculosis lung damage is pulmonary rehabilitation, which has mixed results [427], 
highlighting the need for more targeted therapies to resolve TB-induced fibrosis and scarring. 
Since macrophages produce TGFβ in pulmonary fibrosis, and are a major cellular component of 
granulomas [421], macrophages may be important contributors to fibrosis in TB lesions [428]. 
The environment of the granuloma may contain almost all of the conditions that activate TGFβ, 
including hypoxia [83], nitrogen radicals [69] and metalloproteases [429], so it is likely that the 
disease process activates TGFβ locally at the site of infection. Cutaneous TB lesions in humans 
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have been noted as centers of fibrosis, with lesions containing active TGFβ [430]. Patients with 
TB have peripheral blood monocytes and alveolar macrophages that produce and active more 
TGFβ than cells from healthy controls [243, 245]. TGFβ has also been observed directly in 
granulomas from human TB patients by immunohistochemistry[242]. 
Drug treatment for M. tuberculosis infection [23, 431] is a lengthy process that slowly 
clears bacterial burden in the lung and induces tissue repair in TB-affected lung. The factors that 
promote fibrotic resolution of tuberculous granulomas are poorly understood. This has been a 
challenging topic to address because of difficulties associated with studying human TB and a 
lack of appropriate mouse models demonstrating the granuloma structures seen in humans. Our 
laboratory previously published that drug-treated macaques with TB had fibrotic granulomas, 
and the fibrotic granulomas were most often sterile [432], representing a successful outcome of 
drug treatment. Since macaques recapitulate the spectrum of granuloma types and infection 
outcomes seen in humans, they represent a useful system for studying the process of drug-
associated fibrosis.  Understanding the fibrotic processes that occur in TB may provide insights 
into treatments to safely resolve residual lung fibrosis during or after drug therapy. The objective 
of this study was to determine how the cell types and molecules associated with pulmonary 
fibrosis differ between granulomas associated with active TB and fibrotic changes after 
chemotherapy. This study will open up further exploration of the fibrogenic mechanisms, with 
the aim of developing treatments to minimalize or reverse scarring after drug treatment. 
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A.3 RESULTS 
A.3.1 Macrophages experience spindloid transformation in tuberculous granulomas. 
After the original uptake of mycobacterial organisms by macrophages, a chemokine and cytokine 
cascade leads to monocyte recruitment, differentiation of macrophages, and epithelioid 
transformation. The latter is characterized by a large, plumper, more eosinophilic staining cell 
Figure 46: Macrophages experience spindloid transformation in tuberculous granulomas. H&E stained 
granuloma that demonstrates spindloid transformation of histiocytes. This figures provides microhistological 
examples of: epithelioid transformation of macrophages with elongated nuclei, dashed arrow, top; tapered, spindled 
macrophages further transformed, solid arrow, left; and collagen deposition, arrowhead, right. Magnification at 
200x.   
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with somewhat elongated, sole-shaped nuclei (Fig. 46, dashed arrow). In contained tuberculous 
lesions, especially non-necrotizing ones that do not expand or infiltrate into adjacent bronchial or 
alveolar airspaces, further change then occurs globally in the appearance of these cells.  Cell 
bodies become less plump and more streaming in shape, with nuclei progressing to a more 
tapered, spindled appearance (Fig. 46, solid arrow). A similarity between other aspects of nuclear 
(e.g. chromatin pattern) and cytoplasmic morphology remains between cells in different stages of 
this continuum.  Fibroblasts and associated collagen fiber formation (Fig. 46, arrowhead) is seen 
in both necrotizing and non-necrotizing lesions, followed by the development of dense bands and 
sheets of fibrous connective tissue.  Eosinophils have been linked to promotion of fibrogenesis 
[433], but are rarely abundant in lung granulomas in nonhuman primates (unpublished 
observations). 
A.3.2 Granulomas exhibit a range of collagen deposition before and after drug treatment. 
Our laboratory has previously provided histologic evidence for the resolution of TB pathology 
after two months of chemotherapy in cynomolgus macaques [432]. We used Masson’s trichrome 
staining, a histologic technique for specifically identifying collagen, on pooled granulomas from 
two previously published drug studies [2, 432] to confirm our hemotoxylin and eosin (H&E)-
based findings on the same set of animals. We examined if representative lesions have more 
(Figs. 47A, C, E) or less (Figs. 47B, D, F) collagen present by both histological stains. The more 
collagenous granuloma from an animal with active disease exhibits a faint ring of peripheral 
collagen deposition (Fig. 47A), which is not uncommon in tuberculous lesions, while less 
collagen-rich non-fibrotic granulomas lack this peripheral cuff of collagen (Fig. 47B). After one 
month of drug treatment, some granulomas exhibit a “healing” phenotype [1],  as evidenced by a 
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thickening of the peripheral fibrotic cuff and central fibrous organization (Fig. 47C). Other 
granulomas lack this degree of collagenization, but still exhibit some central fibrous organization 
(Fig. 47D). By two months of chemotherapy, there are many lesions whose phenotype is solidly 
collagenous (Fig. 47E). There are still lesions though that are not completely resolved, and these 
Figure 47: Granulomas exhibit range of collagen deposition before and after drug treatment. Representative 
sections of histology from granulomas pooled from two TB chemotherapy studies [1, 2], each with H&E staining (top 
panel) and Masson’s trichrome staining (bottom panel) for the same lesion. a Granuloma from active disease with 
some peripheral fibrogenesis. b Granuloma from active disease with no apparent collagenization. c Granuloma from 
one month drug treated animal with robust peripheral fibrotic cuffing. d Granuloma from one month drug treated 
animal with some central fibrous organization. e Fibrotic granuloma from two month drug treated animal. f Granuloma 
from two month drug treated animal with pervasive central fibrous organization. g Quantification of all Masson’s 
trichrome sections. Median pixel intensity was calculated from the blue channel of each micrograph and plotted by 
stage of drug therapy. Bars in each column represent medians. Kruskal-Wallis test: p=0.0285. *p<0.05. 
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granulomas are characterized as having some central fibrous development without a robust 
peripheral cuff (Fig. 47F). These data suggest potentially different cellular mechanisms of tissue 
repair in tuberculosis, with various degrees of collagenization. We then quantified the 
photomicrographs for aniline blue-stained collagen to determine how drug treatment modifies 
collagen deposition (Fig. 47G). We found that granulomas from animals with active disease and 
one month of chemotherapy exhibit a wide range of collagen deposition (Fig. 47G). After two 
months of drug therapy, half of the granulomas are highly collagenous, but the other half 
displayed lesser degrees of collagenization (Fig. 47G). To put these data within the context of 
bacterial burden and sterilization, we divided the number of sterile lung granulomas by the total 
number of lung granulomas to get percentages of sterile lung granulomas for all of the animals in 
Figure 48: Antibacterial chemotherapy promotes collagen-associated bacterial clearance. a The number of 
lung granulomas with viable bacterial growth were divided by the total number of lung granulomas and plotted for 
each animal in the three groups. Each dot represents one animal. Bars represent medians. b The median of the 
median pixel intensity of the aniline blue staining was determined. This was then plotted against the percent of lung 
granulomas with viable bacteria. Significance of the interaction between percent of Mtb+ lung granulomas and 
collagen staining (p) and strength of interaction (R2) are shown. Each dot represents one animal, and colors match 
the colors of the treatment groups in part A of this figure. Dotted lines represent 95% confidence intervals. 
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the study (Fig. 48). We found that that the frequency of sterile granulomas increases as drug 
therapy progresses (Fig. 48A), and that this rise is concurrent with a significant increase the 
presence of collagen-rich granulomas (p=0.0002; Fig. 48B).   
A.3.3 Tuberculous granulomas bear signs of TGFβ-driven fibrosis. 
We next wanted to determine whether M2 macrophages and TGFβ were associated with tissue 
repair. Granulomas from animals with active disease, one month of antibiotic therapy (ABX), 
Figure 49: Tuberculous granulomas bear signs of TGFβ-driven fibrosis. Top panels feature granulomas 
stained for collagen I (red), phosphorylated SMAD-2/3 (green), and CD163 (blue). Bottom panels feature 
granulomas stained for TGFβ (red), L- TGFβ (green), and αSMA (blue). Magnification x 200. Scale bar represents 
500 um. a,b Granulomas from animals with active disease. c,d Granulomas from animals after one month of TB 
chemotherapy. e,f Granulomas from animals after two months of TB chemotherapy.  
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and two months of ABX were analyzed by multiparameter immunohistochemistry for collagen I, 
phosphorylated (p) SMAD-2/3 (an intermediary of TGFβ signaling), and CD163 (a marker of 
M2-polarized macrophages in primates[69]) or TGFβ, L- TGFβ, and αSMA. This approach 
provides information on the location and quantity of factors upstream of TGFβ induction and 
TGFβ activation. We found that caseous granulomas from animals with active, untreated disease 
contained strongly-staining fibrils of collagen I that could be visualized in the central region of 
the lesion while pSMAD-2/3+ and CD163+ cells were present along the periphery of the 
structure (Fig. 49A). In similar granulomas from untreated animals, active TGFβ was present 
around the necrotic portion of the lesion (Fig. 49B), an area populated by epithelioid 
macrophages [69, 111]. Latent TGFβ was observed throughout this granuloma, and αSMA was 
strongly present in a region of robust peripheral fibrosis. After one month of drug treatment, 
collagen I was detected around the edge of the structure, suggesting mild peripheral fibrotic 
development (Fig. 49C). Strong pSMAD-2/3 staining was interspersed among the CD163+ cells 
that were localized towards the center of the structure, a position in which they are not normally 
found during active disease. Another granuloma from an animal with one month of drug therapy 
exhibited very little αSMA or active TGFβ, except minor staining in the exterior and in an 
adjacent blood vessel (Fig. 49D). Granulomas from animals two months post chemotherapy 
displayed plentiful collagen I staining, with both peripheral fibrosis and central fibrotic 
organization (Fig. 49E). In this particular lesion, pSMAD-2/3 and CD163 appear to co-localize 
in the fibrosis. We found that αSMA is present in a ring around the periphery of the structure 
(Fig. 49F). The active and latent forms of TGFβ appear to be intermixed within the lesion. These 
data overall indicate that active TGFβ is present in these granulomas and drives expression of 
TGFβ-regulated products including αSMA. 
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A.3.4 Active Mtb infection and disease activates TGFβ and suppresses SMAD-2/3
signaling. 
 We quantified median pixel intensity (MPI) from a collection of granulomas to elucidate how 
latent and active TGFβ, αSMA, pSMAD2/3, collagen and CD163 expression change over the 
three time points we are examining. We found an initial decrease in latent TGFβ levels at the 
initiation of drug treatment, but unchanged levels between one and two months of drug 
therapy (Fig. 50A). In contrast, active TGFβ appeared to decline in animals over the full 
two-month course of drug therapy (Fig. 50B), while the trend in αSMA expression was 
Figure 50: Active Mtb infection and disease activates TGFβ and suppresses SMAD-2/3 signaling. a-f 
Quantification of IHC. Median pixel intensity (MPI) was calculated from red, green, and blue color channels of 
each micrograph and plotted by stage of drug therapy. Bars in each column represent medians. Kruskal-Wallis test 
had p values of less than 0.0001 for TGFβ and αSMA, pSMAD-2/3 (0.0006), L-TGFβ (0.0148), and collagen I 
and CD163 (not significant). *p<0.05. **p<0.01. ***p<0.001. ****p<0.0001.   
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consistent with trend observed for latent TGFβ (Fig. 50C). Interestingly, levels of 
phosphorylated SMAD-2/3 were higher after one month of chemotherapy, but then 
decreased by two months of antibiotics (Fig. 50D). Relative amounts of collagen I and 
CD163 do not change between following antibiotic treatment (Fig. 50E-F). These data 
further demonstrate the role that active TGFβ is playing in drug-promoted tissue repair.  
We used immunologic and biochemical assays to confirm our immunohistochemical 
analysis of TGFβ and collagen. Consistent with our immunohistochemical data, ELISAs for 
active TGFβ demonstrated greater quantities of TGFβ in granulomas from animals during 
active disease and lesser in animals after two months of drug treatment (Fig. 51A). 
Collagen levels were measured by hydroxyproline assay (Fig. 51B), and were unchanged 
between treated and untreated animals, coinciding with our microscopic data (Fig. 50F).  
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Figure 51: Biochemical evidence of TGFβ and collagen. a ELISA for active TGFβ. TGFβ in granulomas 
was converted into pg and then normalized by the total amount of protein in each granuloma as determined by BCA 
assay. Wilcoxon signed rank test was used to compare granulomas from active disease to granulomas from two 
months of drug treatment. b Hydroxyproline assay. Collagen present in granulomas was determined using the 
hydroxyproline assay. Values were converted into pg and then normalized by the total amount of protein in each 
granuloma as determined by BCA assay. 
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A.3.5 TGFβ is strongly associated with collagen I expression.
We used our quantitative immunohistochemical data (Fig. 50) to perform pairwise correlations to 
identify the relationships between these factors. At all study time points, collagen I and pSMAD-
2/3 exhibit a robust positive association (Fig. 52), especially during active disease and one month 
of drug therapy. In these time points, we found that over 50% of the variability in collagen I 
levels was explained by pSMAD-2/3 (Pearson’s r>0.7). In granulomas from animals with active 
disease, or two months of drug treatment, there is a weak but significant association between 
pSMAD-2/3 and CD163 (Fig. 52). However, CD163 and collagen I are not statistically 
associated at any time point of the study (Fig. 52). This is in contrast to active TGFβ, latent 
TGFβ, and αSMA, which are all strongly and positively associated with one another at all 
time points (Fig. 53).  
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Figure 52: TGFβ is strongly associated with the presence of collagen I. IHC values for each granuloma 
were plotted against one another to assess association between collagen I, TGFβ signaling, and M2 macrophages. 
Values were transformed, and Pearson’s test for parametric correlation was used to determine significance. 
Significant correlations are denoted by red symbols. Open circles are significant but r<0.7, while asterisks indicate 
that r>0.7.  
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Figure 53: Active TGFβ is highly associated with its latent form and αSMA. IHC values for each 
granuloma were plotted against one another to assess association between TGFβ, L- TGFβ, and αSMA—which is 
produced by cells activated by TGFβ. Values were transformed, and Pearson’s test for parametric correlation was 
used to determine significance. Significant correlations are denoted by red symbols. Open circles are significant 
but r<0.7, while asterisks indicate that r>0.7. 
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pulmonary pathologies through infection and disease, which typically result in chronic 
fibrocaseous disease [404, 405]. Drug treatment reduces bacterial burden and allows for tissue 
repair, although this does not quickly alter the pathology remaining in the lung as demonstrated 
by computed tomography in both human and non-human primates [350]. Chemotherapy 
additionally leaves individuals vulnerable to relapse; more than half of smear positive TB cases 
have been previously treated for TB [366]. Relapse was originally thought to be cause by 
endogenous sources of Mtb remaining after drug treatment, but 75% of relapse cases in a high 
TB burden cohort were exogenously re-infected [434]. Why is this population prone to 
reinfection after successful chemotherapy? The risk of developing active TB is about 4.5 times 
higher in patients with chronic interstitial lung disease and idiopathic pulmonary fibrosis [435, 
436]. This could be due to the specific pathology of fibrotic lung tissue as it may promote 
colonization and establishment of infection [437]. The residual scar tissue left after drug therapy 
and loss of normal lung architecture could play roles in increasing the risk of relapse. Therefore, 
understanding the mechanism of fibrogenesis in TB and ameliorating tissue damage after drug 
treatment could reduce the risk of reinfection and help shrink the pool of infected individuals. 
A.4 DISCUSSION
The goal of this study was to identify molecular and cellular markers associated with fibrotic 
resolution in experimental tuberculosis infection. Tuberculosis produces a wide range of  
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granulomas, but it has been difficult to identify the specific cells that are the most important 
drivers of fibrosis. Histologic assessment can be used to evaluate the cellular responses to 
infection from a morphological perspective and can provide insights into lesion development and 
resolution. Identifying the cellular origin of some spindle-type cells in granulomas is not always 
possible, but histologic examination can provide important inferences as to whether these cells 
arose from epithelioid macrophages or collagen-producing fibroblasts. Based on our histologic 
Several cell types are likely to play significant roles in driving fibrot i c processes in 
Figure 54: Model that demonstrates the TGFβ-associated processes explores in this study. The red arrow 
around active disease represents processes that activate fibrotic cytokines, which then diminish during the early course 
of drug therapy (smaller arrows that are less red). αSMA and TGFβ drop, represented in green, while pSMAD-2/3 
appears to rise and fall, in blue. Levels of collagen I do not change, shown in purple.  
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observations and immunohistochemical analyses, we hypothesize that collagen-producing 
fibroblast-like cells may originate from several sources, and in some cases not from fibroblasts 
recruited from nearby tissues, but from non-fibroblast-like cells that have undergone a process 
similar to endothelial–mesenchymal progression. Additionally, circulating monocyte-derived 
cells (fibrocytes) can have phenotypes reminiscent of the phenotypes we have identified [438, 
439].  Given the ability of some circulating monocytes to differentiate into fibroblast-like cells 
instead of macrophages, the question of whether subsequent differentiation between 
macrophages and fibroblasts can occur should be considered. The wide range in collagen 
presence, plus the appearance of various collagenous phenotypes suggest that different 
mechanisms for fibrotic resolution occur in tuberculous granulomas. Some granulomas manifest 
both peripheral and central fibrous organization, while others demonstrate only central 
collagenization, or none at all. Future studies should seek to correlate these divergent repair 
mechanisms to lesion specific Mtb burden to determine efficacy of clearance and elucidate the 
immunologic processes of each. 
Our observations that latent TGFβ changes only slightly between granulomas from 
animals with active disease and drug-treated animals suggest that a pool of latent TGFβ 
remains in the lung even after Mtb is cleared. Latent TGFβ is maintained in the lung 
epithelium by latent TGFβ binding proteins where it can remain until activated [440]. Our 
data indicate that conditions within granulomas activate TGFβ, an anti-inflammatory 
cytokine associated with fibrosis. This molecule exerts biological action in the granuloma, 
as is supported by the presence of αSMA in direct proportion to TGFβ. The lower levels of 
TGFβ and αSMA in granulomas of animals on drug therapy suggests that therapy itself does 
not activate more TGFβ, and that the amount activated during active TB is utilized for 
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tissue repair. Interestingly, phosphorylated SMAD-2/3 is lower during active disease, even 
though active TGFβ levels are high. Since SMAD-2/3 is phosphorylated when cells come 
into contact with active TGFβ [417], this suggests that live Mtb somehow block SMAD-2/3 
activation even in the presence of active TGFβ. The presence of αSMA, also an indicator of 
the cellular effects of TGFβ, could be explained by the utilization of alternative TGFβ-
stimulated pathways [441, 442]. The alternative TGFβ signaling pathways may be 
prominent in disease, and since the SMAD-2/3 pathway only becomes used in tissue repair 
once Mtb is cleared, the SMAD-2/3 pathway may be preferential for healing and clearance 
and the alternative pathways preferential for TB pathogenesis. Collagen I levels are similar 
between granulomas with active disease and drug treatment, suggesting that treatment 
only promotes and does not exacerbate fibrosis. Collagen I is strongly associated with 
active TGFβ; over 50% of the variability in levels of collagen I is explained by TGFβ 
signaling through SMAD-2/3, indicating that active TGFβ is likely the main molecular 
driver of fibrosis and tissue repair in tuberculous lesions. CD163 and collagen I are not 
associated in this model, implying that the CD163+ macrophages are not major producers 
of collagen I. Macrophages in granulomas are not a uniform population of cells [69], and 
other CD163- macrophage subsets could be responsible for collagen production in the 
granuloma. Unfortunately, there are no pan-macrophage markers for primates, and our 
efforts to identify the specific population of cells responsible for collagen expression are 
ongoing [69]. Collagen appears to stream from the epithelioid macrophages into the 
caseous necrotic center. Interestingly, this population of cells is not comprised of the M2-
polarized CD163+ macrophages we expected would correlate with fibrosis, but instead 
appear to be M1-polarized cells [69], suggesting the capacity of these cells may be more 
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diverse than previously known. Active TGFβ was mostly localized in the epithelioid 
macrophage region of the granulomas as well. Alternatively, macrophage-expressed 
products could support collagen production by neighboring fibroblasts. These cells could 
potentially be contributors to collagenization, as well as surrounding lung epithelial cells 
transformed by active TGFβ. Further work will include markers for these types of cells and 
determine their association with collagen production in the granuloma. 
A.5 CONCLUSIONS
Fibrosis occurs in TB lesions during and after drug treatment. The goal of this project was to 
determine the cell types and molecules associated with fibrosis in non-human primates with TB. 
We provide additional evidence of activated TGFβ being present in lesions from M. 
tuberculosis-infected lung tissue. Collagen production in active disease and TB 
chemotherapy is strongly associated with TGFβ, suggesting its role as the chief cytokine 
driving tissue repair. Future studies will seek to further explore these results mechanistically 
with hopes of developing adjunct treatment to minimize, or possibly reverse, scar formation after 
TB chemotherapy. 
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A.6 METHODS
A.6.1 Animals
The Institutional Animal Care and Use Committee of University of Pittsburgh approved all 
experiments. The animals were housed and maintained in accordance with standards established 
in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.  
Infections. Cynomolgus macaques (4-9 years of age) imported from China (Valley 
Biosystems, Sacramento, CA) were used for these studies (n=21). Monkeys were infected via 
bronchoscope with 25 CFU of M. tuberculosis Erdman strain. Using published criteria, monkeys 
were determined to have active or latent TB by 6-8 months post-infection, and were randomized 
to treatment or non-treatment groups; treatment was initiated when monkeys developed active 
TB, as determined by clinical and microbiologic signs [65, 111].  
Drug therapy. The samples described in the current study were obtained from macaques 
in a previously published study from our laboratory [1, 2]. Monkeys with active disease were: 
untreated (n=9, 110 granulomas), treated with isoniazid (INH) and rifampin (RIF) for 1 month 
(n=2, 22 granulomas) or 2 months (n=5, 91 granulomas), or treated with INH, RIF, and 
metronidazole (MTZ) for 1 month (n=3, 154 granulomas) or 2 months (n=5, 93 granulomas).   
Necropsies were performed as previously described (35 52). Individual granuloma and 
lung samples were taken from each monkey from sites of infection and surrounding tissue. 
Portions of these samples were homogenized into single cell suspension before storing at -80°C 
for ELISA and hydroxyproline assays, while another portion was formalin-fixed paraffin-
embedded for histology.  
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A.6.2 Hematoxylin and eosin (H&E) staining
Formalin-fixed paraffin-embedded tissue sections were cut and stained with Harris hemotoxylin 
modified (Sigma-Aldrich, St. Louis, MO) and eosin Y solution (Sigma-Aldrich, St. Louis, MO). 
Slides were deparaffinized in deionized water. Slides were then stained with hemotoxylin for 
three minutes. Slides were rinsed under running tap water, rinsed with 70% ethanol, and then 
stained with eosin for three minutes. Slides were rinsed and dehydrated in ethanol, cleared in 
xylene, and then mounted.  Criteria for characterizing granulomas were based on size and shape, 
type of granuloma, and cellular composition. A veterinary pathologist who is an expert in 
macaque tuberculosis (ECK) performed all histologic analyses. 
A.6.3 Masson’s trichrome
Formalin-fixed paraffin-embedded tissue sections were stained with Masson’s trichrome to 
identify connective tissue, muscle and collagen fibers (Sigma-Aldrich, St. Louis, MO). Slides 
were deparaffinized to deionized water. Slides were then immersed in Bouin’s solution overnight 
at room temperature to intensify the subsequent staining. Slides were washed with tap water then 
stained with Harris hematoxylin solution (Sigma-Aldrich, St. Louis, MO) for five minutes. Slides 
were washed again in running tap water for five minutes, rinsed in deionized water, and stained 
in Biebrich Scarlet-Acid Fucshin for five minutes. Slides were rinsed in deionized water and 
placed in phosphotungstic and phosphomolybdic acid solution for five minutes. Slides were 
moved to Aniline Blue solution for five minutes, and then placed in 1% acetic acid solution for 
two minutes. Slides were rinsed in deionized water, dehydrated through alcohol, cleared in 
xylene, and then mounted.  
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A.6.4 Immunohistochemistry
Tissue sections were stained for collagen I (rabbit polyclonal, Abcam, Cambridge, MA, 1:50 
dilution), pSMAD-2/3 (goat polyclonal, Santa Cruz Biotechnology, Dallas, TX, 1:10 dilution), 
CD163 (mouse clone 10D6, Neomarkers, Fremont, CA, 1:30 dilution), L-TGFβ (goat 
polyclonal, R&D Systems, Minneapolis, MN, 1:10 dilution), TGFβ (chicken polyclonal, R&D 
Systems, Minneapolis, MN, 1:10 dilution), and αSMA (mouse clone 1A4, Thermo Fisher, 
Pittsburgh, PA, 1:100 dilution). Antigen retrieval and staining were done as previously 
described [69]. Briefly, formalin fixed paraffin embedded tissues samples were deparaffinized in 
xylene and rehydrated in ethanol. Samples were then placed into a pressure cooker with boiling 
antigen retrieval buffer (Tris-HCl, EDTA, Tween-20) for seven minutes. After allowing for the 
slides to cool, the sections were blocked with 2% fetal bovine serum in phosphate buffered saline 
for 30 minutes. Antibodies and fluorescent tags were incubated on each sample for one hour with 
washes in between with phosphate buffered saline with 0.2% Tween-20. Prolong Gold Mounting 
Medium with DAPI (Invitrogen) was then applied to the slides, which were then cured in the 
dark overnight before being imaged.  
A.6.5 Quantification of histology
Trichrome- and H&E-stained sections were imaged using Provis fluorescent microscope 
(Olympus America, Center Valley, PA) and fluorescently stained slides visualized with a 
FluoView 1000 confocal microscopes (Olympus). For images used for quantitative imaging, care 
was taken to keep the camera settings constant between granulomas and animals. These images 
were then saved as 24-bit TIFF files and read into the language R via the package “EBImage” 
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from Bioconductor (http://www.bioconductor.org/packages/release/bioc/html/EBImage.html). 
For the trichrome slides, the blue channel only was isolated. Red, green, and blue channels were 
pulled from the IHC slides. The median pixel intensity for each channel was then saved and 
exported to Microsoft Excel (Microsoft, Redmond, WA).  
A.6.6 Enzyme-linked immunosorbent assays (ELISAs)
Active TGFβ-1 in granuloma homogenates was measured by using a commercial ELISA 
(eBioscience, San Diego, CA) according to manufacturer’s instructions. Briefly, a high affinity 
protein binding plate was coated with a capture antibody overnight and blocked with assay 
diluent for an hour before adding standards and undiluted granuloma homogenates for overnight 
incubation. TGFβ was detected the next day using a biotinylated detection antibody and 
streptavidin-HRP, and the absorbance was immediately measured at 450nm. Total protein of the 
same samples was quantified by Pierce BCA Protein Assay (Thermo Scientific, Pittsburgh, PA), 
where granuloma homogenates were added to BCA Working Reagent, and the absorbance 
measured at 562 nm after 30 minutes at 37°C. Levels of TGFβ were normalized to total protein 
in granuloma homogenates. 
A.6.7 Hydroxyproline assay
Collagen was detected in homogenized granulomas by using a commercial hydroxyproline kit 
(Sigma Aldrich, St. Louis, MO). Briefly, samples were mixed with hydrochloric acid and 
hydrolyzed at 120°C for 3 hours. These samples and standards were then transferred to a 96-well 
plate and dried. Chloramine T/oxidation buffer was added to wells and incubated at room 
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temperature for five minutes. To this, diluted DMAB reagent was added and incubated at 60°C 
for 90 minutes. Absorbance at 560 nm was then measured. Levels of collagen were normalized 
to total protein in granuloma homogenates.  
A.6.8 Statistics
Quantitative data from Masson’s trichrome staining and immunohistochemical staining were 
visualized using Prism (Graphpad, La Jolla, CA). Analysis of these data was done using the tests 
indicated, typically a one-way ANOVA and a multiple comparison test for either parametric or 
non-parametric data. P values were significant if less than 0.05. Further analysis of the 
immunohistochemical staining was performed with JMP (SAS, Cary, NC). Correlations between 
markers in histological stains were performed using the multivariate function and scatterplots 
were generated. Significance was determined using pairwise correlations with the strength of the 
relationship given as Pearson’s r. 
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APPENDIX C 
MANUSCRIPTS TO BE PUBLISHED 
Chapter 3: Data from this chapter will be incorporated with addition data from collaborators at 
the NIAID Vaccine Research Center and subsequently published as a co-first author manuscript. 
Chapter 4: DiFazio RM, Maiello P, Myers AJ, Rodgers MA, O’Malley M, Tomko J, Frye 
LJ, Fillmore D, Agger EM, Andersen P, Lin PL, and Flynn JL. BCG+H56:CAF01 limits host 
inflammation and bacterial dissemination in a nonhuman primate model of tuberculosis. Soon to 
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Chapter 5: Data from this chapter will subsequently be published in a first author 
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